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variety	 of	 pathogens,	 which	 range	 from	 minute	 single-cell	 organisms	 (bacteria	 and	
yeast)	to	large	parasitic	worms	(helminths).	A	central	component	of	tailoring	immune	
responses	 towards	 different	 pathogens	 involves	 the	 differentiation	 of	 naïve	 CD4+	 T	
helper	 (Th)	 cells	 into	 functionally	 distinct	 sub-classes	 of	 effector	 Th	 cells	 that	 are	
distinguishable	 by	 their	 unique	 cytokine	 profiles.	 Intracellular	 bacteria	 promote	 the	
differentiation	of	 IFNγ+	Th1	cells,	whereas	helminth	and	fungal	material	promote	the	
differentiation	 of	 IL-4/IL-13+	 Th2	 cells	 and	 IL-17+	 Th17	 cells,	 respectively.	
Furthermore,	a	proportion	of	Th	cells	differentiate	into	IL-21+	T	follicular	helper	(Tfh)	
cells	that	required	for	B	cell	activation,	germinal	centre	formation	and	immunoglobulin	
class-switching.	 The	 processes	 that	 regulate	 the	 differentiation	 of	 CD4+	 T	 cells	 are	
multifactorial	and	are	currently	incompletely	understood.		
	
Antigen	 presenting	 cells	 (APC),	 including	 dendritic	 cells	 (DC)	 and	 monocytes,	 are	
required	 for	 the	 initiation	of	CD4+	T	 cell	 responses	and	are	 thought	 to	play	a	 central	
role	 in	 regulating	 CD4+	 T	 cell	 differentiation	 in	 lymph	 nodes	 (LNs).	 In	 particular,	
migratory	 DC	 enable	 the	 presentation	 of	 tissue-derived	 antigen	 to	 CD4+	 T	 cells	 by	
actively	 transporting	antigen	 from	 the	 tissue	 to	 local	LNs	via	 the	afferent	 lymphatics.	
APC	 can	 be	 resolved	 into	many	 developmentally	 and	 phenotypically	 distinct	 subsets,	
which	 have	 been	 proposed	 to	 specialise	 in	 initiating	 a	 particular	 CD4+	 T	 cell	
differentiation	programme	upon	activation.	However,	signals	derived	from	the	antigen	
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itself	 or	 from	 surrounding	 cells	 in	 the	 tissue	 environment	 have	 the	 potential	 to	
influence	 APC	 function.	 Therefore,	 functional	 conditioning	 of	 APC	 by	 antigenic	 or	




in	 the	 regulation	 of	 CD4+	 T	 cell	 differentiation.	 Using	 an	 intradermal	 immunisation	
model,	 the	 requirements	 for	 CD4+	 T	 cell	 responses	 to	 bacterial	 (M.	 smegmatis;	 Ms),	
helminth	 (N.	brasiliensis;	Nb)	 and	 fungal	 (C.	albicans;	Ca)	 antigens	were	assessed	 in	a	
systematic	 fashion.	 Injection	of	 fluorescently-labelled	antigen	revealed	that	migratory	
CD326-	 CD103-	 DC	 (DC2)	 and	 monocytes	 were	 the	 predominant	 APC	 subsets	
associated	with	antigen	uptake.	Restricting	LN	homing	of	migratory	DC2	using	an	Itgax-
cre	 Irf4-flox	 mouse	 model	 significantly	 reduced	 the	 CD4+	 T	 cell	 response	 to	 all	
immunogens,	whereas	depletion	of	monocytes	was	associated	with	a	reduced	CD4+	T	
cell	response	to	Ms.	These	data	show	that	DC2	are	required	for	optimal	Th2	and	Th17	
responses	 and	 act	 in	 concert	with	monocytes	 to	 support	optimal	 Th1	differentiation.	
Importantly,	 transcriptional	 analysis	 revealed	 that	 antigen-carrying	 DC2	 and	
monocytes	 expressed	 context-specific	 transcriptional	 profiles,	 suggesting	 that	
conditioning	of	APC	by	antigenic	or	environmental	signals	was	 involved	 in	regulating	
CD4+	T	cell	polarisation.	Indeed,	IFNγ-conditioning	of	DC2	and	monocytes	was	found	to	
be	 a	 key	 component	 in	 promoting	 effector	 Th1	 responses,	 while	 restricting	 Tfh	 cell	
development.	 On	 the	 other	 hand,	 IFN-I-conditioning	 of	 DC2	was	 required	 to	 amplify	
CD4+	T	 cell	 responses	 to	Nb,	while	 thymic	 stromal	 lymphopoietin	 (TSLP)	 specifically	
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identified	 threat	 with	 a	 remarkable	 level	 of	 specificity	 through	 the	 activation	 of	




cytokine	 profiles,	 arise	 in	 response	 to	 different	 classes	 of	 pathogens	 and	 co-ordinate	
the	 appropriate	 effector	 response	 (Fig	 1.1)	 (1,	 2).	 Viral	 and	 intracellular	 bacterial	
infections	 are	 associated	 with	 IFNγ+	 Th1	 cells	 that	 promote	 microbicidal	 activity	 in	
macrophages	 (3),	whereas	extracellular	bacterial	 and	 fungal	 infections	are	associated	
with	 IL-17+	 Th17	 cells	 that	 promote	 neutrophil	 activity	 and	 the	 release	 of	 anti-
microbial	 peptides	 from	 the	 epithelium	 (4).	 Helminths	 drive	 IL-4/IL-13+	 Th2	 cells,	
inducing	 the	 release	 of	 toxic	 mediators	 from	 mast	 cells	 and	 eosinophils	 as	 well	 as	
promoting	epithelial	contractility	and	mucous	production	to	enhance	worm	expulsion	
(5).	 However,	 the	 activation	 of	 CD4+	 Th	 cell	 subsets	 can	 also	 be	 associated	 with	
pathology	 if	 initiated	 inappropriately.	 Th1	 and/or	 Th17	 cells	 are	 prevalent	 in	 the	
context	 of	 autoimmune	 disease	where	 an	 immune	 response	 is	misdirected	 against	 a	
self-antigen	(2,	6).	 In	contrast,	Th2	cells	are	associated	with	allergic	disease	where	an	
immune	 response	 is	 targeted	against	 an	 innocuous	 foreign	antigen,	 such	as	a	dietary	
protein	(7).		
	




effector	 function.	 Antigen-presenting	 cells	 (APC),	 such	 as	 dendritic	 cells	 (DC)	 and	
monocytes,	 are	particularly	adept	at	 this	process	and	have	been	 the	primary	 focus	of	




The	 skin	 is	 a	 barrier	 organ	 that	 has	 extensive	 interactions	 with	 the	 external	
environment	and	therefore	is	a	common	entry	route	for	infectious	agents	into	the	body,	
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including	 bacteria,	 fungi,	 viruses	 and	 parasites.	 To	 combat	 this,	 the	 skin	 harbours	 a	
dense	 network	 of	 immune	 cells	 that	 are	 poised	 to	 respond	 to	 any	 disruption	 to	
homeostasis	and	are	capable	of	initiating	the	effector	immune	response	best	suited	to	























1.1 The initiation and orchestration of context-appropriate immune 
responses 
Innate	 and	 adaptive	 immune	 cells	 constitute	 two	 complementary	 and	 inter-linked	
systems	 that	 work	 in	 concert	 to	 elicit	 effective	 and	 long-lasting	 immunity.	 Innate	
immune	cells	include	DC,	monocytes,	macrophages,	neutrophils	and	natural	killer	(NK)	




increased	 specificity.	 The	 adaptive	 immune	 system	 consists	 of	 T	 and	 B	 lymphocytes	
that	 express	highly	 specific	 receptors	generated	by	genetic	 shuffling	of	hypervariable	
domains.	 Thus,	 adaptive	 responses	 are	 activated	 in	 an	 antigen-	 and	 context-specific	
manner,	with	the	phenotype	of	T	lymphocytes	and	the	antibody	class	of	B	cells	tailored	
to	the	type	of	pathogen	from	which	the	antigen	originated.	Further,	a	small	proportion	
of	T	and	B	 lymphocytes	are	 retained	as	memory	cells	 following	 the	primary	 immune	
response,	allowing	for	increased	efficiency	in	resolving	infection	upon	re-exposure.		
	
1.1.1 Identification of pathogen- and damage-associated molecular patterns 





damage	 (20).	 Several	 classes	 of	 PRRs	 have	 been	 characterised	 and	 include	 Toll-like	
receptors	 (TLRs),	 C-type	 lectin	 receptors	 (CLRs)	 and	 nucleotide-binding	




released	 from	 dying	 cells,	 such	 as	 S100A9	 (TLR2/4)	 (26,	 27),	 heat-shock	 proteins	




cell	 by	 viruses	 or	 bacteria	 (34-38);	 or	 upon	 phagocytosis	 of	 histones	 (39)	 or	
mitochondrial	DNA	(40)	released	from	dying	cells.	
	
Signalling	 through	 PRRs	 instigates	 an	 activation	 programme	 within	 the	 cell,	
culminating	 in	 cellular	 activation	 and	 the	 production	 of	 inflammatory	 cytokines	 and	
chemokines	 to	 recruit	 additional	 support	 from	neighbouring	 and	 circulating	 immune	
cells	 (41-44).	 The	 specificity	 of	 PRRs	 for	 different	 microbial	 motifs	 induces	 the	
production	 of	 effector	 molecules	 appropriate	 for	 combating	 the	 class	 of	 pathogen	
identified.	This	is	particularly	important	for	APC,	which	are	involved	in	initiation	of	an	






1.1.2 Antigen presenting cells (APC)  
APC,	including	DC	and	monocytes,	are	a	specialised	population	of	innate	immune	cells	
that	 promote	 the	 appropriate	 activation	 and	 differentiation	 of	 T	 cells	 according	 to	
major	histocompatibility	complex	(MHC)-peptide	complex	 interactions	with	the	T	cell	
receptor	 (TCR)	and	environmental	 cues.	APC	 are	 stationed	 throughout	 lymphoid	and	
peripheral	 organs	where	 they	 survey	 the	 local	 environment	 for	 signs	 of	 infection	 or	
damage.	 DC	 are	 particularly	 proficient	 at	 this	 role	 and	 are	 abundant	 in	 peripheral	
tissues	 at	 steady-state	 (45).	 In	 contrast,	 monocytes	 are	 rare	 in	 tissues	 under	
homeostatic	 conditions	 (46)	 but	 are	 rapidly	 recruited	 in	 response	 to	 inflammatory	
signals	 where	 they	 can	 differentiate	 into	 DC-like	 cells	 with	 enhanced	 antigen	
presentation	capacity	(47,	48).		
	
One	 of	 the	 distinguishing	 features	 of	 APC	 is	 their	 ability	 to	 sample	 local	 antigen	 and	
process	 it	 for	presentation	on	MHCII	or	MHCI	molecules	 to	CD4+	Th	cells	or	CD8+	T	
cells,	 respectively	 (49,	 50).	 Exogenous	 antigen	 is	 sampled	 by	 phagocytosis	 (51-53),	
receptor-mediated	endocytosis	(54-56)	or	macropinocytosis	(57,	58),	depending	on	the	
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sub-population	 and	 activation	 state	 of	 the	APC	 (54).	 Inside	 the	 cell,	MHCII	molecules	





cells	 (60).	 However,	 a	 specialised	 subset	 of	 APC	 are	 equipped	 with	 the	 cellular	







and	molecules	 involved	 in	antigen	 sampling	and	 tissue-residence	are	down-regulated	
(65-67).	 Further,	 as	 mentioned	 above,	 the	 types	 of	 PRRs	 engaged	 promote	 the	
expression	of	 the	cytokines,	chemokines	and	other	differentiation	molecules	required	
to	 shape	 the	 appropriate	 adaptive	 immune	 response	 (section	 1.4.2).	 Tissue-resident	




Antigen	 uptake	 in	 the	 absence	 of	 inflammatory	 stimuli	 leads	 to	 spontaneous	
maturation	 of	 tissue-resident	 DC	 enabling	 their	 migration	 to	 local	 LNs	 to	 present	
antigen	to	T	cells	(67,	70,	71).	In	this	context,	the	differentiation	of	regulatory	T	cells	is	
promoted	 to	prevent	 inappropriate	 immune	activation	and	chronic	 inflammation	 (72,	
73).		
	






LNs	 are	 densely	 packed	 with	 naïve	 T	 and	 B	 lymphocytes,	 which	 are	 organised	 into	
distinct	 compartments:	 T	 cells	 are	 located	 in	 the	 paracortex,	 whereas	 B	 cells	 form	
follicular	structures	in	the	cortex	(Fig	1.2).	A	network	of	stromal	cells	and	LN	resident	
immune	 cells	maintain	 the	 LN	 architecture	 and	 regulate	 the	 positioning	 of	 incoming	
cells	through	chemokine	gradients	(74,	75).	Naïve	T	cells	continually	circulate	between	
secondary	 lymphoid	 organs	 via	 the	 lymphatics	 and	 blood,	 scanning	 for	APC	 carrying	
their	cognate	antigen	(8).	Fibroblastic	reticular	cells	located	in	the	paracortex	express	
CCL19	and	CCL21,	thus	retaining	circulating	naïve	T	cells,	which	express	CCR7,	in	the	T	





and	 are	 subsequently	 directed	 to	 the	 appropriate	 location	 by	 chemokine	 gradients.	
Tissue-derived	 migratory	 APC	 express	 CCR7	 and	 are	 recruited	 to	 the	 T	 cell	 area,	
allowing	for	the	co-localisation	of	antigen-carrying	APC	with	naïve	T	cells	(68,	69,	78).	







for	 re-positioning	within	 the	 LN	 or	 exit	 from	 the	 LN	 via	 the	 efferent	 lymphatics.	 For	




















1.1.4 Cytokines and chemokines 
Release	 of	 soluble	 mediators	 is	 an	 important	 method	 of	 cell-to-cell	 communication	
within	 the	 immune	 system;	 and	 is	 a	 vital	 component	 of	 maintaining	 context-
appropriate	immune	responses.	The	cytokine	milieu	is	a	major	determinant	of	CD4+	Th	
cell	differentiation	as	well	as	the	recruitment	and	activation	of	the	required	effector	cell	




1.1.4.1 Epithelial cell-derived cytokines 
Cross-talk	 between	 epithelial	 cells	 and	 the	 immune	 system	 is	 becoming	 increasingly	
evident	 and	 has	 important	 implications	 for	 the	 initiation	 of	 immune	 responses.	
Positioned	 as	 the	 first-line	 of	 cellular	 defence	 at	 barrier	 sites,	 epithelial	 cells	 are	




their	 release,	 TSLP,	 IL-25	 and	 IL-33	 are	 specifically	 associated	 promoting	 Th2	
differentiation	 (98-108).	 The	 reason	 behind	 this	 specific	 association	 with	 Th2	
responses	 is	 currently	 unclear.	 It	 is	 possible	 that	 factors	 specifically	 expressed	 in	
Th1/Th17	 contexts	 counteract	 or	 regulate	 the	 effects	 of	 the	 epithelial	 cell-derived	





is	 required	 for	 the	 biological	 activity	 of	 TSLP	 (110).	 DC	 and	 CD4+	 T	 cells	 are	major	
cellular	 targets	 of	TSLP,	with	TSLP	shown	 to	promote	Th2-inducing	 ability	 in	mouse	







known	as	Tuft	 cells,	 are	a	 significant	source	of	 IL-25	 in	vivo	(126,	127),	 but	 IL-25	can	
also	 be	 produced	 by	 other	 epithelial	 cells	 (128,	 129).	 Type	 2	 innate	 lymphoid	 cells	
(ILC2)	 are	 a	 population	 of	 tissue-resident	 lymphocytes	 that	 lack	 antigen-specific	
receptors	and	are	highly	responsive	to	IL-25	signalling	(130).	ILC2	expand	and	produce	
Th2	associated	cytokines,	such	as	IL-5	and	IL-13,	in	response	to	IL-25	release	(103,	127,	











33	 exposure	 (144,	 145).	 The	 association	 of	 the	 IL-33/ST2	 axis	 in	 Th2	 immunity	 is	
further	 supported	 by	 the	 observation	 that	 the	 genes	 encoding	 for	 IL-33	 and	 ST2	 are	
associated	with	susceptibility	to	allergic	disease	(146,	147).	
 
1.1.4.2 APC-derived cytokines 
APC	production	of	cytokines	is	essential	for	instructing	the	appropriate	differentiation	
of	naïve	CD4+	T	cells.	The	suite	of	cytokines	produced	by	APC	populations	is	extensive,	
and	 includes	 IL-12	 family	 cytokines,	 IL-6,	 type	 III	 interferons	 and	 tumour	 necrosis	
factor	(TNF)α,	which	are	described	below.	
	
The	 IL-12	 family	 consists	of	heterodimeric	 cytokines	 involved	 in	 supporting	Th1	and	
Th17	 responses	 (1).	The	heterodimeric	nature	of	 IL-12	 family	 cytokines	 requires	 the	
co-ordinated	 expression	 of	 two	 independently	 regulated	α	 and	β	 subunits	within	 the	
same	cell	for	production	of	the	bioactive	molecule	(148-152).	Further,	the	IL-12	family	
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subunits	 are	 promiscuous,	 with	 the	 IL-12b	 (p40)	 subunit	 pairing	with	 either	 IL-12a	
(p35)	 or	 IL-23a	 (p19)	 to	 produce	 functional	 IL-12	 or	 IL-23,	 respectively	 (153,	 154).	
Pairing	of	IL-12a	(p35)	with	Ebi3	gives	IL-35,	which	is	produced	by	Tregs	and	not	APC	






APC-derived	 IL-6	 is	 another	 important	 factor	 involved	 in	 regulating	 CD4+	 Th	 cell	
responses,	 with	 documented	 roles	 in	 supporting	 Th17	 and	 T	 follicular	 helper	 cell	
differentiation	 pathways	 (1).	 IL-6	 expression	 is	 strongly	 induced	 in	 response	 to	 TLR	
engagement	 or	 inflammatory	 mediators	 (158,	 159).	 Two	 pathways	 of	 IL-6	 signalling	
have	 been	 documented,	 involving	 membrane-bound	 or	 soluble	 forms	 of	 the	 IL-6R,	
respectively	(160).	Both	signalling	pathways	are	important	for	the	regulation	of	CD4+	
Th	 cell	 responses,	 with	membrane-bound	 signalling	 involved	 in	 Th17	 differentiation	
from	 naïve	 CD4+	 Th	 cells	 and	 trans-signalling	 (soluble)	 associated	 with	 the	
maintenance	of	Th17	cells	(161).		
	
Type	 III	 interferons	 (IFNλ)	 are	 structurally	 related	 to	 the	 IL-10	 cytokine	 family	 but	
function	in	a	similar	manner	to	other	interferon	species	(discussed	in	sections	1.1.4.4.	
and	1.1.4.5.)	(162).	As	such,	IFNλ	expression	is	associated	with	exposure	to	viral	(163,	
164)	 or	 bacterial	 components	 (165,	 166).	 While	 most	 cell	 types	 are	 capable	 of	
producing	 IFNλ	under	 the	appropriate	 conditions,	DC	are	major	producers	of	 IFNλ	 in	
both	 mice	 and	 humans	 (164,	 167,	 168).	 IFNλ	 species	 signal	 through	 a	 dimerised	
receptor	consisting	of	 IL-28RA	and	IL-10-RB	subunits	(169)	 to	 induce	expression	of	a	
well	characterised	module	of	genes	known	as	interferon-stimulated	genes	(ISGs)	(170).	
In	 terms	 of	 their	 effects	 on	 CD4+	 T	 cell	 differentiation,	 IFNλ	 species	 are	 generally	
thought	to	promote	Th1	differentiation	and	restrict	Th2	differentiation.	Several	papers	
have	reported	expression	of	the	Th2	lineage-defining	transcription	factor,	GATA-3,	and	
Th2	cytokines	were	suppressed	 in	mouse	and	human	CD4+	T	cells	 in	 the	presence	of	
IFNλ	 (171-174).	 Further,	 a	 study	 performed	 in	 a	 mouse	 model	 of	 allergic	 airway	
inflammation	 showed	 that	 IFNλ	 inhibition	 of	 Th2	 differentiation	 occurred	 via	 DC,	
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whereby	IFNλ	promoted	the	up-regulation	of	IL-12p70	and	the	down-regulation	of	the	




TNFα	 is	 a	 pleiotropic	 proinflammatory	 cytokine	 that	 can	 be	 produced	 by	 many	 cell	
types,	including	monocyte-derived	DC	and	plasmacytoid	DC	in	response	to	PAMPs	(175,	
176).	 As	 TNFα	 can	 signal	 through	 either	 TNFR1,	which	 is	 ubiquitously	 expressed,	 or	
TNFR2,	which	 is	 specifically	 expressed	 by	 immune	 cells,	 its	 biological	 effects	 are	 far-










distinct	 groups	 of	 chemokines	 are	 associated	 with	 different	 types	 of	 immunogenic	
challenge.	 The	 chemokines	 CCL17	 and	 CCL22	 are	 closely	 associated	 with	 Th2	
responses,	 with	 elevated	 levels	 present	 in	 serum	 and	 tissue	 samples	 of	 atopic	
dermatitis	and	asthmatic	patients	(185-187).	Peripheral	DC	express	CCL17	and	CCL22	
at	 steady-state	 (188),	 but	 TSLP	 signalling	 significantly	 up-regulates	 both	 transcripts	
(112-115),	 linking	 their	 expression	 with	 a	 Th2-inducing	 environment.	 CCL17	 and	





recruit	 Il4-expressing	Th2	cells	 to	 the	dermis	(194)	and	CCR4	blocking	antibodies	are	
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effective	 at	 reducing	 Th2	 cell	 recruitment	 and	 ameliorating	 inflammation	 in	 allergic	
airway	inflammation	models	(195,	196).		
	
In	 contrast	 to	 CCL17	 and	CCL22,	 CXCL9	 and	CXCL10	 are	 closely	 associated	with	Th1	
responses,	as	their	expression	is	induced	by	IFNγ	signalling	(197,	198).	Both	CXCL9	and	
CXCL10	 signal	 through	 CXCR3,	which	 is	 expressed	 on	Th1	 cells,	 NK	 cells	 (199,	200),	
NKT	cells	(201)	and	CD8+	cytotoxic	T	cells	(202).	CXCR3	signalling	plays	an	important	
role	 in	 recruiting	 these	 cell	 types	 to	 tissues	 undergoing	 infectious	 or	 inflammatory	
processes	(203-205).	In	addition,	CXCL9	and	CXCL10	are	implicated	in	supporting	Th1	
differentiation	by	promoting	the	interaction	between	APC	and	CD4+	Th	cells,	as	well	as	
regulating	 the	 localisation	 of	 recently	 primed	 CD4+	 Th	 cells	 within	 the	 LN	 (206).	
Positioning	of	 primed	Th1	 cells	 in	 interfollicular	 or	medullary	 regions	of	 the	 LN	was	
found	to	be	CXCR3	dependent	(206)	and	may	reinforce	the	Th1	programme	over	other	
Th	 cell	 differentiation	 programmes	 (207).	 Thus,	 chemokine	 signalling	 may	 be	 an	
important	 factor	 in	 regulating	 the	 differentiation	 of	 CD4+	 Th	 cells	 in	 addition	 to	
promoting	their	recruitment	to	inflammatory	sites.	
	
1.1.4.4 Type I interferons (IFN-I) 
IFN-I	are	a	group	of	inflammatory	cytokines	that	can	be	released	from	most	cell	types	




The	 IFN-I	 family	 consists	 of	 13	 closely	 related	 IFNα	 species,	 IFNβ	 and	 a	 number	 of	
poorly	defined	IFN-I	species,	including	IFNδ,	IFNε,	IFNκ,	IFNτ	and	IFNω.	All	IFN-I	signal	
through	 a	 heterodimeric	 receptor	 consisting	 of	 IFNAR1	 and	 IFNAR2	 subunits,	 which	
are	 ubiquitously	 expressed	 (216).	 Within	 target	 cells,	 IFNAR	 signalling	 induces	
expression	 of	 a	 well-defined	 module	 of	 genes,	 collectively	 known	 as	 IFN-stimulated	




The	role	of	 IFN-I	within	the	 immune	system	is	 far-reaching	and	our	understanding	 is	
being	 continually	 refined.	 IFN-I	 production	 is	 one	 of	 the	 first	 indictors	 of	 pathogen	
invasion	and,	as	such,	positively-regulates	 the	expression	of	PRRs	and	their	signalling	
molecules	 in	a	 feed-forward	 loop	(218,	219).	 In	addition,	 IFN-I	have	been	reported	to	
influence	 CD4+	T	 cell	 differentiation	 in	 a	 number	 of	models.	 Firstly,	 IFN-I	 have	 been	
implicated	 in	 supporting	 tolerogenic	 responses	 by	 enhancing	 the	 differentiation	 of	
regulatory	T	cells	in	the	intestine	(220,	221).	Secondly,	IFN-I	synergise	with	IL-18	and	
IL-12	 to	 support	 a	 Th1-inducing	 environment	 in	 vivo	 (222,	 223),	 promoting	 STAT4	
phosphorylation	 which	 is	 required	 for	 the	 initiation	 of	 the	 Th1	 differentiation	
programme	 (224).	 Finally,	 IFN-I	 have	 a	 described	 role	 in	 negatively	 regulating	 Th2	
(225,	226)	 and	Th17	 induction	 (227,	228).	 The	 IFN-I-mediated	 negative	 regulation	 of	
Th2	 differentiation	 is	 due	 to	 the	 active	 suppression	 of	 the	 Th2-lineage	 defining	
transcription	 factor	 GATA-3	 in	 human,	 but	 not	mouse,	 CD4+	T	 cells	 (226).	 However,	





1.1.4.5 Interferon-γ (IFNγ) 
IFNγ	 is	 an	 inflammatory	 cytokine	 central	 to	 anti-viral	 and	 anti-bacterial	 immune	
responses.	Major	sources	of	 IFNγ	 in	vivo	 include	Th1	cells,	NK	cells,	CD8+	T	cells	and	







IFNγ-activated	 macrophages	 up-regulate	 molecules	 associated	 with	 antigen	
presentation	 (239),	 release	 reactive	 oxygen	 species	 and	 have	 enhanced	microbicidal	
activity	(240,	241),	which	together	support	the	resolution	of	infection.	Mice	lacking	the	
Ifng	 gene	 fail	 to	 activate	 macrophages	 and	 rapidly	 succumb	 to	 infection	 with	
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lymphocytic	 choriomeningitis	 virus	 (242)	 or	 Mycobacterium	 bovis	 (243).	 Likewise,	
individuals	with	defects	 in	 IL-12	or	 IFNγ	signalling	are	highly	susceptible	 to	 infection	
with	 Mycobacterium	 species,	 including	 Mycobacterium	 tuberculosis	 (244,	 245).	
Together,	 these	 data	 exemplify	 the	 essential	 and	 non-redundant	 role	 of	 IFNγ	 in	 anti-
viral	and	anti-bacterial	immunity.	
	
1.1.4.6 Th2 cytokines: IL-4, IL-5 and IL-13 
Th2	 cells	 were	 originally	 characterised	 by	 their	 production	 of	 IL-4	 (246),	 but	
subsequent	 studies	 have	 identified	 that	 Th2	 cells	 also	 produce	 IL-5	 and	 IL-13	 (247,	
248).	 All	 three	Th2	 cytokines	 are	 located	 on	 the	 same	 chromosomal	 region,	which	 is	
regulated	 by	 the	Th2	 lineage-defining	 transcription	 factors	GATA-3	 and	 STAT6	 (249-
252).	 Interestingly,	 recent	 studies	 suggest	 that	 the	 spatial	 and	 temporal	 regulation	of	
these	 cytokines	 is	 distinct,	 with	 IL-5	 and	 IL-13	 expression	 detectable	 after	 IL-4	
expression	 (106,	 121,	 253).	 The	 specific	 signals	 involved	 in	 activating	 the	 Th2	
differentiation	 programme	 are	 still	debated	 (section	 1.3.2);	 but,	 as	mentioned	 above,	
TSLP,	 IL-25	 and	 IL-33	 signalling	 can	 directly	 promote	 IL-13	 production	 in	 some	
circumstances	(106,	116-121).		
	
IL-4	 and	 IL-13	 are	 closely	 related	 cytokines	 that	 share	 a	 receptor	 subunit	 and	 signal	
transduction	 pathways	 (254).	 Functionally,	 IL-4	 and	 IL-13	 have	 documented	 roles	
promoting	 IgG1	 and	 IgE	 class-switching	 (255-258),	 as	 well	 as	 co-ordinating	 the	
recruitment	 and	 activation	 of	 mast	 cells	 (259),	 basophils	 (260)	 and	 alternatively	
activated	macrophages	(142,	261,	262).	In	addition,	IL-13	is	associated	with	promoting	









1.1.4.7 Th17 cytokines: IL-17A and IL-17F 
Th17	cells	are	characterised	by	their	production	of	IL-17A	and	IL-17F,	which	are	part	of	
the	 IL-17	 cytokine	 family.	 IL-17A	 and	 IL-17F	are	 closely	 related	 cytokines	 that	 share	
sequence	homology,	chromosomal	location	and	form	homodimers	for	signalling	(270).	
Interestingly,	there	have	been	also	reports	of	IL-17A	forming	heterodimers	with	IL-17F,	
which	were	more	 prevalent	 from	 fully	 differentiated	Th17	 cells	 (271).	Multiple	APC-







and	 inflammatory	 chemokines	 (281).	 This	 process	 is	 particularly	 important	 for	





1.1.5 Activation of T lymphocytes 
T	lymphocytes	are	a	major	component	of	cell-mediated	immunity	and	are	identified	by	
expression	of	a	T	cell	receptor	(TCR).	Distinct	populations	of	conventional	T	cells	are	
associated	 with	 protective	 immunity	 against	 different	 types	 of	 pathogens.	 CD8+	
cytotoxic	 T	 lymphocytes	 are	 highly	 efficient	 at	 killing	 virus	 infected	 cells	 via	
granzyme/perforin	or	Fas/FasL	dependent	mechanisms	(287,	288),	whereas	CD4+	Th	





specific	 T	 cells.	 Rearrangement	 of	 gene	 segments	 encoding	 the	T	 cell	 receptor	 (TCR)	
creates	 a	 vast	 repertoire	 of	 T	 cells,	 each	with	 specificity	 to	 a	 different	 antigen	 (289).	
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Peptide-MHC	complexes	on	APC	transiently	interact	with	T	cells	until	they	coming	into	
contact	 with	 a	 cognate	 TCR.	 This	 binding	 promotes	 the	 formation	 of	 a	 cluster	 of	
interactions	 allowing	 for	 directed	 signalling	 between	 the	 APC	 and	 T	 cell	 (290).	 In	
addition	 to	 TCR	 engagement	 by	 peptide-MHC	 complexes,	 APC	 provide	 further	
stimulatory	signals	to	T	cells	via	contact-dependent	interactions	to	ensure	sufficient	T	
cell	 activation	 and	 prevent	 anergy	 (291,	 292).	 A	 number	 of	 these	 co-stimulatory	
interactions	have	been	documented	and	include:	APC-CD80/86	with	T	cell-CD28	(293),	
APC-CD40	with	T	 cell-CD40L	 (294)	 and	APC-OX40L	with	T	 cell-OX40	 (295).	CD4+	Th	
cells	 require	 additional	 signals	 from	 APC	 to	 instigate	 the	 appropriate	 differentiation	
programme.	This	aspect	of	CD4+	T	cell	responses	is	covered	in	detail	in	section	1.3.	
	
1.1.6 T cell-dependent activation of B lymphocytes 
The	 other	 arm	 of	 the	 adaptive	 immune	 response	 is	 humoral	 immunity,	 which	 is	
mediated	by	B	cells	and	their	production	of	antigen-specific	antibodies.	As	with	CD4+	T	
lymphocytes,	 the	 specificity	 of	 the	 B	 cell	 response	 exists	 at	 two	 levels:	 (1)	 antigen-
specificity	 is	 mediated	 by	 immunoglobulin	 gene	 rearrangement	 and	 somatic	
hypermutation	to	generate	high	affinity	antibodies;	(2)	context-specificity	is	mediated	





initiated	 by	 B	 cell	 receptor	 recognition	 of	 free	 soluble	 antigen	 (301)	 or	 antigen	
associated	with	APC	(302-305)	or	follicular	DC	(306).	Activated	B	cells	re-localise	to	the	
B-T	 border	 in	 a	 CCR7-dependent	 manner	 to	 interact	 with	 antigen-specific	 Tfh	 cells	
(307)	which	provide	vital	 signals	 for	B	 cell	 survival,	differentiation	and	proliferation.	
CD40	stimulation	by	Tfh	cells	is	necessary	for	the	survival	(308)	and	proliferation	(309,	
310)	of	B	cells	and	the	formation	of	germinal	centres	(GC)	(311)	where	activated	B	cells	
undergo	 somatic	 hypermutation	 (312).	 IL-21-derived	 from	 Tfh	 is	 also	 an	 important	
survival	 and	 proliferative	 signal	 for	 GC	 B	 cells	 (313,	 314).	 Context-specific	 cytokines	
produced	 by	 Tfh	 cells	 regulate	 the	 appropriate	 immunoglobulin	 class-switching	 of	
activated	B	cells,	with	IFNγ	shown	to	promote	IgG2a	class-switching	and	IL-4	shown	to	
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promote	 IgG1	 and	 IgE	 class-switching	 (315).	 During	 iterative	 cycles	 of	 somatic	
hypermutation	 within	 the	 GC,	 Tfh	 select	 for	 B	 cells	 with	 the	 highest	 affinity	 class-
switched	antibodies.	Following	this	process,	IL-21	produced	by	Tfh	cells	then	facilitates	





1.2 Cutaneous immunity 
The	skin	serves	as	a	physical	and	immunological	barrier	that	is	required	to	orchestrate	
protective	 immunity	against	pathogenic	 insults	and	exclude	commensal	microbes	and	
environmental	antigens.	Healthy	skin	consists	of	 two	anatomically	distinct	 layers:	 the	
epidermis,	 an	 avascular	 layer	 made	 up	 of	 keratinocytes;	 and	 the	 dermis,	 a	 highly	
vascularised	layer	consisting	of	fibroblasts	and	a	network	of	collagen	and	elastin	fibres	
(14).	 The	 structure	 of	 the	 skin	 is	 similar	 between	 mice	 and	 humans,	 allowing	 for	
relevant	 and	 translational	 study	 of	 cutaneous	 immune	 responses	 in	 mouse	 models	
prior	 to	 human	 testing.	 However,	 it	 should	 be	 noted	 that	 there	 are	 some	 marked	
differences	between	the	skin	of	mice	and	humans.	Most	notably,	mouse	skin	is	densely	
populated	 with	 hair	 follicles,	 whereas	 human	 skin	 has	 large	 inter-follicular	 regions	
containing	 ridge-like	 structures,	 known	 as	 papillae.	 Papillae	 provide	 the	 skin	 with	
tensile	 strength	 (317,	 318)	 and	 increase	 the	 dermal	 capillary-epidermis	 interface	 to	







cells	 (14,	 321).	 An	 additional	 skin-resident	 T	 cell	 population,	 known	 as	 γδ	 dendritic	
epidermal	T	cells	(DETCs),	is	also	found	in	the	epidermis,	but	only	in	mice	(322).	With	a	
repertoire	 of	 PRRs,	 keratinocytes	 possess	 immunological	 functions	 and	 produce	
inflammatory	 chemokines	 and	 cytokines,	 such	 as	 TSLP,	 in	 response	 to	 pathogenic	
stimuli	(323).		
	
The	 dermis	 is	 populated	 with	 a	 diverse	 range	 of	 immune	 cells	 (14,	 321),	 including	
dermal	 DC	 subsets	 (reviewed	 in	 section	 1.5)	 (324),	 macrophages,	 mast	 cells,	 type	 2	
innate	 lymphoid	 cells	 (325),	 αβ	 T	 cells	 and	 γδ	 T	 cells	 (326).	 Inflammatory	 signalling	
rapidly	 recruits	 neutrophils	 and	monocytes	 into	 the	 dermis	 to	 assist	with	 containing	
and	 resolving	 infection	 (53,	327,	328).	 Inflammation	also	enhances	 the	activation	and	
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pathogens,	 including:	 bacteria	 (Staphylococcus	 aureus,	 Mycobacterium	 leprae),	
intracellular	 parasites	 (Leishmania	 major),	 helminths	 (hookworm),	 fungi	 (Candida	
albicans)	and	viruses	(Herpes	simplex;	HSV).	Experimentally,	the	immune	response	to	
cutaneous	infection	or	immunisation	is	studied	using	mouse	models	where	pathogens	
are	 applied	 epicutaneously	 to	mechanically	 disrupted	 skin	 (331)	 or	 injected	 directly	
into	 the	 dermis	 (332,	 333).	 Th1	 responses	 are	 associated	 with	 bacterial	 infection	 or	
immunisation,	 which	 are	 modelled	 in	 mice	 by	 injecting	 laboratory	 S.	 aureus	 strains	
(327)	or	non-pathogenic	Mycobacterium	species	such	as	M.	smegmatis	(333)	or	Bacillus	
Calmette-Guérin	 (BCG)	 (111,	 326,	 332).	 In	 contrast,	 helminths	 and	 their	 associated	
products	drive	strong	Th2	responses.	Some	helminths,	such	as	the	hookworm	Necator	
americanus,	enter	their	host	through	the	skin	at	a	larval	stage,	before	progressing	to	the	
lung	and	 intestine,	where	 they	mature	 (334).	Nippostrongylus	brasiliensis	 is	used	as	a	
model	of	human	hookworm	in	rodents	(335),	with	injection	of	live	or	non-viable	larvae	
shown	 to	 drive	 Th2	 responses	 in	 the	 skin-dLNs	 (333,	 336-338).	 Cutaneous	 Th17	




also	occur	 in	 the	 skin.	 Atopic	 dermatitis	 (AD)	 is	 an	 inflammatory	 skin	 condition	 that	
often	precedes	the	onset	of	other	allergic	diseases,	such	as	asthma	and	food	allergy.	AD	
is	 characterised	 by	 dry	 pruritic	 lesions,	 skin	 barrier	 dysfunction	 and	 the	
overexpression	of	Th2	cytokines	(340).	Consequently,	mast	cells	and	eosinophils	are	a	
component	 of	 the	 associated	 inflammatory	 infiltrate	 and	 the	majority	 of	 AD	patients	
have	elevated	serum	IgE	(341).	Allergic	immune	responses	can	be	modelled	in	the	skin	
of	 mice	 by	 intradermally	 injecting	 known	 allergens	 (336)	 or	 by	 topically	 applying	








23	 and	 the	 IL-23	 receptor	 have	 associations	 with	 PV	 (347,	 348)	 and	 are	 known	 to	
support	 the	 inflammatory	 roles	of	Th17	cells	 (349).	As	 such,	 the	 IL-23/Th17	axis	has	
become	the	central	focus	for	the	treatment	of	PV,	with	monoclonal	antibodies	targeting	
IL-23	 and	 IL-17	 approved	 for	 use	 in	 the	 clinic	 (350-354).	 In	 mice,	 PV	 is	 modelled	
through	application	of	the	TLR7	ligand	imiquimod,	which	drives	a	strong	inflammatory	




number	 of	 distinct	 insults.	 The	 accessibility	 of	 the	 skin	 for	 easy	 therapeutic	
intervention	makes	it	an	attractive	route	for	the	administration	of	immune-modulating	
therapies	and	preventative	vaccines.	Thus,	 an	understanding	how	cutaneous	 immune	





1.3 Context-specific activation of CD4+ T lymphocytes 




subsets	 that	 are	 identifiable	 by	 their	 signature	 cytokine	 profiles	 (246).	 Since	 then,	 a	
growing	 body	 of	 literature	 has	 demonstrated	 the	 involvement	 of	 APC-derived	




development	 of	 highly	 sensitive	 single-cell	 technologies	 will	 likely	 uncover	 further	
functional	distinctions	among	CD4+	T	cells	and	better	characterise	the	context-specific	
nature	 of	 CD4+	 T	 cell	 responses.	 Indeed,	 there	 is	 a	 documented	 degree	 of	 plasticity	
between	these	seven	subsets,	whereby	CD4+	T	cells	can	display	transcriptional	profiles	
and	 functions	associated	with	more	 than	one	subset	 (315,	360-362)	or	be	 re-directed	
from	one	subset	 to	another	depending	exogenous	cues	(363-366).	Thus,	 the	extent	by	








Figure	1.3:	 CD4+	T	 cells	 differentiate	 into	 functionally	 distinct	 subsets	 depending	 on	 the	 context	of	 their	






1.3.1 Th1 cells 
Th1	are	defined	by	their	production	of	 IFNγ	(246)	 and	are	associated	with	protective	
immunity	against	intracellular	pathogens	including	bacteria,	viruses	and	protozoa	(2).	
Th1-derived	 IFNγ	 promotes	 the	 resolution	 of	 infection	 by	 inducing	 anti-microbial	
activity	by	macrophages	(240,	367-369)	and	supporting	IgG2a	class-switching	 in	mice	
(256,	 257)	 and	 IgM,	 IgG	 and	 IgA	 class-switching	 in	 humans	 (370).	 The	 Th1	
transcriptional	programme	is	invoked	by	the	Th1	lineage-defining	transcription	factor	
Tbet	 (371),	 which	 is	 up-regulated	 in	 response	 to	 IFNγ	 (372,	373)	 or	 IL-27	 signalling	
(374).	Tbet	permits	expression	of	IL-12Rβ	(375),	rendering	pre-Th1	cells	responsive	to	
IL-12	signalling	which	is	essential	for	Th1	differentiation	and	IFNγ	production	in	both	
mice	 and	 humans	 (236,	376).	However,	 in	vivo	 data	 suggest	 that	 there	 is	 a	 degree	 of	
redundancy	in	promoting	Th1	differentiation,	with	IL-12,	IFNγ	and	IL-27	all	implicated	
in	promoting	Tbet	expression	 (377)	 and	 IFN-I	shown	 to	promote	 IFNγ	production	by	
human	CD4+	T	cells	(378,	379).	
	
1.3.2 Th2 cells 
Th2	cells	produce	IL-4,	IL-5	and	IL-13	(246)	and	are	associated	with	helminth	infection,	
exposure	 to	 venoms	 and	 allergic	 disease	 (380).	 The	 transcription	 factor	 GATA-3	 is	
central	 to	 Th2	 differentiation,	 promoting	 the	 transcription	 of	 the	 Th2-characteristic	
cytokines	 while	 preventing	 polarisation	 into	 other	 T	 helper	 subsets	 (250,	 251,	 381).	




that	 the	Th2	 population	 is	 heterogeneous,	 containing	 subpopulations	 of	 effector	 Th2	
cells	 with	 distinct	 cytokine	 profiles	 as	 well	 as	 T	 follicular	 helper	 (Tfh)	 cells,	 which	
support	antibody	production	(253,	385,	386).	 In	 the	LN,	 the	majority	of	 IL-4+	CD4+	T	
cells	express	features	of	Tfh	cells,	including	expression	of	BCL6,	CXCR5,	PD1	and	IL-21	
(387-390)	 (discussed	 further	 in	 section	 1.3.5),	 whereas	 effector	 Th2	 subsets	 are	
detected	in	tissues	(253).	The	distinguishing	features	of	effector	Th2	cells	and	IL-4+	Tfh	
cells	suggests	that	additional	layers	of	regulation	are	involved	in	the	generation	of	Th2	
responses.	 Indeed,	 the	 epithelial	 cell	 derived	 cytokines	 TSLP,	 IL-25	 and	 IL-33	 are	
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required	 for	 inducing	 IL-5	 and	 IL-13	 expression	 by	 CD4+	 T	 cells	 (106,	 121).	 This	
effector	 “checkpoint”	 is	 potentially	 regulated	 by	 distinct	 transcriptional	 modulators,	
such	 as	 the	 nuclear	 receptor	 peroxisome	 proliferator	 activated	 receptor-γ	 (PPARγ),	
which	is	required	for	allergic	and	anti-helminth	Th2	responses	through	its	regulation	of	
the	IL-33	receptor	on	CD4+	T	cells	(391).	In	addition,	a	recent	study	has	demonstrated	











402).	 However,	 while	 these	 studies	 suggest	 that	 OX40	 signalling	 may	 support	 Th2	
responses,	it	is	unclear	whether	that	role	is	specifically	promoting	Th2	polarisation	or	
merely	co-stimulatory	(403).	The	report	that	OX40L	deficient	APC	fail	to	induce	T	cell	
proliferation	suggests	 that	 the	primary	role	 for	OX40	 is	as	a	co-stimulatory	signalling	
molecule	 (404).	 Thus,	 further	 investigation	 into	 OX40	 signalling	 is	 required	 to	
determine	its	role	in	regulating	CD4+	T	cell	differentiation.		
	
1.3.3 Th17 cells 
Th17	cells	are	characterised	by	production	of	IL-17	(227,	276)	and	are	associated	with	
resolving	 extracellular	 bacterial	 and	 fungal	 infections	 through	 the	 recruitment	 and	
activation	 of	 neutrophils	 (281,	 405).	 Th17	 cells	 are	 also	 strongly	 implicated	 in	
pathogenesis	of	 autoimmune	diseases,	with	aberrant	 IL-17	production	determined	 to	
be	 a	 significant	 cause	 of	 pathology	 in	 multiple	 sclerosis	 (406),	 rheumatoid	 arthritis	
(407)	and	psoriasis	(408).	IL-6	and	TGFβ	were	initially	identified	as	critical	signals	for	
Th17	differentiation	 in	vitro	 (276-278)	 and	were	 found	 to	 promote	 expression	 of	 the	
Th17	 lineage-defining	 transcription	 factor	 RORγt	 (409,	 410).	 However,	 subsequent	
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studies	 have	 demonstrated	 that	 IL-1,	 IL-21	 and	 IL-23	 can	 also	 support	 Th17	
differentiation	in	combination	with	IL-6	or	TGFβ	(272-275).	It	is	not	clear	whether	the	
specific	 combination	 of	 differentiation	 signals	 impacts	 the	 function	 of	 the	 resulting	
Th17	cells.	A	transcriptomic	comparison	of	in	vitro	generated	Th17	cells	induced	with	
IL-23/IL-6	or	IL-6/TGFβ	revealed	2000	differentially	expressed	genes	(272),	suggesting	
that	 functional	 differences	may	 exist.	 Interestingly,	 IL-23/IL-6	 Th17	 cells	 specifically	
expressed	Tbx21	(Tbet)	and	Cxcr3	and	could	produce	IFNγ	in	response	to	IL-12	(272).	
The	identification	of	Tbet+	Th17	cells	with	the	capacity	to	produce	IFNγ	in	autoimmune	
settings	 suggests	 that	 these	 multi-functional	 Th17	 cells	 may	 represent	 a	 pathogenic	
CD4+	 T	 cell	 subset	 (272,	366,	 411).	 Indeed,	 fate-mapping	 of	 IL-17-producing	 CD4+	 T	
cells	 did	 not	 detect	 deviation	 in	 cytokine	 production	 in	 a	 C.	 albicans	 yeast	 infection	
model	 (366).	 As	 IL-6	 or	 IL-21	 signalling	 promotes	 the	 up-regulation	 of	 the	 IL-23	
receptor	on	CD4+	T	cells	(412),	it	is	thought	that	IL-23	serves	as	a	secondary	activation	
signal	 to	 promote	 production	 of	 inflammatory	 cytokines	 by	 Th17	 cells	 (349)	 and,	
therefore	is	a	useful	target	for	regulating	Th17	responses	(413,	414).		
	
1.3.4 Th9 and Th22 cells 
CD4+	T	cell	production	of	IL-9	or	IL-22	has	previously	been	attributed	to	Th2	and	Th17	
cells,	 respectively.	 However,	 new	 evidence	 suggests	 that	 IL-9	 and	 IL-22-producing	
CD4+	T	cells	represent	distinct	Th	subsets	termed	Th9	(415)	and	Th22	cells	(182,	416).	
Like	 Th2	 cells,	 Th9	 cells	 are	 associated	 with	 helminth	 infection	 and	 allergic	 disease	
(417,	418),	but	require	IL-4	and	TGFβ	signalling	(415,	419)	as	well	as	the	transcription	
factor	Pu.1	for	their	development	(420).	Th22	cells	have	a	specific	role	in	maintaining	
barrier	 homeostasis,	 promoting	 anti-microbial	 peptide	 release	 in	 infectious	 settings	
(421-424)	as	well	as	tissue	repair	processes	(182,	425).	The	aryl	hydrocarbon	receptor	
(Ahr)	 is	required	 for	Th22	development	(184,	426,	427),	 as	 is	 IL-6	and	TNF	signalling	
(175,	183).		
	
1.3.5 Regulatory CD4+ T cells (Tregs) 
Effector	 CD4+	 T	 cells	 support	 antibody	 production	 and	 promote	 immune	 cell	
recruitment	 and	 activation.	 These	 functions	 are	 only	 required	 in	 the	 context	 of	 a	
pathogenic	 insult	 and	can	cause	significant	 tissue	damage	 if	 initiated	 inappropriately.	
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Tregs	are	a	 subset	of	CD4+	T	 cells	 that	play	a	key	 role	 in	maintaining	 immunological	
tolerance	 to	 self	 and	 innocuous	 antigens.	 This	 function	 is	 achieved,	 in	 part,	 through	
production	of	anti-inflammatory	cytokines,	such	as	IL-10	and	TGFβ	(428,	429).	Natural	
Tregs	 develop	 in	 the	 thymus	 during	 the	 process	 of	 negative	 selection,	 whereby	 all	
newly	developed	T	cells	are	tested	for	reactivity	to	self-antigens	prior	to	being	released	
into	 circulation.	 Strong	 reactivity	 results	 in	 apoptosis,	 whereas	 strong-intermediate	
TCR	 affinity	 induces	 natural	 Tregs	 (430).	 In	 the	 periphery,	 naïve	 CD4+	 T	 cells	
differentiate	into	inducible	(i)Tregs	under	specific	conditions.	Like	effector	Th	cells,	the	
signals	 received	 by	 the	 CD4+	 T	 cell	 during	 antigen	 presentation	 regulates	 the	
differentiation	 process,	 with	 TGFβ	 and	 IL-2	 signalling	 a	 strong	 determinant	 of	 iTreg	
differentiation	through	induction	of	the	Treg-defining	transcription	factor	FoxP3	(431-




1.3.6 T follicular helper (Tfh) cells 
An	important	function	of	CD4+	T	cells	is	to	support	B	cell	function,	germinal	centre	(GC)	
formation,	 class	 switching	 and	 affinity	 maturation	 (84,	 85,	 438).	 Recently,	 a	 distinct	
subset	of	CD4+	T	cells	that	specialise	in	promoting	B	cell	responses	has	been	identified	
and	characterised	(389,	390,	439).	Tfh	cells	can	be	distinguished	from	other	lineages	of	












The	 differentiation	 pathway	 of	 Tfh	 cells	 is	 a	 multistep	 process	 that	 involves	 many	
signals.	 During	 the	 priming	 of	 naïve	 CD4+	 T	 cells	 by	 APC,	 IL-6	 and	 inducible	 co-
stimulator	(ICOS)	signalling	are	vital	 for	 initiating	the	Tfh	differentiation	programme,	
by	promoting	expression	of	BCL6,	CXCR5	and	IL-21	(390,	393-396).	An	IL-21	autocrine	
signalling	 loop	 acts	 as	 a	 growth	 factor	 for	 Tfh	 cells,	 further	 supporting	 their	
differentiation	 (396).	 Additional	 signals	 have	 also	 been	 implicated	 in	 positively	
supporting	Tfh	differentiation	in	vivo,	including	IFN-I,	IL-27	and	Notch	signalling	(445-
447).	 In	 contrast,	 IL-2	 is	 a	 potent	 inhibitor	 of	Tfh	 differentiation	 (389,	448)	 and	Tfh-




Tfh	 differentiation	 programme,	 with	 the	 presence	 of	 B	 cells	 essential	 for	 Tfh	
development	(207,	450).	B	cells	serve	as	APC	and	provide	ICOSL	stimulation	(390,	393,	
451)	to	ensure	effective	proliferation	and	differentiation	of	Tfh	cells.	The	co-evolution	
of	 Tfh	 and	 B	 cell	 responses	 is	 evident	 from	 studies	 showing	 that	 the	 phenotype,	
cytokine	 profile	 and	 positioning	 of	 Tfh	 cells	 alters	 according	 to	 the	 stage	 of	 the	 GC	
reaction	(452).		
	










1.4 APC regulation of CD4+ T cell differentiation 
The	 APC-derived	 signals	 involved	 in	 initiating	 distinct	 CD4+	 T	 cell	 differentiation	
pathways	 have	 been	 established	 and	well	 characterised.	 The	 exception	 to	 this	 is	 the	
Th2	differentiation	pathway,	where	 there	remain	a	number	of	questions	 surrounding	
the	 involvement	 of	 specific	 instructive	 signals.	 In	 addition,	 it	 is	 unclear	what	 factors	
govern	 the	 expression	 of	 APC-derived	 differentiation	 signals	 in	 vivo.	 A	 number	 of	
hypotheses	 relating	 to	 these	 questions	 have	 been	 proposed	 and	 include:	 (1)	 the	
existence	of	specialised	and	functionally	pre-programmed	APC	subsets,	 (2)	 functional	
conditioning	 of	 APC	 by	 antigenic	 or	 environmental	 cues	 and	 (3)	 the	 strength	 of	






Figure	1.4:	Hypotheses	 pertaining	 to	APC	 regulation	of	 CD4+	T	 cell	differentiation.	 (1:	APC	lineage-defined	
specialisation)	Developmentally	distinct	APC	subsets	specialise	in	promoting	the	differentiation	of	a	particular	CD4+	
T	 cell	 phenotype	 upon	 activation.	 (2:	 Context-specific	 conditioning	 of	 APC)	 Antigenic	 and	 environmental	 cues	
regulate	APC	function,	activating	the	programme	required	to	promote	a	context-appropriate	CD4+	T	cell	response.	




1.4.1 APC lineage-defined regulation of CD4+ T cell differentiation 
APC	 include	 populations	 of	 DC	 and	 monocytes,	 each	 with	 the	 potential	 to	 express	
differentiation	signals	and	regulate	CD4+	T	cell	responses.	Further,	the	DC	population	
consists	 of	 many	 developmentally	 and	 phenotypically	 distinct	 subsets	 that	 can	 be	
defined	 by	 the	 transcription	 factors	 involved	 in	 their	 development	 (460).	 Whether	




phenotypes	 was	 noted	 when	 different	 APC	 subsets	 were	 targeted	 (461),	 attributing	
functional	specialisations	to	each	APC	subset.	This	is	reviewed	in	detail	in	section	1.5.		
	
Moreover,	 transcriptomic	 analysis	 of	 APC	 populations	 has	 revealed	 that	 each	 subset	
has	a	distinct	repertoire	of	PRRs	(462-466),	which	would	suggest	a	specialised	ability	to	
recognise	and	respond	to	different	stimuli.	However,	the	functional	characterisation	of	
these	 observations	 is	 somewhat	 lacking,	 particularly	 in	 relation	 to	 CD4+	 T	 cell	
responses.	It	has	been	shown	that	different	subsets	of	lung	DC	are	required	to	respond	
to	TLR3	and	TLR7	ligands	 in	order	to	 induce	a	CD8+	cytotoxic	T	cell	response	 in	vivo	
(467),	 which	 is	 consistent	with	 the	 reported	 dichotomic	 expression	 of	Tlr3	 and	Tlr7	
transcripts	by	the	DC	subsets	investigated	(460,	463).	Similarly,	cytokine	production	in	




1.4.2 Conditioning of APC function by signals from antigenic and environmental cues 




factor	 in	 the	 regulation	 of	 CD4+	 T	 cell	 responses.	 There	 are	 many	 examples	
demonstrating	that	engagement	of	different	PRRs	 leads	to	context-specific	expression	




of	 fungal	 associated	 PRRs	 is	 shown	 to	 support	 IL-6	 and	 IL-23	 production,	which	 are	
involved	 in	 Th17	 differentiation	 (150,	 339,	 473).	 Further,	 helminths	 or	 helminth-
derived	products	 confer	APC	with	 the	ability	 to	 induce	Th2	differentiation	 (333,	476-
478),	although	the	mechanism/s	by	which	this	occurs	are	currently	unknown.	
	
In	 addition	 to	 directly	 affecting	 APC	 function,	 PAMPs	 and	 DAMPs	 can	 profoundly	
influence	 APC	 function	 indirectly	 through	 the	 context-specific	 response	 of	 other	 cell	
types.	Epithelial	cells	play	an	important	role	in	responding	to	cellular	damage	through	
the	 release	 of	 soluble	 mediators,	 such	 as	 TSLP,	 IL-25	 and	 IL-33	 (90).	 Th2-inducing	
organisms	and	agents	seemingly	lack	the	conserved	structures	recognised	by	“classic”	
PRRs	 but	 are	 associated	 with	 tissue	 damage.	 Large	 multi-cellular	 organisms	 cause	
















on	 ILC2,	 promoting	 their	 activation	 and	 production	 of	 IL-5	 and	 IL-13	 (103,	106,	138,	




of	 polarising	 molecules.	 The	 involvement	 of	 innate	 immune	 populations	 in	 tailoring	
immune	responses	is	explored	further	in	section	1.6.	
	
1.4.3 TCR signal strength, antigen availability and co-stimulation in the regulation of CD4+ 
T cell differentiation 
Several	 lines	of	evidence	have	 indicated	that	 the	strength	of	 interaction	between	APC	
and	CD4+	T	cells	may	be	an	additional	determinant	of	CD4+	T	cell	differentiation	(490).	
Experiments	in	which	the	dose	of	antigen	or	the	number	of	T	cells	was	titrated	showed	
that	 lower	availability	of	 antigen,	 low	TCR	avidity	or	higher	numbers	of	T	 cells	were	
associated	 with	 the	 generation	 of	 Th2	 and	 iTreg	 cells.	 Conversely,	 high	 antigen	
availability,	high	TCR	avidity	and	lower	T	cell	numbers	were	associated	with	Th1,	Th17	
and	 Tfh	 responses	 (491-499).	 Furthermore,	 T	 cells	 destined	 for	 Th1	 differentiation	
were	found	to	have	longer	contact	times	with	DC	than	Th2	cells;	and	Th1-inducing	DC	
expressed	 higher	 levels	 of	 co-stimulatory	 molecules	 compared	 to	 Th2-inducing	 DC	
(498).	 Interestingly,	 CD4+	 T	 cells	 expressing	 identical	 TCRs	 give	 rise	 to	 effector,	
memory	 and	 follicular	 phenotypes	 in	 vivo	 despite	 being	 stimulated	 with	 the	 same	





1.5 Regulation of CD4+ T cell responses by skin-derived DC subsets  
DC	 are	 particularly	 potent	 APC	 that	 are	 involved	 in	 the	 induction	 of	 CD4+	 T	 cell	
responses	 (9,	 11,	 500).	 The	 skin	 harbours	 four	 phenotypically	 and	 developmentally	
distinct	DC	subsets:	one	in	the	epidermis	and	three	in	the	dermis	(501).	Epidermal	DC,	
known	 as	 Langerhans	 cells,	 are	 unique	 to	 the	 skin,	whereas	dermal	DC	 subsets	 align	
with	subsets	found	in	the	lung,	intestine	and	other	tissues.	DC	in	the	skin-dLNs	can	be	
classified	 into	 the	 four	 skin-derived	 migratory	 (mig)	 DC	 subsets,	 as	 well	 as	 two	 LN	
resident	 subsets	 that	 closely	 align	with	 the	well	 characterised	 splenic	DC	 subsets.	 In	
addition,	 a	 small	 population	 of	 plasmacytoid	 DC	 can	 also	 be	 resolved	 from	 LN	







migrate	 to	 the	 skin-dLNs	where	 they	 interact	with	T	 cells.	The	 LN	also	 contains	 two	 populations	 of	 resident	 DC,	
resDC1	and	resDC2,	that	are	related	to	splenic	DC	subsets.	Small	numbers	of	pDC	can	also	be	found	in	the	LN.		 	
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1.5.1 Langerhans cells 
Langerhans	 cells	 (LC)	 are	 the	 only	 DC	 subset	 located	 in	 the	 epidermis	 and	 are	
identifiable	 by	 cell	 surface	 expression	 of	 langerin	 (CD207),	 E-cadherin,	 CD205	 and	
CD326	 (502-508).	 Unlike	 conventional	 DC,	 LC	 are	 continually	 replenished	 from	 a	
precursor	pool	(509)	that	is	seeded	into	the	epidermis	by	fetal	liver	monocytes	and	yolk	
sac	macrophages	during	embryonic	development	 (510,	511).	 Further,	LC	 rely	on	GM-
CSF,	 IL-34	 and	 TGFβ	 rather	 than	 Flt3L	 for	 their	 development	 (504,	512-515).	 LC	 are	
radio-resistant,	 which	 allows	 for	 the	 use	 of	 chimeric	 mouse	 model	 systems	 to	
specifically	 assess	 LC	 function	 in	 vivo	 (509).	 Conversely,	 the	 survival	 and	 antigen	




Due	 to	 their	 positioning	 in	 the	 epidermis,	 LC	 are	 the	 first	 line	 of	 defence	 against	
invading	 pathogens	 and	 as	 such	 regularly	 sample	 antigen	 by	 projecting	 dendrites	
through	tight	junctions	into	the	cornified	epithelial	layer	(520,	521).	Following	antigen	







psoriatic	 lesions	 contain	 high	 numbers	 of	 LC	 in	 humans	 (524).	 Additional	 studies	 in	
mice	have	shown	that	LC	are	a	major	source	of	IL-6	and	specific	depletion	of	LC	in	the	
context	of	an	epicutaneous	yeast	infection	significantly	reduces	the	number	Th17	cells	
in	 the	 dLNs	 (331,	339).	 Other	 studies	have	 shown	 that	 LC	 play	 a	 role	 in	 driving	Th2	
associated	 immune	 responses	 following	 epicutaneous	 application	 of	 protein	 antigen	






led	 to	 a	 reduced	 number	 of	 Tregs	 and	 improved	 effector	 immune	 responses	 in	 a	
Leishmania	major	 model	 (527).	 Further,	 LC	 were	 found	 to	 mediate	 the	 induction	 of	




that	 even	 after	 activation	with	 adjuvants,	 LC	 failed	 to	 induce	 an	 effector	 or	memory	
CD4+	T	cell	responses	(529).	Thus,	 the	 function	of	LC	 in	 the	regulation	of	CD4+	T	cell	
differentiation	appears	to	be	diverse	and	dependent	on	context-specific	signals.		
	
1.5.2 Dermal DC1 
Conventional	DC	 are	 derived	 from	bone	marrow	pre-DCs	 and	 rely	 on	 Flt3L	 for	 their	
development	 (513,	 530).	 A	 subset	 of	 conventional	 DC	 additionally	 require	 the	
transcription	 factors	 IRF8	 (531,	532),	 Id2	 (533,	534),	 BATF3	 (64,	513,	535)	 and	BCL6	
(536)	 for	 their	 development.	 These	DC	 are	 collectively	 known	 as	 the	 peripheral	DC1	
subset	and	are	closely	related	to	the	CD8α+	lymphoid	DC1	lineage	(513,	535).	A	recent	
comprehensive	analysis	of	DC	subsets	has	 identified	XCR1	to	be	a	unifying	marker	of	
DC1	 across	 tissues	 and	 species	 (507).	 In	 the	 periphery,	 the	 majority	 of	 murine	 DC1	





MHCI	 molecules	 to	 CD8+	 T	 cells	 (64,	 535,	 540),	 a	 function	 which	 vital	 for	 the	
development	of	anti-viral	and	anti-tumour	 immune	responses	(541-543).	DC1	are	the	
only	dermal	DC	subset	that	induces	significant	CD8+	T	cell	proliferation	in	response	to	
HSV	 (544),	 indicating	 that	 cross-presentation	 is	 a	 specialised	 function	of	dermal	DC1.	
Indeed,	dermal	DC1	efficiently	cross-present	antigens	derived	from	keratinocytes	(545)	




In	 addition	 to	 their	 cross-presenting	 capacity,	 DC1	 are	 thought	 to	 be	 a	 significant	
source	of	the	Th1-polarising	cytokine	IL-12	(549-551).	However,	it	should	be	noted	that	
the	majority	of	 this	 evidence	has	been	derived	 from	a	mouse	strain	 that	only	 reports	
expression	 of	 the	 IL-12b	 subunit.	 Despite	 this,	 DC1-derived	 IL-12	 has	 a	 documented	
role	in	supporting	Th1	development	(331,	551-553)	and	NK	cell	activation	(486),	while	
suppressing	Th2	responses	(550).	Indeed,	BATF3-KO	mice,	that	have	significantly	fewer	
dermal	DC1	compared	 to	WT	mice,	 fail	 to	develop	 IFNγ+	Th1	cells	 in	 response	 to	an	
epicutaneous	C.	albicans	 infection	(331)	or	an	 intradermal	L.	major	 infection	(551).	 In	
the	 L.	 major	 model,	 this	 resulted	 increased	 pathology	 and	 a	 failure	 to	 control	 the	




1.5.3 Dermal DC2 
The	other	population	of	conventional	DC	are	known	as	DC2	and	are	identifiable	across	
tissues	and	species	by	expression	of	CD172a	(signal	regulatory	protein	(SIRP)α)	(507).	




hypothesis	 that	 murine	 DC2	 may	 be	 derived	 from	 developmentally	 distinct	 subsets	
(554).	 Indeed,	 a	 number	 of	 different	 transcription	 factors	 have	 been	 implicated	 in	
regulating	 DC2	 development	 and	 function,	 including	 IRF4	 (555),	 Notch2	 (556)	 and	
KLF4	 (557).	 IRF4	expression	 is	one	of	 the	defining	 factors	of	 the	DC2	population	but	





DC2	 into	 two	 populations	 using	 CD11b	 expression	 (111,	 229,	 333).	 CD11b-	 DC	 are	
described	as	the	“triple	negative	(TN)”	DC	subset	due	to	their	low	expression	of	CD326,	
CD103	 and	 CD11b	 (111),	 and	 will	 be	 referred	 to	 as	 TN	 DC2	 throughout	 this	 thesis.	
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Additional	 distinctions	 can	 be	made	within	 the	DC2	population	 by	 assessing	 CD301b	






in	 promoting	Th2	 (476,	557,	559,	561,	563-565),	 Th17	 (566,	567),	 Treg	 (434)	 and	Tfh	
differentiation	 (568).	 Intriguingly,	 KLF4-dependent	 DC	 have	 been	 reported	 to	 be	
important	for	Th2	immunity	but	not	Th17	responses	(557),	whereas	DC	dependent	on	
IRF4	 for	 their	 migration	 are	 required	 for	 driving	 Th2	 (559,	 561,	 565)	 and	 Th17	






In	 addition	 to	 promoting	 CD4+	 T	 cell	 responses,	 dermal	 DC2	 subsets	 are	 the	 major	
migratory	 DC	 population	 that	 transports	 antigen	 from	 the	 skin	 to	 the	 skin-dLNs.	
Intradermal	injection	of	fluorescent	BCG	(332)	or	non-viable	N.	brasiliensis	(333)	larvae	
revealed	that	migratory	DC2	made	up	the	majority	of	antigen-carrying	cells	in	the	dLN.	














migDC	 is	 less	 clear,	however.	LN	 resDC	appear	 to	play	an	 important	 role	 in	 initiating	
and	 regulating	T	 cell	 responses	 to	 antigens	 that	 passively	 enter	 the	 LN	 in	 the	 lymph	
(572,	573).	 Interestingly,	 resDC1	and	 resDC2	subsets	are	 spatially	 compartmentalised	
to	 facilitate	 their	 functional	 specialisations.	 Cross-presenting	 DC1	 are	 located	 within	
the	 paracortex	 requiring	 a	 deeper	 penetrance	 of	 antigen,	 whereas	 DC2	 that	 initiate	
CD4+	 T	 cell	 responses	 are	 positioned	 near	 the	 lymphatic	 sinus	 (572-574).	 Another	
potential	function	of	resDC	is	to	present	antigen	received	from	migratory	cells	that	are	
less	adept	at	antigen	presentation,	such	as	LC	and	monocytes	(575,	576).	There	is	also	
evidence	 of	 migDC	 transferring	 antigen	 to	 resDC1	 in	 a	 HSV	 infection	 model,	 where	
resDC1	were	required	to	induce	a	CD8+	T	cell	response	(577).	Thus,	investigation	into	
the	 transfer	 of	 antigen	 between	 cell	 populations	 will	 be	 of	 interest	 to	 further	
understand	the	respective	functions	of	resDC	and	migDC.			
	





to	 viruses	 sensed	 through	 the	 TLR7	 or	 TLR9	 signalling	 pathways	 (210-213).	 Indeed,	
pDC	 depleted	 mice	 fail	 to	 generate	 sufficient	 anti-viral	 responses	 in	 some	 infection	






1.6 The contribution of innate immune cell populations to the regulation of 
CD4+ T cell responses 
DC	 are	 not	 the	 only	 population	 of	 innate	 immune	 cells	 involved	 in	 the	 regulation	 of	
CD4+	T	 cell	 responses.	 The	 recognition	 of	 inflammatory	 stimuli	 drives	 the	 activation	







presence	 of	 M-CSF	 (586).	 Monocytes	 can	 be	 broadly	 divided	 into	 conventional	 and	
patrolling	 subsets	 based	 on	 phenotypic	 and	 functional	 characteristics.	 Conventional	
monocytes	(Ly6Chi	in	mice	and	CD14+	CD16-	in	humans)	are	rapidly	recruited	to	sites	
of	 inflammation	 where	 they	 differentiate	 into	 macrophage-	 or	 DC-like	 cells	 (this	 is	
described	in	further	detail	below)	(587,	588).	Conversely,	patrolling	monocytes	(Ly6Clo	
in	mice	and	CD14-	CD16+	in	humans)	highly	express	integrin	molecules,	such	as	LFA1	
and	 CX3CR1	 (587,	 588),	 which	 allows	 them	 to	 survey	 the	 vascular	 endothelium	 for	
signs	of	inflammation	or	injury	(589).	Conventional	monocytes	are	highly	abundant	in	
the	blood	of	mice	and	their	roles	in	inflammatory	processes	are	better	understood	than	




Conventional	monocytes	are	 released	 from	 the	bone	marrow	 into	 the	 circulation	 in	a	




monocyte	 activation	 and	 recruitment	 to	 inflammatory	 foci	 (47,	591-593).	 In	 addition,	
inflammation	 and	 infection	 increase	 the	 rate	 of	 monopoiesis,	 with	 evidence	 that	
inflammatory	 mediators	 can	 modulate	 monocyte	 function	 within	 the	 bone	 marrow	
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itself.	 Low	 concentrations	 of	 circulating	 TLR	 ligands	 were	 demonstrated	 to	 enhance	
CCR2-dependent	monocyte	egress	from	the	bone	marrow	by	stimulating	mesenchymal	
stem	 cells	 (594).	 Another	 study	 demonstrated	 that	 NK	 cell-derived	 IFNγ	 primed	
monocyte	precursors	within	the	bone	marrow	in	a	T.	gondii	model	(486).	
	
Monocytes	 also	 have	 the	 capacity	 to	 differentiate	 into	macrophages	 (53,	595-598)	 or	
DC-like	 cells	 (47,	 587,	 599-602)	 under	 certain	 conditions.	 In	 vitro,	 GM-CSF	 and	 IL-4	
promote	 the	 differentiation	 of	 monocytes	 into	 DC-like	 cells	 (will	 be	 referred	 to	 as	
monocyte-derived	 DC)	 in	 an	 IRF4-dependent	 manner	 (603).	 Interestingly,	 in	 the	
absence	 of	 IRF4,	 GM-CSF	 and	 IL-4-treated	monocytes	 differentiate	 into	macrophages	
(603),	 indicating	 that	 IRF4	 may	 regulate	 monocyte	 differentiation.	 Inflammatory	
settings	are	associated	with	the	development	of	monocyte-derived	DC	in	vivo	(176,	328,	
604),	with	IFNγ	signalling	implicated	in	driving	monocyte-to-DC	differentiation	in	a	T.	




cells	 have	 been	 implicated	 in	many	 different	 inflammatory	 and	 infectious	 processes.	
The	 involvement	 of	 monocyte-derived	 cells	 is	 best	 characterised	 in	 the	 context	 of	





Listeria	monocytogenes	 (176)	 or	T.	gondii	 infections	 (606).	 Interestingly,	Ccr2-/-	mice	
also	uncovered	a	role	for	monocyte-derived	cells	in	driving	eosinophilic	allergic	airway	
inflammation	 through	 their	 production	 of	 CCL24	 and	 promotion	 of	 IL-13	 production	
(604).	This	suggests	that	monocytes	may	also	support	Th2	responses.	In	line	with	this,	
monocytes	 have	 been	 found	 to	 accumulate	 in	 schistosome	 granulomas	 where	 they	
differentiate	 into	 protective	 alternatively	 activated	 macrophages	 (607,	 608).	 In	
addition,	 monocyte-derived	 cells	 are	 associated	 with	 Th17	 inflammation	 and	 fungal	
infections	 (12,	 609).	 Depletion	 of	 monocytes	 using	 a	 Ccr2-/-	 or	 CCR2-DTR	 mouse	
models	was	 shown	 to	 protect	mice	 from	 experimental	 autoimmune	 encephalitis	 and	
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prevent	 the	 associated	 inflammatory	 CD4+	 T	 cell	 response	 (609,	 610).	 Depletion	 of	
CD11c+	 DC	 resulted	 in	 no	 protection,	 indicating	 that	 monocyte-derived	 cells	 can	 be	
significant	drivers	of	Th17	inflammation	in	vivo	(609).	
	
The	 precise	 role	 that	 monocyte-derived	 cells	 play	 in	 regulating	 CD4+	 T	 cell	
differentiation	 is	 unclear	 and	 appears	 to	 be	 dependent	 on	 the	model.	Monocytes	 are	
efficient	 at	 transporting	 antigen	 to	 the	 local	 LNs	 (12,	 602,	 604,	 605)	 and	 their	
differentiation	 into	 DC-like	 cells	 greatly	 enhances	 their	 ability	 to	 induce	 T	 cell	
responses	 (328,	600,	 604).	 Therefore,	 it	 is	 possible	 that	monocytes	may	 serve	 as	 the	
primary	APC	responsible	for	initiating	CD4+	T	cell	responses	in	some	cases.	However,	
in	many	models,	depletion	of	monocytes	only	partially	affects	the	CD4+	T	cell	response	
or	monocytes	 are	 not	 sufficient	 to	 drive	 CD4+	T	 cell	 responses	 in	 the	 absence	 of	DC	
(176,	600,	605).	In	these	cases,	the	co-operation	between	monocytes	and	DC	may	be	an	
important	 factor	 in	 the	 regulation	of	CD4+	T	 cell	 responses,	whereby	DC	provide	 the	
necessary	 co-stimulatory	 signals	 for	 CD4+	 T	 cell	 activation	 and	 monocyte-derived	
cytokines	play	a	role	 in	guiding	the	differentiation	pathway	(13,	600,	605).	Additional	
support	for	this	hypothesis	was	provided	by	a	study	showing	that	monocytes	regulate	
Th1	 and	 Tfh	 fates	 in	 a	 Plasmodium	model	 (207).	 Together,	 there	 is	 a	 large	 body	 of	
literature	 demonstrating	 that	 monocyte-derived	 cells	 are	 associated	 with	 many	
different	inflammatory	processes	in	which	they	may	play	a	role	in	shaping	the	adaptive	
immune	 response.	 Further	 investigation	 is	 needed	 to	 determine	 the	 precise	 role	 of	




Macrophages	 are	 a	 tissue-resident	 population	 of	 embryonic	 origin	 that	 are	 self-
maintained	 under	 steady-state	 conditions	 (611-614).	 However,	 in	 some	 tissues,	
monocyte-derived	 macrophages	 contribute	 to	 the	 macrophage	 pool	 (595-597),	
particularly	in	inflammatory	contexts	(615-617).	Dermal	and	LN-resident	macrophages	







key	 role	 in	 tissue	 surveillance.	 Upon	 activation	 by	 PAMPs,	 DAMPs	 or	 cytokines,	
macrophages	undergo	a	context-specific	differentiation	programme	which	ranges	from	
a	 “classical”	 M1	 phenotype	 to	 an	 “alternatively	 activated”	 M2	 phenotype.	 While	
imperfect,	 the	M1/M2	paradigm	does	align	with	 the	Th1/Th2	paradigm	(619),	 as	M1	
and	 M2	 macrophages	 are	 strongly	 associated	 with	 bacterial	 (620)	 and	 helminth	
infections	 (621),	 respectively.	 The	 M1	 programme	 is	 triggered	 by	 microbial	
components	 (622,	623)	 and	 IFNγ	 (240,	624),	which	promote	microbicidal	 activity	and	
the	 production	 of	 iNOS,	 IL-1,	 IL-12,	 IL-23,	 IL-27	 and	 TNFα	 (625).	 As	 such,	 M1	





In	 contrast	 to	M1	macrophages,	 the	M2	programme	 is	 induced	 by	 the	 canonical	 Th2	
cytokines	 IL-4	 and	 IL-13	 (261,	 627),	 which	 drive	 the	 expression	 of	 M2	 signature	
molecules,	including	arginase	1,	Relm-α,	Ym1	and	the	mannose	receptor	(CD206)	(625,	
628-631).	M2	macrophages	 also	 produce	 CCL17	 (185,	 632),	 which	 is	 involved	 in	 the	



















proximity	 to	 infected	 tissue.	 Pro-inflammatory	 cytokines	 and	 chemokines,	 as	well	 as	
PRR	 ligands,	 further	 support	 neutrophil	 activation	 in	 the	 tissue	 environment.	
Neutrophils	are	first-line	responder	cells	and	once	activated	are	efficient	at	containing	





of	 DC	 (487,	 636,	 637),	 T	 cells	 (405)	 and	 NK	 cells	 (638).	 Undetermined	 neutrophil-
derived	 factors	have	also	been	 shown	 to	promote	DC	and	NK	activation	 in	vitro	(636,	
638-641),	 suggesting	 that	 neutrophils	may	 also	 facilitate	 innate	 cell	 recruitment	 and	
activation	in	inflammatory	contexts.	Further,	mouse	and	human	neutrophils	reportedly	
express	MHCII	 under	 certain	 conditions	 and	 are	 capable	 of	 directly	 inducing	 CD4+	T	
cell	 responses	 (642,	 643).	 A	 subsequent	 study	 demonstrated	 that	 GM-CSF	 culture	 of	
neutrophils	 could	 induce	a	 “hybrid”	 cell	 that	had	properties	both	neutrophils	 and	DC	




Eosinophils,	 basophils	 and	 mast	 cells	 are	 specifically	 associated	 with	 Th2	 immune	
responses	 and	 the	 mediators	 they	 release	 upon	 activation	 drive	 allergic	 symptoms	
(646,	647).	Mast	cells	are	long-lived	resident	cells	in	the	skin	and	acquire	IgE	for	their	









is	 regulated	 by	 IL-5	 derived	 from	 ILC2	 and	 Th2	 cells	 (651-653),	 but	 additional	





In	 terms	 of	 regulating	 CD4+	 T	 cell	 responses,	 a	 number	 of	 studies	 have	 shown	
involvement	 of	 Th2-associated	 granulocytes.	 Eosinophils	 and	 mast	 cells	 have	 been	
implicated	in	regulating	CD4+	T	cell	responses	by	promoting	APC	activation	(658,	659)	
and	migration	(660,	661).	In	particular,	mast	cell-derived	TNFα	promoted	DC	migration	
to	 the	 skin-dLNs	 in	 a	 contact	hypersensitivity	model	 (662).	 Similarly,	 an	unidentified	
eosinophil-derived	 factor	 promoted	 DC	 activation	 migration	 to	 the	 lung-dLNs	 in	 a	
model	of	 allergic	 airway	 inflammation	 (663).	 Like	neutrophils,	 eosinophils	 (664-667),	




findings	 is	 unclear.	 While	 Th2-associated	 granulocytes	 may	 not	 directly	 present	
antigen,	 they	 are	 early	 sources	 of	 IL-4	 which	 could	 be	 key	 to	 promoting	 Th2	
differentiation	in	vivo	(674-678).		
	
1.6.4 Innate lymphoid cells (ILCs) 
ILCs	are	a	population	of	 cells	 that	share	 the	 lineage	and	morphology	of	 lymphocytes,	
but	 lack	 antigen	 specific	 receptors.	 ILCs	 can	 be	 classified	 into	 a	 number	 of	 distinct	
populations	 that	 align	 with	 T	 cell	 subsets	 in	 their	 transcription	 factor	 and	 cytokine	
expression	profiles.	NK	cells	(section	1.6.5)	are	the	innate	equivalent	of	CD8+	cytotoxic	




function	 appears	 to	 be	 redundant	 in	 the	 presence	 of	 a	 competent	 adaptive	 immune	
system.	 Severe	 combined	 immunodeficiency	 (SCID)	 patients	 that	 received	
haematopoietic	 stem	 cell	 transplants	 showed	no	 increased	 susceptibility	 to	 infection	
even	though	their	ILC	numbers	were	significantly	lower	than	healthy	individuals	(682).	
However,	 there	 is	 evidence	 that	 increased	 presence	 of	 particular	 ILC	 subsets	 are	





and	 ILC3	 responsive	 to	 IL-23	 (684).	 Upon	 activation,	 ILC	 subsets	 rapidly	 produce	
signature	 cytokines	 that	 can	 indirectly	 influence	 CD4+	 T	 cell	 differentiation	 via	 APC.	
Indeed,	 ILC2-derived	 IL-13	 is	necessary	 to	promote	migration	of	DC	 from	 the	 lung	 to	
the	 mediastinal	 LNs	 to	 initiate	 Th2	 differentiation	 following	 papain	 administration	
(139).	 It	 is	 currently	unclear	whether	 these	 findings	are	applicable	 to	 skin	DC,	which	
also	express	 the	 IL-13	 receptor	 (571).	Activated	 ILC3	produce	 IL-22	but	also	express	
membrane-bound	 lymphotoxin	 α1β2	 which	 has	 been	 shown	 to	 promote	 IL-23	





sufficient	 to	 induce	 CD4+	 Th	 cell	 proliferation	 and	 Th2	 differentiation	 ex	 vivo	 (686,	
687).	 A	 recent	 study	 has	 also	 demonstrated	 that	 human	 epidermal	 ILC2	 express	 the	
MHC-like	 molecule	 CD1a,	 which	 is	 involved	 in	 the	 presentation	 of	 lipid	 antigens	 to	





1.6.5 Natural killer (NK) cells 
NK	 cells	 are	 an	 innate	 lymphoid	 cell	 population	 with	 documented	 cytolytic	 activity	
(691)	 and	 the	 capacity	 to	 rapidly	 produce	 inflammatory	 cytokines	 upon	 activation	
(692).	 IFNγ	 is	 the	predominant	cytokine	produced	by	activated	NK	cells	and	thus,	NK	
cells	are	most	strongly	associated	with	Th1	responses.		
	
NK	cell	 activation	 can	occur	via	a	number	of	distinct	pathways.	Firstly,	 inflammatory	
cytokines	produced	by	APC	or	another	innate	immune	cells	can	induce	IFNγ	production	
by	NK	cells.	IL-12,	IL-18,	IFN-I,	IL-15	and	IL-2	have	all	been	shown	to	support	NK	cell	
activation	 and	 IFNγ	 production	 in	 vivo	 (233,	 235,	 691,	 693,	 694).	 Secondly,	 NK	 cells	
express	a	repertoire	of	receptors	that	detect	and	respond	to	cellular	stress	signals	or	
MHCI-related	 molecules.	 NKG2D,	 NKp46	 and	 Ly49D	 are	 among	 the	 stimulatory	
receptors	expressed	by	NK	cells	and	have	been	shown	to	promote	cytolytic	activity	and	
cytokine	 production	 (695).	 Interestingly,	 TLR	 stimulation	 of	 macrophages	 or	
monocytes	 induces	 the	 up-regulation	 of	NKG2D	 ligands	 (696,	697),	which	may	 act	 to	
support	 NK	 cell	 activation.	 Lastly,	 NK	 cell	 activation	 can	 occur	 in	 direct	 response	 to	
PAMPs	 and	 DAMPs	 via	 PRR	 signalling.	 A	 series	 of	 studies	 have	 reported	 TLR	mRNA	
expression	 in	 NK	 cells	 and	 NK	 cell	 activation	 in	 response	 to	 TLR	 ligands	 (698-700);	






induced	 septic	 shock	 (703-707).	 As	 such,	 NK	 cells	 are	 central	 to	 creating	 the	
appropriate	environment	to	support	Th1	differentiation	and	effector	function.	NK	cell-
derived	IFNγ	can	directly	support	Th1	differentiation	by	acting	on	naïve	CD4+	T	cells	
(708-710),	presumably	by	promoting	Tbet-induced	up-regulation	of	 IL-12Rβ	 (375)	 as	
described	in	section	1.3.1.	The	cytolytic	activity	of	NK	cells	can	also	regulate	CD4+	T	cell	
responses,	 with	 NK	 cells	 shown	 to	 lyse	 Tregs	 following	 BCG	 immunisation	 (711).	
Further,	NK	cells	can	indirectly	support	Th1	development	by	promoting	activation	and	
cytokine	production	by	DC,	monocytes	and	macrophages	(47,	486,	592,	707,	712-716).	
In	 particular,	 NK	 cell-derived	 IFNγ	 is	 necessary	 to	 promote	 the	 differentiation	 of	
	50	






1.7 Translation of mouse immunology to humans 
Mouse	 models	 are	 an	 important	 tool	 in	 biomedical	 research	 and	 have	 provided	
valuable	 insights	 into	the	 functional	roles	of	 immune	cells	and	signalling	molecules	in	
vivo.	The	murine	immune	system	recapitulates	the	human	immune	system	remarkably	
well	 given	 that	 the	 two	species	 have	 evolved	 separately	 for	 at	 least	 65	million	 years	





Firstly,	 recent	 studies	 have	 highlighted	 the	 potential	 disadvantages	 of	 utilizing	 very	
“clean”	 specific-pathogen	 free	 (SPF)	 mice	 for	 immunological	 research	 (721,	 722).	
Microbial	experience	plays	an	important	role	in	educating	innate	and	adaptive	immune	
cells	 to	 be	more	 responsive	 to	 future	 pathogenic	 challenges	 (723-725).	 Indeed,	 some	
memory	T	cell	subsets	are	absent	from	SPF	mice,	but	are	present	in	tissues	from	wild	
mice	and	adult	humans	(722).	Therefore,	going	forward,	wild	mice	may	be	a	useful	tool	





murine	 APC	 and	 are	 required	 for	 the	 recognition	 of	 profilin,	 a	 component	 of	 the	
intracellular	parasite	T.	gondii	(727,	728).	Study	of	the	human	genome	has	revealed	that	
the	 gene	 for	 TLR12	 is	 completely	 absent	 in	 humans	 and	 TLR11	 is	 present	 as	 a	
pseudogene	 (729).	However,	human	APC	have	 retained	 the	 capacity	 to	 recognise	and	
respond	 to	 T.	 gondii,	 indicating	 that	 an	 unidentified	 PRR	 performs	 this	 function	 in	
humans.	Conversely,	Tlr10	 is	widely	expressed	by	human	immune	cells	(730)	but	 is	a	
pseudogene	 in	 mice.	 The	 functional	 role	 of	 TLR10	 has	 yet	 to	 be	 agreed	 upon,	 with	
experimental	 evidence	 supporting	 both	 inflammatory	 and	 anti-inflammatory	
properties	 (731,	 732).	 Overall,	 the	 way	 in	 which	 murine	 and	 human	 immune	 cells	
recognise	 and	 respond	 to	 pathogenic	 stimuli	 may	 be	 distinct.	 Further	 comparative	
studies	 are	 required	 to	 ascertain	 the	 functional	 significance	 of	 these	 differences	 as	
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current	 experimental	 evidence	 suggests	 that	 the	 resulting	 effector	 responses	 are	
similar.		
	
Finally,	 the	 relatively	 recent	 characterisation	 of	 various	 unconventional	 invariant	 or	
semi-invariant	T	cell	populations	has	highlighted	significant	differences	in	the	make-up	
of	the	T	cell	compartment	between	mice	and	humans.	For	example,	mucosal-associated	
invariant	T	 (MAIT)	 cells	 and	NKT	cells	 are	present	 in	both	mice	and	humans	but	 the	
frequency	 of	 these	 cells	 differs	 greatly.	 MAIT	 cells,	 which	 recognise	 vitamin	 B	
derivatives	 (733),	 are	 abundant	 in	 humans	 (1-10%	 and	 20-40%	 of	 all	 T	 cells	 in	 the	
peripheral	blood	and	liver,	respectively)	(734,	735),	but	are	relatively	rare	in	laboratory	










Overall,	mouse	models	are	exceptionally	useful	 for	assessing	 immunological	 functions	
in	 an	 in	vivo	 setting	However,	 care	 needs	 to	 be	 taken	when	 using	 such	data	 to	 draw	
conclusions	about	human	biology.		 	
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1.8 Rationale and aims 
APC	play	a	crucial	role	in	regulating	CD4+	T	cell	proliferation	and	differentiation,	which	
is	 central	 to	protective	 immunity	 against	 bacterial,	 helminth	 and	 fungal	 infections	 as	
well	 as	 autoimmune	 and	 allergic	 pathology.	 However,	 the	 factors	 that	 influence	 APC	
regulation	 of	 T	 cell	 differentiation	 in	 vivo	 are	 currently	 debated.	 In	 particular,	 the	
processes	 and	 instructive	 signals	 required	 for	 initiation	 of	 Th2	 responses	 have	
remained	elusive	despite	intensive	investigation.		
	
Experiments	 in	 which	 specific	 APC	 subsets	 were	 depleted/deleted	 in	 immunised	 or	
infected	mice	 have	 produced	 data	 that	 supports	 the	hypothesis	 that	 APC	 subsets	 are	
pre-programmed	 to	 promote	 a	 particular	 CD4+	 T	 cell	 differentiation	 pathway	 upon	
activation	 (section	 1.5).	 However,	 there	 is	 also	 evidence	 of	 APC	 plasticity,	 whereby	
signals	 from	the	antigen	 itself	or	surrounding	cells	can	 influence	the	ability	of	APC	to	
induce	a	particular	CD4+	T	cell	differentiation	programme	(section	1.4.2).		
	
This	 thesis	 aims	 to	 expand	 and	 clarify	 the	 current	 knowledge	 on	 the	 cell	 types	 and	
signalling	molecules	 involved	 in	 influencing	CD4+	T	 cell	 fate.	 In	particular,	 this	 thesis	
aims	 to	 evaluate	 the	 respective	 roles	 APC	 lineage-defined	 function	 and	 APC-






























2.1.1 Maintenance and ethical approval 
Specific-pathogen	free	(SPF)	mice	(Table	2-1)	were	bred	and	housed	at	the	Biomedical	
Research	 Unit,	 Malaghan	 Institute	 of	 Medical	 Research	 (MIMR),	 Wellington,	 New	
Zealand.	 Mice	 were	 maintained	 on	 standard	 rodent	 chow	 and	 acidified	 water	 ad	
libitum,	with	a	12-hour	light/dark	cycle.	Sex	and	age	matched	mice	of	6-12	weeks	of	age	
were	 used	 for	 all	 experiments.	 All	 experimental	 protocols	 were	 approved	 by	 the	































2.1.2 Mouse strains 
Wildtype	strains	
C57BL/6J	express	the	CD45.2	(Ptprcb)	allele.	The	CD45.2	protein	can	be	detected	on	all	
immune	 cells.	 Breeding	 pairs	 were	 originally	 from	 the	 Jackson	 Laboratories	 (Bar	
Harbor,	ME,	USA).	
	
B6-SJL-PtprcaPep3b/BoyJArc	 (B6	 congenic)	 express	 the	CD45.1	 (Ptprca)	 allele.	The	




Langerin-DTReGFP	 mice	 express	 a	 transgene	 containing	 the	 high	 affinity	 diphtheria	
toxin	 receptor	 (DTR)	 and	 enhanced	 green	 fluorescent	 protein	 (eGFP)	 fusion	 protein	
under	control	of	the	Cd207	promoter.	Intraperitoneal	(i.p.)	administration	of	diphtheria	
toxin	 (DT)	 results	 in	 the	 selective	 and	 transient	 depletion	 of	 langerin	 (CD207)+	 cells	
including	 Langerhans	 cells	 and	 dermal	 DC1	 (740).	 Breeding	 pairs	 on	 a	 C57BL/6	
background	were	obtained	from	Dr.	Bernard	Malissen	(INSERM,	France).	
	
CCR2-DTRCFP	mice	 express	 a	 transgene	 containing	 the	 high	 affinity	 DTR	 and	 cyan	
fluorescent	 protein	 (CFP)	 fusion	 protein	 under	 control	 of	 the	 Ccr2	 promoter.	
Administration	 of	 DT	 results	 in	 the	 selective	 and	 transient	 depletion	 of	 CCR2	
expressing	 cells,	 including	monocytes	 (12).	Breeding	 pairs	 on	 a	 C57BL/6	 background	






BATF3-KO	 mice	 lack	 exons	 1	 and	 2	 of	 the	 gene	 encoding	 the	 transcription	 factor	
BATF3.	BATF3	is	required	for	the	development	of	tissue	resident	DC1,	and	its	deletion	




CRLF2-KO	 (referred	 to	 as	 TSLPR-KO)	mice	have	a	neomycin	 resistance	 cassette	 in	
place	of	 all	 exons	of	 the	Crlf2	 gene	 (116).	As	a	 result,	TSLPR-KO	mice	 lack	 the	TSLPR	
protein,	which	renders	all	cells	in	the	mouse	unresponsive	to	TSLP.	C57BL/6	mice	were	
used	 as	 controls	 for	TSLPR-KO	mice.	 Breeding	 pairs	on	 a	 C57BL/6	 background	were	
provided	 by	 Dr.	William	 E.	 Paul	with	 the	 permission	 of	 Dr.	Warren	 J.	 Leonard	 (NIH,	
Bethesda,	MD,	USA).		
	
IL-25-KO	mice	 have	 their	 il25	 gene	 interrupted	 by	 a	 LacZ-Neomycin	 construct	 and	
thus,	 are	 unable	 to	 produce	 IL-25	 protein	 (741).	 Heterozygous	 mice	 were	 used	 for	
breeding	purposes	and	offspring	were	genotyped	for	wildtype	(WT)	and	knockout	(KO)	
alleles.	Mice	genotyped	as	having	two	WT	alleles	(+/+)	were	used	as	controls	for	mice	




Itgaxcre	mice	 express	 Cre	 recombinase	 under	 control	 of	 the	 Itgax	 (CD11c)	 promotor	






Klf4fl/fl	mice	 have	 loxP	 sequences	 flanking	 exons	 2	 and	 3	 of	 the	 Klf4	 gene	 (743).	
Crossing	Klf4fl/fl	mice	to	CD11ccre	mice	results	 in	a	reduced	number	of	CD172a+	DC	 in	










the	 skin	 dLNs	 (563).	 Itgaxcre-neg.Irf4fl/fl	(IRF4WT)	 littermates	were	 used	 as	 controls	 for	
Itgaxcre-pos.	Irf4fl/fl	(IRF4ΔCD11c)	mice.	Bone	marrow	from	IRF4WT	and	IRF4ΔCD11c	mice	on	a	
C57BL/6	 background	 was	 kindly	 provided	 by	 Dr.	 Andrew	Macdonald	 (University	 of	
Manchester,	UK)	and	used	to	reconstitute	lethally	irradiated	C57BL/6	hosts.		
	
Ifnarfl/fl	mice	have	 loxP	 sequences	 flanking	exon	3	of	 the	gene	encoding	 for	 the	type	I	
interferon-αβ	 receptor	 (IFNAR)	 (745).	Crossing	 Ifnarfl/fl	mice	 to	CD11ccre	mice	deletes	
IFNAR	from	all	CD11c	expressing	cells,	rendering	them	unresponsive	to	IFN-I	signalling	






silencer	 sequences	 (747).	 CD4cre	 mice	 can	 be	 crossed	 with	 mice	 containing	 a	 loxP	
flanked	gene	of	interest,	which	results	in	the	deletion	of	that	gene	sequence	in	CD4/Cre	





differentiation	 (748).	Cd4cre-neg.Bcl6fl/fl	(BCL6WT)	 littermates	were	 used	 as	 controls	 for	






4C13R	mice	have	 transgenic	expression	of	 the	 fluorescent	proteins	AmCyan	and	DS-
Red	under	the	control	of	the	Il4	and	Il13	regulatory	elements	respectively.	This	mouse	
strain	 was	 generated	 using	 a	 BAC	 clone	 containing	 the	 Th2	 locus	 control	 region.	
Reporter	 constructs	 were	 inserted	 to	 the	 appropriate	 regions	 by	 homologous	
recombination	(325).	Mice	heterozygous	for	the	reporter	constructs	were	generated	for	
experimental	use	by	crossing	homozygous	4C13R	mice	with	C57BL/6,	B6	congenic	or	
TSLPR-/-	 mice.	 4C13R	 breeding	 pairs	 on	 a	 C57BL/6	 background	 were	 originally	
provided	by	Dr.	William	E.	Paul	(NIH,	MD,	USA).	
	
2.1.3 Generating bone marrow chimeras 
Mice	 greater	 than	 8	 weeks	 of	 age	 were	 fasted	 overnight	 before	 being	 exposed	 to	
500cGy	 radiation	 twice,	 three	 hours	 apart	 using	 a	 Gammacell®	3000	Elan	 irradiator	
(Best®	 Theratronics,	 Canada).	 Irradiated	 mice	 were	 transferred	 to	 individually	
ventilated	cages	and	rested	overnight.	The	following	day,	bone	marrow	was	harvested	
from	 donor	mice	 and	 1.5x107	 bone	marrow	 cells	 suspended	 in	 IMDM	were	 injected	
intravenously	(i.v.)	into	irradiated	recipients.	Mice	were	maintained	on	drinking	water	





2.2 Solution and buffer compositions 
	
Alsever’s	solution	
20.5mg/mL	 dextrose,	 4.2mg/mL	 sodium	 chloride	 and	 8.0mg/mL	 sodium	 citrate	 (all	
from	 BDH	 Laboratory	 Supplies,	 UK)	 were	 dissolved	 in	 distilled	 H2O.	 The	 pH	 of	 the	









PBS	 powder	without	 calcium	 chloride	 and	magnesium	 chloride	was	 purchased	 from	
Sigma-Aldrich	 (MO,	 USA)	 and	 was	 made	 up	 according	 to	 the	 manufacturer’s	


















Incomplete	 IMDM	 was	 supplemented	 with	 1%	 penicillin-streptomycin	 (Invitrogen™,	




Difco™	 LB	 powder	 (Miller)	 was	 purchased	 from	 BD	 Biosciences	 (CA,	 USA)	 and	 was	
made	up	according	to	the	manufacturer’s	instructions	by	dissolving	25g	LB	powder	in	


















2.3 Preparation of microbes and helminths 
2.3.1 Candida albicans (Ca) 












at	 600nm	on	 a	 plate	 reader	 (Tecan,	 Switzerland)	 and	 correlated	 to	 cell	 counts	 done	



















fecal	 pellets	 collected	 from	seven	 to	 ten	 days	 post	 infection.	 A	 paste	was	made	 from	
softened	fecal	material	by	mixing	with	charcoal	and	placed	on	a	sponge	covered	with	
filter	 paper	 in	 a	 petri	 dish.	 The	 paste	was	 incubated	 at	 26°C	 for	 seven	 days,	 during	





A	 50µL	 aliquot	 of	 well	 mixed	 larval	 suspension	 was	 counted	 under	 a	 stereoscopic	




L3	 Nb	 larvae	 were	 suspended	 in	 PBS	 containing	 400U	 penicillin,	 400µg/mL	
streptomycin	 and	 400µg/mL	 neomycin	 (all	 from	 Sigma-Aldrich,	 MO,	 USA)	 and	
incubated	for	two	hours	at	room	temperature.	Larvae	were	washed	thrice	with	sterile	
PBS,	re-suspended	at	20,000	larvae/mL	and	killed	by	three	freeze-thaw	cycles.	Dead	L3	




2.3.3 Mycobacterium smegmatis (Ms) 















Ms	was	 stored	 at	 -70°C	until	 use.	 Titration	 studies	were	 performed	on	 each	 batch	 to	
determine	the	optimal	concentration	for	immunisation.	
	
2.3.4 Labelling model organisms for in vivo tracking 
A	500µL	aliquot	of	 either	bacteria,	 yeast	or	worm	suspension	was	mixed	with	500µL	
0.1M	 sodium	bicarbonate	 solution	 by	 inversion.	 10µg	AF488	NHS	 Succinimidyl	 Ester	
(Molecular	Probes™,	ThermoFisher	Scientific,	MA,	USA)	was	 added	 to	 the	 suspension	









2.4 Preparation of haptens 
2.4.1 1-Fluoro-2,4-dinitrobenzene (DNFB) 
DNFB	 was	 purchased	 from	 Sigma-Aldrich	 (MO,	 USA)	 and	 dissolved	 in	 1:4	 olive	
oil/acetone	solution	to	a	final	concentration	of	0.3%.	
	
2.4.2 Dibutyl phthalate: Fluorescein isothiocyanate (DBP:FITC) 
Dibutyl	phthalate	(DBP)	was	purchased	from	Sigma-Aldrich	(MO,	USA)	and	mixed	at	a	
1:1	ratio	with	acetone.	DBP/acetone	solution	was	stored	at	room	temperature	until	use.	




2.5 In vivo treatments 
2.5.1 Intradermal immunisation model 
The	 intradermal	 (i.d.)	 immunisation	 model	 was	 performed	 as	 described	 (336).	 Mice	
were	anesthetised	by	administering	100mg/kg	ketamine	and	3mg/kg	xylazine	by	 i.p.	
injection.	 Model	 organisms	 were	 prepared	 as	 described	 in	 section	 2.3	 and	 injected	
intradermally	 at	 the	 optimal	 concentration	 into	 the	 ear	 pinnae	 of	 anesthetised	mice.	
PBS	was	 injected	 into	 the	ear	pinna	of	 control	 animals.	To	assess	DC	 responses,	 cells	
were	 isolated	 from	 the	 ear	 dLN	 one	 to	 two	 days	 after	 i.d.	 injection.	 To	 assess	 T	 cell	
responses,	cells	were	isolated	from	the	ear	dLN	five	to	seven	days	after	i.d.	injection.		
	
2.5.2 Epicutaneous application of haptens 
Mice	were	anesthetised	by	administering	100mg/kg	ketamine	and	3mg/kg	xylazine	by	
intraperitoneal	(i.p.)	injection.	Haptens	were	prepared	as	described	in	section	2.4	and	
10µL	solution	was	applied	 to	 the	dorsal	 and	ventral	halves	of	 the	ear	with	a	pipette.	
Olive	 oil/acetone	 or	 acetone	 was	 applied	 to	 the	 ears	 of	 control	 mice.	 If	 applying	





2.5.3 Blocking T cell egress from the lymph node 










2.5.4 Blocking IFNAR signalling 





2.5.5 Depleting monocytes 
500µg	anti-GR-1	(clone	RB6-8C5;	BioXCell,	NH,	USA)	was	administered	by	i.p.	injection	
on	day	-2.	On	day	zero,	500µg	anti-GR-1	was	co-administered	with	antigen	preparation	
i.d.	 into	 the	 ear	 pinna.	 Two	 days	 later,	 mice	 received	 a	 250µg	 top-up	 dose	 by	 i.p.	
injection.	 Control	 mice	 received	 the	 same	 dose	 of	 rat	 IgG2b	 isotype	 (clone	 LTF-2;	
BioXCell,	NH,	USA).	
	
2.5.6 Depleting natural killer cells 
200µg	anti-NK1.1	(clone	PK136;	BioXCell,	NH,	USA)	was	administered	by	i.p.	injection	
on	days	zero,	 two	and	four.	Control	mice	received	the	same	dose	of	rat	 IgG2a	 isotype	
(clone	C1.18.4;	BioXCell,	NH,	USA).	
	
2.5.7 Neutralising interferon-γ  
500µg	anti-IFNγ	(clone	XMG1.2;	BioXCell,	NH,	USA)	was	administered	by	 i.p.	 injection	
on	 days	 zero	 and	 two	 of	 the	 experimental	 protocol.	 Control	mice	 received	 the	 same	
dose	of	rat	IgG1	isotype	(clone	HRPN;	BioXCell,	NH,	USA).	
	
2.5.8 Diphtheria toxin treatment 





2.6 Tissue harvest and processing 
2.6.1 Lymph nodes 




LNs	 were	 pressed	 through	 a	 70µM	 cell	 strainer	 using	 the	 rubber	 end	 of	 a	
syringe.	 Cells	 were	 washed	 through	 with	 10mL	 IMDM	 and	 pelleted	 by	




LNs	 were	 placed	 in	 1mL	 IMDM	 containing	 100µg/mL	 Liberase	 TL	 and	
100µg/mL	 DNase	 I	 (both	 from	 Roche,	 Germany)	 and	 broken	 up	 using	 a	 25G	
needle	 prior	 to	 incubation	 at	 37°C	 for	 25	 minutes.	 In	 the	 last	 5	 minutes	 of	
incubation,	 EDTA	 was	 added	 at	 a	 final	 concentration	 of	 10mM.	 Cells	 were	
collected	 and	 filtered	 through	 a	 70µm	 cell	 strainer	 with	 10mL	 IMDM	 and	




Spleens	were	 isolated	 from	 euthanized	mice	 and	 placed	 in	 cold	 PBS	 containing	 0.1%	
bovine	 serum	 albumin	 (BSA)	 and	 2mM	 EDTA.	 To	 prepare	 a	 single	 cell	 suspension,	
spleens	were	pressed	through	a	70µm	cell	strainer	using	the	rubber	end	of	a	syringe.	
The	cell	strainer	was	rinsed	regularly	with	PBS	+	0.1%	BSA	+	2mM	EDTA	to	wash	the	
cells	 into	 the	 collection	 tube.	 Cells	were	 then	 pelleted	 by	 centrifugation	 and	washed	
with	 50mL	 PBS	 +	 0.1%	 BSA	 +	 2mM	 EDTA.	 To	 prevent	 cells	 from	 clumping,	 the	 cell	
pellet	was	resuspended	in	10mL	PBS	containing	1mM	Ca2+,	0.5mM	Mg2+	and	0.1%	BSA	
and	 incubated	 for	 15	minutes	 at	 25°C	 in	 the	 presence	 of	 5.9µg/mL	DNase	 I	 (Roche,	
Germany)	 under	 constant	 agitation.	 The	 cell	 suspension	was	 then	 filtered	 through	 a	
70µm	cell	strainer	before	 the	 cells	were	pelleted	by	 centrifugation.	To	 lyse	red	blood	
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cells,	 the	 cell	 pellet	 was	 resuspended	 in	 10mL/spleen	 ACT	 buffer	 for	 10	 minutes	 at	
37°C.	 The	 cells	 were	 washed	 twice	 with	 PBS	 before	 proceeding	 to	 enrichment	 or	
staining	protocols.			
2.6.3 Counting of viable cells 
Aliquots	 of	 single	 cell	 suspensions	 were	 diluted	 in	 Trypan	 Blue	 dye	 (Gibco™,	
ThermoFisher	 Scientific,	 MA,	 USA)	 and	 applied	 to	 a	 haemocytometer.	 Cells	 that	
excluded	the	dye	were	counted	as	viable.	
	
2.7 T cell re-stimulation 
Cells	 were	 plated	 out	 in	 96-well	 plates	 with	 2x106	 cells	 per	 well	 and	 pelleted	 by	
centrifugation	 at	 250xg	 for	 2	 minutes.	 The	 supernatant	 was	 removed	 and	 cells	
resuspended	 in	 cIMDM	 containing	 50ng/mL	 phorbol	 12-myristate	 13-acetate	 (PMA;	
Sigma-Aldrich,	MO,	USA),	1µg/mL	ionomycin	free	acid	(Merck	Millipore,	Germany)	and	
1µL/mL	 GolgiStop™	 (BD	 Biosciences,	 CA,	 USA)	 and	 incubated	 at	 37°C	 for	 5	 hours.	
Control	 cells	 were	 resuspended	 in	 cIMDM	 containing	 1µL/mL	 GolgiStop™	 and	
incubated	at	37°C	for	5	hours.	
	
2.8 Flow cytometry 
2.8.1 Antibodies 
Monoclonal	 antibodies	 specific	 for	 murine	 antigens	 were	 purchased	 from	 BD	
Biosciences	 including	 BD	 Pharmingen™	 and	 BD	 Horizon™	 (San	 Diego,	 CA,	 USA),	
BioLegend	 (San	 Diego,	 CA,	 USA),	 eBioscience	 (San	 Diego,	 CA,	 USA)	 or	 purified	 and	
conjugated	in-house.	
	
All	 antibodies	 were	 titrated	 to	 determine	 the	 optimal	 concentration	 before	 use.	 For	
each	experiment,	antibody	cocktails	were	prepared	in	FACS	buffer	within	a	few	hours	
of	staining.	Antibodies	were	centrifuged	at	14,000xg	for	2	minutes	to	pellet	aggregates	




2.8.2 Staining of cell surface molecules 
Cells	were	plated	out	into	a	96-well	round	bottom	plate	with	5x106-1x107	cells	per	well.	
Following	 centrifugation	 at	 250xg	 for	 2	minutes,	 pelleted	 cells	were	 resuspended	 in	
100µL	 of	 FcR	 block	 (2.4G2,	 home-made)	 and	 incubated	 for	 10	 minutes	 at	 4°C.	 Cells	
were	pelleted	by	centrifugation	at	250xg	for	2	minutes	and	supernatant	discarded.	Cells	
were	resuspended	 in	100µL	of	antibody	cocktail	 followed	by	 incubation	at	4°C	 for	20	
minutes	before	being	washed	twice	with	100µL	FACS	buffer.	To	visualise	biotinylated	
antibodies,	 cells	 were	 incubated	 at	 4°C	 for	 a	 further	 20	 minutes	 in	 FACS	 buffer	
containing	 diluted	 fluorescently	 labelled	 streptavidin	 and	 washed	 twice	 with	 FACS	
buffer.	 After	 the	 final	 wash,	 samples	 were	 resuspended	 in	 200µL	 FACS	 buffer	
containing	 the	 viability	 dye	 4',6-diamidino-2-phenylindole	 (DAPI;	 Invitrogen™,	





specificity	 Conjugates	 Clone	 Supplier	
CD3ε	 BV786	 145-2C11	 BD	Horizon™	
CD4	 BV605,	Pac	Blue	 RM4-5	 BD	Horizon™,	BD	Pharmingen™	
CD8	 FITC	 2.43	 Home-made	
CD11b	 BUV737	 M1/70	 BD	Horizon™	
CD11c	 BV786	 HL3	 BD	Horizon™	
CD24	 BV650	 M1/69	 BD	Horizon™	
CD44	 BUV737	 IM7	 BD	Horizon™	
CD45.1	 APC	 A20	 eBioscience	
CD45.2	 FITC	 104	 BD	Pharmingen™	
CD45R	(B220)	 BUV395,	PerCP	 RA3-6B2	 BD	Horizon™,	BD	Pharmingen™	
CD64	(FcγR1)	 APC	 X54-5/7.1	 BioLegend	
CD86	 BUV395	 GL-1	 BD	OptiBuild™	
CD103	 PE	 M290	 BD	Pharmingen™	
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CD138	 PE	 281-2	 BD	Pharmingen™	
CD169	 AF594,	PE	 3D6.112	 BioLegend	
CD172a	(SIRPα)	 BUV395	 P84	 BD	OptiBuild™	
CD185	(CXCR5)	 Biotin	 2G8	 BD	Pharmingen™	
CD197	(CCR7)	 APC	 4B12	 BioLegend	
CD273	(PD-L2)	 BV421	 TY25	 BD	Horizon™	
CD274	(PD-L1)	 PE	 MIH1	 eBioscience	
CD279	(PD1)	 PECy7	 29F.1A12	 BioLegend	
CD301b	(MGL2)	 PE	 URA-1	 BioLegend	
CD317	(BST2)	 APC	 297	 BioLegend	
CD326	(EpCAM)	 BV711	 G8.8	 BD	Horizon™	
GL7	 FITC	 GL7	 BioLegend	
IgD	 APC-H7	 11-26c.2a	 BD	Pharmingen™	
KLRG1	 APC	 2F1	 eBioscience	
Ly6A/E	(Sca1)	 PECF594	 D7	 BD	Horizon™	
Ly6C	 PECy7	 HK1.4	 BioLegend	
MHCII	 AF647	 3JP	 Home-made	
MHCII	 BV605,	Pac	Blue	 M5/114	 BD	Horizon™,	BioLegend	
NK1.1	 BV650	 PK136	 BD	Horizon™	
Streptavidin	 FITC,	PECy7	 -	 BD	Pharmingen™	
TCRβ	 BV605	 H57-597	 BD	Horizon™	
XCR1	 BV421	 ZET	 BioLegend	
 





the	dark	at	37°C	 for	30	minutes.	Cells	were	washed	 twice	with	FACS	buffer	and	 then	
stained	for	cell	surface	markers	as	described	(2.8.2).		
	
2.8.4 Staining of intracellular cytokines 
Intracellular	 cytokine	 staining	 (ICS)	was	performed	with	a	BD	Cytofix/Cytoperm™	kit	
(BD	 Biosciences,	 CA,	 USA)	 as	 per	 the	 manufacturer’s	 instructions.	 Firstly,	 cells	 were	
stained	with	a	fixable	viability	dye	(Invitrogen™,	ThermoFisher	Scientific,	MA,	USA)	in	
PBS	 for	 30	minutes	 at	 4°C.	 After	washing	with	 PBS	 twice,	 cells	were	 stained	 for	 cell	
surface	markers	as	described	(2.8.2).	After	the	final	wash,	cells	were	fixed	by	incubating	
in	 100µL	 Fixation/Permeabilization	 solution	 for	 20	 minutes	 at	 4°C	 after	 which	 cells	
were	 pelleted	 and	 washed	 with	 1X	 Perm/Wash	 diluted	 in	 distilled	 H2O.	 To	 ensure	
thorough	 rinsing,	 cells	were	 incubated	 for	15	minutes	at	4°C	 in	Perm/Wash	solution.	
Cells	were	pelleted	and	resuspended	in	100µL	Perm/Wash	solution	containing	diluted	
antibodies	against	cytokines	of	interest.	Cells	were	stained	for	20	minutes	at	4°C	before	
being	washed	with	 Perm/Wash	 solution.	 To	 prevent	 background	staining,	 cells	were	
incubated	 for	 a	 further	 20	minutes	 in	 Perm/Wash	 at	 4°C	 before	 being	 pelleted	 and	






specificity Conjugates Clone Supplier 
CXCL9		 AF647	 MIG-2F5.5	 BioLegend	
IgG1	 BV421	 RMG1-1	 BioLegend	
IgM	 APC	 II/41	 BD	Pharmingen™	
IL-4	 PE	 11B11	 BD	Pharmingen™	
IL-17A	 PECy7	 eBio17B7	 eBioscience	
IL-17F	 AF488	 eBio18F10	 eBioscience	
IFNγ	 APC	 XMG1.2	 BD	Pharmingen™	
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2.8.5 Intranuclear protein staining 
Staining	of	intranuclear	proteins	such	as	transcription	factors	was	carried	out	using	a	
FoxP3/Transcription	 factor	 staining	 kit	 (eBioscience,	 CA,	 USA)	 or	 a	 TrueNuclear™	
Transcription	 factor	 buffer	 set	 (BioLegend,	 CA,	 USA)	 as	 per	 the	 manufacturer’s	
instructions.	 Firstly,	 cells	 were	 stained	 with	 a	 fixable	 viability	 dye	 (Invitrogen™,	
ThermoFisher	Scientific,	MA,	USA)	in	PBS	for	30	minutes	at	4°C.	After	washing	with	PBS	
twice,	 cells	were	 stained	 for	 cell	 surface	markers	 as	 described	 (2.8.2).	 Following	 the	
final	wash,	cells	were	fixed	by	incubating	in	100µL	Fixation/Permeabilization	solution	
for	 one	hour	 at	 room	 temperature	 after	which	 cells	were	 pelleted	 and	washed	 twice	
with	1X	Perm	buffer	diluted	 in	distilled	H2O.	 If	 applicable,	 cells	were	 resuspended	 in	
100µL	 Perm	 buffer	 containing	 diluted	 antibodies	 against	 cytokines	 of	 interest.	 Cells	
were	stained	for	20	minutes	at	4°C	before	being	washed	twice	with	Perm	buffer.	After	
the	 final	 wash,	 cells	were	 resuspended	 in	 Perm	 buffer	 containing	 diluted	 antibodies	
specific	for	intranuclear	proteins	of	interest.	Cells	were	incubated	at	room	temperature	









GATA-3	 AF647	 L50-823	 BD	Pharmingen™	
RORγt	 BV421	 Q31-378	 BD	Horizon™	
Tbet	 PE	 4B10	 BioLegend	
 
2.8.6 Acquisition of data  
All	data	was	acquired	on	a	LSRFortessa	SORP™	or	a	LSRII	SORP™	flow	cytometer	with	
FACSDiva	software	(Becton	Dickinson,	San	Jose,	CA,	USA;	see	Appendix	A	for	cytometer	









2.8.7 Analysis of flow cytometry data 
All	data	was	analysed	using	FlowJo	software	(Treestar	Inc,	CA,	USA).	Doublets	and	dead	




was	 performed	 on	 concatenated	 data.	 1000	 iterations	 and	 a	 perplexity	 factor	 of	 20	
were	used	for	all	tSNE	analyses.		
	
2.9 Cell enrichment and sorting 
2.9.1 Dendritic cell enrichment 
Dendritic	cells	were	enriched	from	ear	dLNs	using	a	Dynabead®	Mouse	DC	Enrichment	
kit	 (Invitrogen™,	 ThermoFisher	 Scientific,	MA,	 USA)	 according	 to	 the	manufacturer’s	
instructions.	 Briefly,	 cells	 from	 digested	 LNs	 were	 incubated	 in	 isolation	 buffer	
containing	biotinylated	antibodies	against	CD2,	CD3,	CD49b,	mIgM	and	Ter-119	for	20	
minutes	 at	 4°C.	 Cells	 were	 washed	 and	 then	 incubated	 under	 agitation	 in	 isolation	
buffer	containing	Depletion	MyOne™	Streptavidin	Dynabeads®	for	15	minutes	at	4°C.	
Tubes	were	 then	 placed	 in	 a	DynaMag™	 for	3	minutes	 and	 the	 supernatant	 collected	
and	 placed	 in	 a	 DynaMag™	 for	 an	 additional	 3	 minutes.	 The	 supernatant	 containing	
enriched	DC	was	collected	and	the	cells	counted.	
	
2.9.2 CD4+ T cell enrichment 






in	 isolation	 buffer	 containing	 FlowComp™	Dynabeads®	 for	 15	minutes	 at	4°C.	 Tubes	
were	then	placed	in	a	DynaMag™	for	3	minutes	and	the	supernatant	discarded.	Beads	
were	then	resuspended	 in	FlowComp™	Release	Buffer,	and	 incubated	 for	10	minutes,	
under	agitation,	 at	 room	 temperature.	Tubes	were	again	placed	 in	a	DynaMag™	 for	3	
minutes,	but	this	time	the	supernatant	was	collected	and	the	cells	counted.	
	





2.10 Molecular Biology 
2.10.1 RNA extraction 
RNA	was	 extracted	 from	purified	DC	 populations	 using	 a	Quick-RNAä	MicroPrep	 kit	






2.10.2 RNA to cDNA conversion 
Directly	 following	RNA	 extraction,	 sample	RNA	was	 converted	 to	 cDNA	using	 a	High	
Capacity	RNA-to-cDNA	kit	 (Applied	Biosystems,	ThermoFisher	Scientific,	MA,	USA)	as	
per	 the	 manufacturer’s	 instructions.	 Reverse	 transcription	 mix	 was	 added	 to	 RNA	






2.10.3 Pre-amplification of cDNA 
cDNA	was	pre-amplified	prior	to	qRT-PCR	to	ensure	appropriate	detection	of	genes	of	
interest.	 Pre-amplification	was	 performed	using	 a	 Sso-Advancedä	 PreAmp	 Supermix	
kit	 (Bio-Rad,	 CA,	 USA)	 as	 per	 the	manufacturer’s	 protocol.	 A	 pre-amplification	 assay	
pool	 was	 prepared	 in	 nuclease-free	 water	 to	 include	 all	 TaqMan®	 probes	 targeted	
against	genes	of	interest	(Table	2-5).	An	aliquot	of	the	assay	pool	was	mixed	with	the	
Sso-Advanced	PreAmp	Supermix	and	added	to	the	cDNA	for	each	sample.	The	mix	was	
incubated	 in	 a	 Veriti	 PCR	 ThermoCycler.	 Samples	 were	 initially	 held	 at	 95°C	 for	 3	
minutes	to	activate	the	polymerase	and	denature	the	DNA	and	then	run	for	12	cycles	
(15	 seconds	 at	 95°C	 and	 4	 minutes	 at	 58°C)	 to	 amplify	 the	 DNA.	 qRT-PCR	 was	 run	
directly	on	the	amplified	product.		
	
2.10.4 Quantitative real-time polymerase chain reaction (qRT-PCR) 
qRT-PCR	was	performed	using	the	TaqMan®	Gene	Expression	Assay	platform	(Applied	
Biosystems,	 ThermoFisher	 Scientific,	 MA,	 USA)	 according	 to	 the	 manufacturer’s	
instructions.	 Reactions	were	 performed	 in	duplicate	 in	 a	 total	 volume	 of	 20µL	which	
contained	TaqMan®	Universal	Master	Mix	II,	TaqMan®	probes	(Table	2-5)	and	8µL	of	




















2.10.5 Analysis of data 
For	analysis	and	presentation	of	qRT-PCR	data,	relative	expression	was	calculated	 for	
genes	 of	 interest	 by	 normalising	 against	 a	 housekeeping	 gene	 (Gapdh)	 for	 each	
population	using	 the	 following	 formula:	2^-(CTgene	of	interest-CTGapdh).	To	determine	 fold	
change	 (FC)	between	 treatment	groups	and	PBS	control	 groups,	 the	2-ΔCT	values	 for	
each	 gene	 were	 averaged	 over	 the	 biological	 replicates	 for	 the	 PBS-treatment	 cell	
populations.	The	2-ΔCT	values	 for	 treatment	populations	were	then	divided	by	the	2-
ΔCT	 value	 for	 their	 corresponding	 PBS	 control.	 These	 values	 were	 then	 log2	
transformed	for	graphical	display	(log2FC).	To	determine	statistical	significance,	a	One-




2.11 Single-cell RNA sequencing 
Single-cell	 RNA	 sequencing	 (scRNASeq)	was	 performed	 in	 collaboration	with	 Dr.	 Ido	
Amit’s	 laboratory	 (Weizmann	 Institute,	 Israel)	 according	 to	 their	 massively-parallel	
scRNASeq	 protocol	 (MARSeq)	 (751).	 Briefly,	 LN	 cells	 from	 mice	 immunised	 with	
AF488-labelled	 immunogen	 or	 PBS	 control	 animals,	 were	 stained	 with	 an	 antibody	
cocktail	containing:	CD45,	TCRβ,	CD19,	MHCII,	CD11c,	CD11b,	Siglec	F	and	FcεR1.	Single	
cells	 were	 then	 index	 sorted	 into	 384-well	 plates	 containing	 lysis	 buffer,	 RNase	





The	 library	 preparation	 protocol	 is	 outlined	 in	 Fig	 2.2.	 The	 library	 was	 pair-end	
sequenced	using	an	Illumina	HiSeq	2500	(Illumina	Inc,	San	Diego,	CA,	USA).	Sequencing	
data	 was	 analysed	 by	 Pierre	 Bost	 and	 Eyal	 David	 using	 the	 Amit	 laboratory’s	
Bioinformatic	 pipeline	 (751),	 which	 utilises	 the	 PAGODA	 pipeline	
(https://github.com/hms-dbmi/pagoda2)	 with	 the	 expression	 values	 and	 variance	
scaled	as	published	by	Lake	et	al	(752).	Cells	with	a	unique	molecule	 identifier	(UMI)	









2.12 Data analysis and statistics 
2.12.1 Data visualisation and display 
Plots	 displaying	 flow	 cytometry	 data	were	 generated	 using	 FlowJo	 software	 (version	
10;	Treestar	Inc.,	CA,	USA).	All	graphical	displays	were	generated	using	GraphPad	Prism	





was	 not	 possible,	 then	 individual	 data	 points	 are	 displayed	 on	 graphs	 from	 a	
representative	experiment.			
	
2.12.2 Calculation of cell numbers 
Frequencies	 at	 which	 individual	 cell	 populations	 were	 present	 among	 live	 cells	 was	
determined	 from	 flow	 cytometry	 data.	 These	 values	 were	 used	 to	 extrapolate	 cell	
numbers	 from	 counts	 taken	 from	single	 cell	 suspensions	 using	 a	 haemocytometer	 as	
described	(2.6.3).	
	
2.12.3 Gene Set Enrichment Analysis 
Gene	 Set	 Enrichment	 Analysis	 (GSEA)	 (753,	 754)	 (www.broad.mit.edu/gsea/)	 was	
performed	by	 Evelyn	Hyde	 and	 used	 to	 evaluate	 the	 enrichment	 of	 pre-defined	 gene	
sets	 in	 skin	 samples	 from	 healthy	 skin	 compared	 to	 lesional	 skin	 from	 Atopic	
Dermatitis	(AD)	or	Psoriasis	Vulgaris	(PV)	patients.	Gene	sets	comprised	of	the	human	
orthologs	of	mouse	genes	upregulated	 (FC	≥	1.5	and	p	 ≤	0.01)	 in	skin-dLN	migratory	
DC2	 following	Nb	 immunization	 (229),	 and	 the	 TSLP	 and	 IFN-I	 response	 genes	 from	
WikiPathways	or	Gene	Ontology,	respectively.	The	complete	gene	sets	can	be	found	in	
the	 Appendix	 E.	 The	 following	 GEO	 data	 sets	were	 used:	 GSE6012	 (755),	 GSE27887	
(756)	 and	 GSE58558	 (757,	 758)	 for	 AD,	 and	 GSE13355	 (759),	 GSE30999	 (760),	
GSE53552	 (761)	 for	PV.	Gene	 sets	with	a	Normalized	Enrichment	Score	>1	and	False	
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microarray	 but	 included	 data	 for	 3	 genes	 of	 interest	 (CCL17,	 LY6D	 and	 CAPG).	 This	
study	was	therefore	not	used	to	determine	the	common	CEGs,	but	the	fold	change	data	
for	 the	genes	available	 is	 included	and	was	determined	using	the	same	method	as	 for	
GSE6012.	
	
2.12.4 Statistical analysis 
Statistical	tests	were	carried	out	using	GraphPad	Prism	software	(version	5	for	Mac	OS	
X;	 GraphPad	 Software,	 CA,	 USA).	 Analysis	 of	 variance	 (ANOVA)	 tests	were	 chosen	 to	
conduct	statistical	analyses	given	that	sample	distribution	(including	distributions	that	
are	significantly	non-normal),	small	group	sample	sizes	(5≤n≤15),	unequal	group	sizes	
and	 unequal	 sample	 distributions	 between	 groups	 have	 been	 demonstrated	 to	 not	
impact	test	robustness	(764-766).	When	comparing	more	than	two	groups,	a	One-Way	
ANOVA	with	Holm-Sidak’s	 post-test	was	 used	 to	 assess	 statistical	 significance.	When	

















3 Intradermal immunisation with 
different immunogens is 
associated with distinct patterns 









(768).	 Many	 bacterial	 antigens	 induce	 IFNγ-producing	 Th1	 cells,	 whereas	 helminth	
antigens	 promote	 IL-4/IL-13-producing	 Th2	 cells.	 Fungal	 antigens	 drive	 IL-17-
producing	Th17	cells.	In	addition,	CD4+	T	cells	can	differentiate	into	B	cell	supporting	T	
follicular	helper	(Tfh)	cells,	regulatory	cells	(Tregs)	or	IL-9/IL-22-producing	Th9/Th22	









The	 recruitment	of	 these	 cell	 types	 and	 their	 response	 to	 inflammatory	 insults	 could	
therefore	play	an	 important	 role	 in	 conditioning	APC	or	even	T	 cells	directly.	 Indeed,	
some	 propose	 that	 basophil-derived	 IL-4	 contributes	 to	 the	 initiation	 of	 Th2	
differentiation	 (675,	 770).	 Further,	 IFNγ	 derived	 from	 NK	 cells	 has	 been	 shown	 to	
promote	the	differentiation	of	monocytes	into	monocyte-derived	DC	producing	the	Th1	
polarising	cytokine	IL-12	(47,	486).	Thus,	it	is	imperative	to	assess	the	recruitment	and	
activation	 profiles	 of	 innate	 immune	 cells	 during	 the	 initial	 phases	 of	 an	 immune	




regulation	 of	 CD4+	 T	 cell	 responses	 has	 stemmed	 from	 studies	 focused	 on	 the	
generation	of	one	Th	phenotype	utilising	a	single	antigen/infection	model	(10,	13,	47,	
331,	 339,	 486,	 550-553,	 559,	 561-563,	 566-570,	 770,	 771).	 Thus,	 without	 direct	
comparison	studies,	it	is	difficult	to	determine	which	factors	are	generally	involved	in	
the	 initiation	 of	 CD4+	T	 cell	 responses	 and	which	 factors	 are	 specifically	 involved	 in	
supporting	 a	 particular	 CD4+	 T	 cell	 phenotype.	 The	 distinction	 between	 these	 two	
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types	of	signal	has	important	implications	for	the	design	of	immunotherapies	where	the	
induction	 of	 the	 appropriate	 signals	 is	 vital	 for	 therapeutic	 success.	 The	 overarching	
aim	of	this	thesis	was	to	address	this	current	limitation	in	the	literature	by	performing	
a	 side-by-side	assessment	of	 the	 requirements	 for	Th1,	Th2	and	Th17	differentiation	
using	a	simple	immunisation	model.		
	
An	 intradermal	 (i.d.)	 ear	 immunisation	model	was	developed	by	Dr.	Graham	Le	Gros	
and	colleagues	to	assess	Th2	response	to	allergens	(336).	The	significant	advantage	of	
this	 model	 is	 that	 the	 immune	 response	 generated	 to	 i.d.	 administered	 antigen	 is	
contained	 within	 one	 LN.	 This	 allows	 for	 easy	 assessment	 of	 priming	 events	 in	 the	
auricular	LN.	Further,	fluorescent	labelling	of	an	immunogen	prior	to	injection	enables	
straightforward	tracking	of	cells	that	carry	material	from	the	ear	skin	to	the	LN	(333).	





brasiliensis;	 Nb)	 and	 a	 fungus	 (Candida	 albicans;	 Ca)	 were	 selected	 to	 serve	 as	
immunogens	 in	 the	 present	 study.	Ms	 is	 a	 fast-growing	mycobacterial	 species	 that	 is	
considered	 to	 be	 non-pathogenic,	 but	 can	 cause	 skin	 and	 soft	 tissue	 infections	 in	
humans	(772,	773).	Similar	 to	other	mycobacterial	species,	Ms	 is	a	relatively	 large	(3-
5µm)	rod-shaped	bacterium	that	is	protected	by	a	thick	lipid-rich	cell	wall	(774,	775).	
Many	 PRRs	 are	 involved	 in	 the	 detection	 of	 mycobacteria	 by	 the	 immune	 system,	
including:	TLR2	(lipoprotein	and	lipomannan)	(776-778),	TLR9	(bacterial	DNA)	(779),	
Dectin-1	 (α-glucan)	 (780),	 DC-SIGN	 (mannosylated	 lipoarabinomannan)	 (781-783),	
Mincle	 (trehalose-6,6’-dimycolate)	 (784,	 785)	 and	 NOD2	 (muramyl	 dipeptide)	 (776,	
786,	 787).	 Recognition	 of	 mycobacteria	 via	 these	 pathways	 is	 associated	 with	








PRRs	 involved	 in	 immune	 cell	 recognition	 of	 helminths,	 including	 Nb,	 are	 unclear.	
There	is	evidence	that	helminths	and	their	excretory/secretory	products	activate	TLRs	
(2	 and	 4)	 and	 C-type	 lectin	 receptors	 expressed	 by	 APC	 (790-792).	 However,	 it	 is	
difficult	 to	 determine	 whether	 these	 PRRs	 are	 recognising	 ligands	 derived	 from	 the	
helminths	themselves	or	from	their	associated	microbiota.	Indeed,	some	authors	have	














The	 knowledge	 gained	 from	 systematically	 assessing	 and	 comparing	 immune	
responses	 to	Ms,	Nb	 and	 Ca	 will	 hopefully	 assist	 in	 identifying	 key	 determinants	 of	







The	 regulation	 of	 CD4+	 T	 cell	 differentiation	 is	 an	 intricate	 process	 that	 potentially	
involves	many	populations	of	innate	immune	cells	and	cytokines.	The	accumulation	and	
activation	 of	 certain	 innate	 immune	 cell	 populations	 is	 correlated	 with	 the	
development	of	particular	CD4+	T	cell	responses.	However,	further	research	is	required	
to	 determine	 which	 of	 these	 cell	 types	 actively	 contribute	 to	 shaping	 CD4+	 T	 cell	
responses.		
	
The	 overall	 aim	 of	 this	 chapter	 was	 to	 establish	 a	 model	 that	 would	 allow	 for	 a	
systematic	 side-by-side	 comparison	 of	 the	 immune	 cells	 and	 cytokines	 involved	 in	
regulating	 CD4+	 T	 cell	 differentiation	 to	 distinct	 immunogens.	 This	 model	 was	 then	
used	 to	 identify	 and	 characterise	 the	 patterns	 of	 immune	 cell	 recruitment	 and	




• The	 development	 of	 a	 mouse	 skin	 immunisation	 model	 that	 allowed	 for	 the	
assessment	of	immune	responses	elicited	to	different	types	of	immunogen.	
• The	 characterisation	 of	 the	 CD4+	 T	 cell	 phenotypes	 elicited	 following	 skin	
immunisation	with	different	types	of	immunogen.	
• The	temporal	characterisation	of	innate	immune	cell	populations	present	in	the	
dLN	 after	 administration	 of	 immunogens	 associated	 with	 Th1,	 Th2	 or	 Th17	
responses.	
• The	identification	and	characterisation	of	antigen-carrying	cells	in	the	dLNs	of	






3.3.1 Developing a model to assess the requirements for Th1, Th2 and Th17 
differentiation 
In	 order	 to	 systematically	 assess	 the	 roles	 of	 cell	 types	 and	 cytokines	 in	 regulating	
CD4+	T	 cell	 responses,	 a	murine	 intradermal	 (i.d.)	 immunisation	model	was	 adapted	
from	 published	 studies	 (336).	 This	 is	 a	 simple	 model	 whereby	 immunogens	 are	





serve	 as	 immunogens	 in	 this	 study.	Mycobacterium	 smegmatis	 (Ms),	Nippostrongylus	
brasiliensis	 (Nb)	 and	 Candida	 albicans	 (Ca)	 have	 been	 previously	 characterised	 as	
promoting	Th1,	Th2	and	Th17	responses	respectively	(331,	336,	788).	For	the	purposes	




cytokines	 by	 intracellular	 staining	 (Fig	 3.1A).	 This	 protocol	 allowed	 for	 the	
measurement	of	Th1,	Th2	and	Th17	responses	in	the	same	experiment	by	quantifying	









7	days.	Cells	were	 re-stimulated	with	50ng/mL	PMA	and	1µg/mL	 ionomycin	 in	 the	presence	of	GolgiStop™	for	5	
hours,	stained	for	surface	molecules	and	intracellular	cytokines	and	analysed	by	flow	cytometry.	(B)	Gating	strategy	






3.3.2 Intradermal immunisation with Ms, Nb and Ca elicits distinct CD4+ T cell cytokine 
profiles 








Next,	 the	 full	 cytokine	 profile	 elicited	 by	 the	 different	 immunogens	was	 assessed.	 As	
expected,	 IFNγ	 was	 the	 predominant	 cytokine	 produced	 by	 CD4+	 T	 cells	 in	 Ms-
immunised	mice.	The	numbers	and	frequencies	of	IL-4+	and	IL-17A+	CD4+	T	cells	after	
Ms	immunisation	were	not	significantly	higher	than	PBS	controls	(Fig	3.2A).	In	the	LNs	
of	Nb-immunised	mice,	 IL-4+	 cells	made	 up	 a	 significant	 proportion	 of	 total	 CD4+	T	
cells.	 While	 only	 a	 third	 of	 the	 number	 of	 IL-4+	 cells,	 IFNγ+	 cells	 also	 made	 up	 a	
significant	 proportion	of	 the	 CD4+	T	 cells	 in	Nb-immunised	mice.	 The	 number	 of	 IL-
17A+	cells	was	not	significantly	increased	compared	to	controls	(Fig	3.2B).			
	
Th17	 and	 Th1	 responses	 are	 typically	 assessed	 in	 Ca	 infection	 and	 immunisation	
models	 (331,	 339,	 804).	 In	 line	with	 this,	 the	 number	 and	 frequency	 of	 IL-17A+	 and	
IFNγ+	 CD4+	 T	 cells	 were	 significantly	 increased	 following	 Ca	 immunisation.	
Surprisingly,	 the	number	and	 frequency	of	 IL-4+	CD4+	T	 cells	were	also	 significantly	




cells	 in	Ms-treated	mice	 and	 IL-4+	 cells	 in	Nb-treated	mice.	 It	was	 hypothesised	 that	
Th17	cells	may	quickly	leave	the	LN	after	priming,	thus	limiting	their	detection	in	the	
LN.	 To	 investigate	 this	 possibility,	Ca-immunised	mice	 received	 a	 dose	 of	 FTY720	 or	
H2O	 two	 days	 after	 immunisation.	 FTY720	 disrupts	 sphingosine-1-phosphate	
signalling,	 preventing	 T	 cell	 egress	 from	 the	 LN	 (750).	 FTY720	 treatment	 markedly	
increased	 the	 number	 and	 frequency	 of	 IL-17A+	 cells	 following	 Ca	 immunisation,	
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suggesting	that	Th17	cells	were	elicited	in	response	to	Ca,	but	rapidly	left	the	LN	(Fig	
3.2D).	 In	 contrast,	 the	 numbers	 of	 IFNγ+	 and	 IL-4+	 cells	 remained	 unchanged	 with	
FTY720	 treatment	 (Fig	3.2E-F),	 indicating	 that	 these	 cells	were	 not	 rapidly	 recruited	
out	of	the	LN.			
	
Given	 the	 presence	 of	 multiple	 populations	 of	 cytokine	 producing	 CD4+	 T	 cells	
following	 i.d.	 immunisation,	 it	was	of	 interest	to	characterise	the	abundance	of	multi-
functional	 CD4+	 T	 cells.	 Using	 Boolean	 analysis,	 single,	 double	 and	 triple	 cytokine	
producing	CD4+	T	cells	were	identified	using	IL-4,	IL-17A	and	IFNγ	staining.	Following	
Ms	 immunisation,	 >95%	 of	 cytokine-producing	 CD4+	 T	 cells	 were	 single	 producers,	
with	IFNγ+	single-producing	CD4+	T	cells	making	up	81%	of	all	cytokine-positive	cells	
(Fig	3.3A).	 In	Nb-treated	mice,	>87%	of	 cytokine-producing	CD4+	T	 cells	were	 single	
producers.	Of	 the	 total	 IFNγ+	CD4+	T	 cell	 population,	>30%	also	 produced	 IL-4.	 IL-4	
single	producers	and	IFNγ	single	producers	made	up	the	rest	of	the	cytokine-producing	
CD4+	 T	 cell	 population	 (Fig	 3.3B).	 Ca-immunised	 mice	 had	 a	 mixed	 CD4+	 T	 cell	
response;	 however,	 <10%	 of	 cytokine-producing	 CD4+	 T	 cells	were	 double	 or	 triple	
producers	(Fig	3.3C).		
	
Th17	 cells	 are	 known	 to	 produce	 IL-17F	 in	 addition	 to	 IL-17A.	Boolean	 analysis	was	
performed	 on	Ca-treated	 LN	 cells	 using	 IL-17F,	 IL-17A	 and	 IFNγ	 staining.	 Of	 the	 IL-
17A+	 CD4+	 T	 cells,	 60%	 also	 expressed	 IL-17F.	 	 The	 remainder	 of	 cytokine-positive	
cells	were	single	producers	of	IL-17F,	IL-17A	or	IFNγ	(Fig	3.3D).		
	
Together,	 these	 data	 show	 that	Ms,	Nb	 and	 Ca	 drive	 distinct	 CD4+	 T	 cell	 responses,	
distinguishable	by	their	cytokine	profiles.	Ms	and	Nb	are	associated	with	predominant	
IFNγ+	and	IL-4+	cells,	respectively.	Ca	drives	a	mixed	response,	eliciting	 IFNγ+,	 IL-4+	
and	 IL-17A+	 cells.	 Despite	 this	 mixed	 response,	 the	 majority	 of	 cytokine-producing	
CD4+	T	cells	were	single-producers	of	the	cytokines	assessed,	with	the	exception	being	
IL-17A+	 cells	 that	 could	 also	 produce	 IL-17A,	 and	 IL-17F.	 The	 frequency	 of	 IL-17A+	























3.3.3 Cytokine production by CD4+ T cells corresponds with the expression of lineage-
defining transcription factors 
Activation	of	 lineage-defining	 (“master”)	 transcription	 factors	 following	priming	 is	 an	
important	 determinant	 of	 CD4+	T	 cell	 differentiation	 and	 cytokine	 production	 (806).	
Tbet	 regulates	 Th1	 differentiation	 and	 IFNγ	 production	 (371,	 807),	 whereas	 GATA-3	
promotes	 Th2	 differentiation	 and	 expression	 of	 Th2	 characteristic	 cytokines	 (250).	
RORγt	 promotes	 Th17	 differentiation	 and	 production	 of	 IL-17A/F	 by	 CD4+	 T	 cells	
(409).	Therefore,	 it	was	of	 interest	 to	use	 transcription	 factor	 staining	 to	 confirm	 the	
lineage	of	cytokine-producing	CD4+	T	cells	following	i.d.	immunisation.	To	do	this,	cells	
were	isolated	from	the	LNs	of	immunised	mice	and	processed	as	in	Fig	3.1A.	After	ICS	







CD4+	T	cells	express	GATA-3,	but	Th2	cells	highly	express	GATA-3	 (250,	808).	 In	 line	
























3.3.4 T follicular helper cells are induced in intradermal immunisation models 
Tfh	 cells	 are	 a	 distinct	 subset	 of	 CD4+	 T	 cells	 that	 express	 CXCR5,	 PD1	 and	 the	
transcription	 factor	 BCL6	 and	 play	 an	 important	 role	 in	 supporting	B	 cell	 responses	
(389,	390,	393).	To	 investigate	Tfh	cell	responses	 following	i.d.	 immunisation,	LN	cells	




identified	 based	 on	 CXCR5	 and	 PD1	 expression	 (Fig	 3.5A).	 CXCR5+	 PD1+	 cells	 were	
CD44+	 and	 also	 expressed	 the	 Tfh	 master	 transcription	 factor	 BCL6	 (Fig	 3.5B).	
Following	immunisation	with	Ms,	Nb	or	Ca,	the	number	and	frequency	of	Tfh	cells	was	
significantly	higher	 than	PBS	 controls	 (Fig	 3.5	 C-D).	 Tfh	 cells	were	most	 pronounced	













and	 can	 be	 identified	 by	 expression	 of	 CXCR5	 and	 PD1.	 Tfh	 and	 Teff	 cells	 were	
distinguishable	by	their	expression	of	CXCR5	and	lineage-defining	transcription	factors.	















3.3.5 Characterisation of innate immune cells in the LNs of immunised mice using 
scRNASeq and flow cytometry  
Innate	immune	cells	make	up	a	small	proportion	of	total	LN	cells	but	are	key	players	in	
the	regulation	of	CD4+	T	cell	differentiation.	Therefore,	it	was	important	to	understand	
the	 composition	 of	 the	 innate	 immune	 compartment	 in	 the	 first	 few	 days	 following	
immunisation	with	different	immunogens.	In	collaboration	with	Dr.	Ido	Amit’s	team	at	
the	 Weizmann	 Institute	 of	 Science	 in	 Israel,	 single-cell	 RNA	 sequencing	 (scRNASeq)	
(751)	was	 performed	 on	13,827	 nonB/T	 cells	 (TCRβ-,	 CD3-,	 CD19-)	 one	 or	 two	days	
after	 immunisation	 with	Ms,	Nb	 or	 Ca,	 or	 after	 PBS	 treatment.	 Clustering	 using	 the	
Pathway	 and	 Gene	 Set	 Over-Dispersion	 Analysis	 (PAGODA)2	 pipeline	 (752,	 809)	
identified	 ten	 distinct	 cell	 clusters	 (Fig	 3.6).	 The	 largest	 cluster	 was	 annotated	 as	 a	
monocyte	 population	 due	 to	 their	 specific	 expression	 of	Plac8	 and	 Ly6c2	 (463,	 810).	
Migratory	DC	populations	were	also	abundant	and	could	be	identified	by	their	specific	
expression	 of	Fscn1	 and	Ccr7	(571).	 Populations	 of	 other	 innate	 immune	populations	







and	 LNs	 were	 harvested	 for	 analysis	 on	 day	 one,	 two	 or	 three.	 Multi-colour	 flow	
cytometry	 allowed	 for	 the	 identification	 of	 nine	 distinct	 innate	 populations:	
neutrophils,	 eosinophils,	 basophils,	 mast	 cells,	 NK	 cells,	 migDC,	 resDC,	 pDC	 and	
monocytes	(Fig	3.7A).	In	these	experiments,	nonB/T	cells	were	defined	as	TCRβ-,	B220-
,	CD3-.	As	some	pDC	express	B220,	pDC	were	identified	from	ungated	cells.	MigDC	and	




immunisation	 with	Ms,	 Nb	 and	 Ca,	 consistent	 with	 the	 recruitment	 of	 immune	 cell	














that	 the	 composition	of	 cell	 types	was	 similar	between	LNs	 from	Ms-	 and	Nb-treated	
mice	 (Fig	 3.8).	 But,	 a	 greater	 proportion	 of	 monocytes	 was	 noted	 following	 Ms	
immunisation.	Further,	NK	cells	were	over-represented	 in	Ms-treated	mice	 (Figs	3.7B	
and	 3.8).	 The	 LNs	 of	Ca-treated	mice	 had	 a	 greater	 diversity	within	 the	 nonB/T	 cell	
compartment	compared	to	Ms	and	Nb	LNs,	which	was	more	evident	in	flow	cytometry	




flow	 cytometry	 data	 (Fig	 3.8B).	 The	 undefined	 cells	 are	 likely	 to	 include	 pDCs,	 ILCs,	





populations	 of	 innate	 immune	 cells	 present	 in	 the	 LNs	 of	 immunised	mice.	 The	 LNs	



















Figure	 3.7:	 Flow	 cytometric	 characterisation	 of	 innate	 immune	 cell	 populations	 following	 intradermal	
immunisation.	Mice	were	 immunised	with	Ms,	Nb	or	Ca	by	i.d.	 injection.	Control	animals	received	PBS.	After	one,	
two	 or	 three	 days,	 the	 dLNs	 were	 processed	 for	 flow	 cytometric	 analysis.	 (A)	 Gating	 strategy	 showing	 the	
identification	 of	 innate	 immune	 cell	 populations	 in	 the	 dLN	 after	 immunisation.	 (B)	 Quantification	 of	 total	 cells,	
















3.3.6 Migratory DC and monocytes transport immunogenic material to the dLNs 
One	function	of	recruited	innate	immune	cells	is	to	transport	antigens	from	the	tissue	
to	 the	 LN	 for	 presentation	 to	 adaptive	 immune	 cells.	 To	 identify	 the	 cell	 types	
associated	with	antigen	in	vivo,	Ms,	Nb	and	Ca	were	 fluorescently	 labelled	prior	 to	 i.d.	
injection.	 Flow	 cytometry	 could	 then	 be	 used	 to	 identify	 cells	 (Ag+)	 that	 had	 direct	
interaction	 with	 the	 immunogenic	 material	 and	 could	 presumably	 present	 their	
associated	antigens	to	T	cells.	Time	course	experiments	showed	that	Ag+	cells	could	be	
detected	one	day	after	immunisation,	but	the	frequency	of	Ag+	cells	peaked	on	day	two	












In	 total,	 6399	Ag+	 cells	were	 sequenced	 and	 passed	 quality	 control.	 Clustering	 of	 all	
Ag+	cells	using	the	PAGODA2	pipeline	revealed	six	discrete	clusters,	comprising	of	four	
distinct	 cell	 types	 (Fig	3.10A).	MigDC	were	 the	most	abundant	antigen-carrying	 cells,	
making	 up	 two	 distinct	 clusters.	 These	 migDC	 clusters	 were	 separated	 based	 on	
activation	 status	 rather	 than	 lineage,	 with	 migDC	 (2)	 expressing	 higher	 levels	
activation-associated	 transcripts	 including:	 Cd40,	 Cd86,	 Il12b,	 Ccl17	 and	 Ccl22	
compared	 to	migDC	 (1)	 (Fig	3.10A,	C-D).	Monocytes	were	 the	 second	most	abundant	
Ag+	cell	population.	Like	migDC,	monocytes	made	up	two	distinct	clusters	separated	by	
activation	status.	The	monocyte	(2)	cluster	had	higher	expression	of	MHCII-associated	
genes	 (H2-Aa,	 H2-Ab1,	 H2-Eb1	 and	 Cd74),	 as	 well	 as	 MHCII	 and	 CD11c	 protein,	
compared	to	the	monocyte	(1)	cluster	(Fig	3.10A).	In	addition,	the	monocyte	(2)	cluster	
had	higher	expression	of	 inflammatory	 cytokine	 transcripts	 including	 Il12b	 and	Cxcl9	
(Fig	 3.10B,	 D).	 The	 corresponding	 lower	 expression	 of	 “canonical”	 monocyte	 genes	
(Plac8,	 Ly6e,	 Ccr2	 and	 Ly6c2)	 in	 the	 monocyte	 (2)	 cluster	 suggests	 that	 this	 cluster	
represents	monocytes	differentiating	 into	DC	or	macrophages	 (Fig	3.10A	and	B).	The	






from	scRNASeq	 experiments,	 the	Ag+	 population	 consisted	 of	migDC,	monocytes	 and	
neutrophils	(Fig	3.11A).	MigDC	were	a	prominent	population	among	Ag+	cells	and	were	
identifiable	by	their	high	expression	of	MHCII	and	CCR7	(Fig	3.11B).	Non-DC	could	be	
resolved	 into	 monocyte	 and	 neutrophil	 populations	 based	 on	 their	 differential	
expression	 of	MHCII	 and	 Ly6C	 (Fig	 3.11A).	 Ly6G	 is	 a	 specific	marker	 of	 neutrophils;	
however,	 not	 all	 Ag+	 experiments	 had	 Ly6G	 data.	 Pre-gated	 Ly6G+	 neutrophils	 and	
Ly6G-	 Ly6C+	 monocytes	 were	 overlayed	 to	 compare	 their	 expression	 of	 MHCII	 and	
Ly6C.	 This	 analysis	 showed	 that	 MHCII,	 Ly6C	 gating	 was	 sufficient	 to	 discriminate	
between	the	majority	of	monocytes	and	neutrophils	(Fig	3.11B).	A	small	proportion	of	














selected	marker	 genes	 across	 all	 cells	 are	 shown	 in	 the	 lower	 heatmap.	 The	 top	 panel	 indicates	 the	 condition-
specificity	of	Ag+	 cell	 clusters.	The	bottom	panel	 shows	 the	 fluorescence	 intensity	of	marker	proteins	across	 cell	
clusters.	 (B)	 Volcano	 plot	 comparing	 gene	 expression	 between	 the	 monocyte	 (1)	 and	 monocyte	 (2)	 clusters.	






Figure	 3.11:	 Flow	 cytometric	 characterisation	 of	 antigen-carrying	 cells.	 LN	 cells	 were	 isolated	 from	 mice	




3.3.7 The cellular composition of antigen-carrying cells is distinct between different 
immunogens 





Ms	 antigen	 was	 distinct	 compared	 to	 Nb	 and	 Ca	 antigen.	 Monocytes	 made	 up	 a	
significant	proportion	of	Ms+	cells	at	both	time	points	measured,	whereas	Nb+	and	Ca+	
monocytes	were	rare	(<20%),	particularly	on	day	two.	 In	some	mice,	Nb+	monocytes	
could	 be	 detected	 on	 day	 one,	 but	 this	 finding	 was	 not	 consistent	 across	 all	








































by-side	 comparisons	 of	 innate	 and	 adaptive	 immune	 responses	 to	 Ms,	 Nb	 and	 Ca.	
scRNASeq	and	flow	cytometry	technologies	were	used	to	construct	a	detailed	picture	of	
the	immune	cell	phenotypes	in	the	LNs	of	immunised	mice.	Clear	patterns	of	 immune	
cell	 recruitment	 and	 activation	 were	 noted	 between	 mice	 treated	 with	 different	
immunogens.	 These	 data	 prompted	 the	 generation	 of	 hypotheses	 surrounding	 the	
regulation	of	CD4+	T	cell	differentiation	that	are	explored	in	further	chapters.			
	
3.4.1 Intradermal ear immunisation model 
The	 i.d.	 immunisation	 model	 was	 identified	 as	 a	 useful	 tool	 to	 assess	 the	 roles	 of	
immune	cell	populations	and	cytokines	in	the	regulation	of	CD4+	T	cell	differentiation.	
Importantly,	 the	 i.d.	 injection	 route	 is	 physiologically	 relevant,	 with	 the	 skin	 being	 a	
major	 site	 of	 microbial	 and	 pathogen	 invasion.	 Further,	 the	 accessibility	 of	 the	 skin	
makes	 the	 i.d.	 injection	 route	 suitable	 for	 the	administration	of	 immunotherapeutics,	








the	 dLN	 at	 different	 time	 points	 following	 immunisation	 allowed	 for	 a	 detailed	
characterisation	of	the	cell	types	and	cell	states	induced	by	the	selected	immunogens.	
Non-viable	organisms	were	used	in	this	study	to	maintain	some	of	the	immunological	
complexity	 associated	with	 a	 natural	 infection,	 such	 as	 the	 presence	 of	multiple	 PRR	
ligands,	which	would	be	lost	using	antigen-adjuvant	formulations.	The	choice	was	made	
to	 use	 non-viable	 organisms	 due	 to	 biosafety	 considerations	 and	 to	 prevent	
dissemination	and	involvement	of	organs	other	than	the	skin.	However,	a	limitation	of	




Further,	 a	 limitation	 to	 using	 a	 whole	 organism	 immunisation	 strategy	 instead	 of	
protein	 or	 peptide	 strategies	was	 the	 inability	 to	 track	 antigen-specific	 CD4+	T	 cells	
from	 their	 naïve	 state	 to	 activated	 effectors	 and	memory	 cells.	 Future	 studies	would	
benefit	 greatly	 from	 the	 use	 of	 transgenic-TCR	T	 cells	 or	 tetramer	 staining	 to	 assess	
antigen-specific	 proliferation,	 cytokine	 production	 and	 lineage-defining	 markers.	 As	





The	 primary	 method	 used	 to	 assess	 CD4+	 T	 cell	 differentiation	 was	 intracellular	
cytokine	 staining	 following	 a	 polyclonal	 re-stimulation.	 This	method	 allowed	 for	 the	
simultaneous	measurement	 of	 Th1,	 Th2	 and	 Th17	 cells	 -	which	 is	 not	 possible	with	
currently	available	cytokine	reporter	mice.	However,	polyclonal	re-stimulation	reports	
the	 potential	 for	 a	 CD4+	 T	 cell	 to	 make	 a	 particular	 cytokine,	 rather	 than	 active	
production	(812).	Reassuringly,	the	frequency	of	cytokine	producers	was	similar	to	the	
frequency	 of	 unstimulated	 cells	 stained	 for	 lineage-defining	 transcription	 factors.	
Further,	the	 frequency	of	 IL-4+	cells	was	comparable	between	re-stimulated	cells	and	
unstimulated	 cells	 from	 mice	 that	 report	 IL-4	 transcription	 through	 expression	 of	
AmCyan.	 Together,	 the	 information	 assembled	 from	 reporter	 mice,	 intranuclear	







injected	 immunogens	was	actively	 transported	 from	 the	ear	 tissue	 to	 the	LN.	Passive	
diffusion	of	fluorescently-labelled	organisms	in	the	lymph	would	presumably	result	in	
the	 presence	 of	 Ag+	 sub-capsular	 sinus	 macrophages	 and	 resDC	 (573).	 A	 small	
population	 of	 Ag+	macrophages	was	 noted	 in	 scRNASeq	 experiments	 but	 these	 cells	
had	 high	 expression	 of	 C1q	 transcripts	 indicative	 of	 monocyte-derived	 T	 cell	 zone	
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macrophages	(598).	Further,	Ag+	resDC	were	not	detected	at	any	of	the	measured	time	
points	 by	 scRNASeq	 or	 flow	 cytometry	 and	 did	 not	 up-regulate	 activation	 markers,	
indicating	 that	 they	 had	 not	 been	 exposed	 to	 immunogenic	material	 (Fig	 4.4).	 Thus,	
fluorescent	 labelling	 provided	 a	 powerful	 tool	 to	 identify	 and	 characterise	 cells	 that	
have	 had	 direct	 interaction	 with	 the	 immunogens	 and	 transport	 material	 from	 the	
tissue	to	the	LN.		
	
3.4.2 CD4+ T cell responses to bacterial, helminth and fungal derived antigens 
Intradermal	 immunisation	with	non-viable	Ms,	Nb	 and	Ca	 resulted	 in	distinct	CD4+	T	
cell	 responses,	measured	by	 cytokine	production,	 transcription	 factor	expression	and	
Tfh	marker	expression.	The	simultaneous	assessment	of	these	parameters	in	the	same	
experiment	allowed	for	a	detailed	characterisation	and	comparison	of	the	CD4+	T	cell	







has	 been	 tested	 in	 vaccines	 formulations	 against	M.	 tuberculosis	due	 to	 its	 ability	 to	
induce	effector	Th1	cells	(788,	814).	In	addition	to	effector	Th1	cells,	a	population	of	Tfh	





In	contrast	 to	Ms,	 the	predominant	CD4+	T	cell	phenotypes	present	 in	 the	LNs	of	Nb-
treated	mice	were	IL-4+	cells	and	CXCR5+	PD1+	Tfh	cells.	Distinguishing	Th2	effector	
cells	 from	Tfh	 cells	 in	 the	 LN	has	 proved	 to	 be	 difficult	 in	many	Th2	models,	 as	Th2	





from	 distinct	 differentiation	 pathways	 or	 serve	 as	 different	 phases	 in	 a	 Th2	
differentiation	 programme.	 Figure	 3.5	 shows	 that	 CXCR5	 and	 GATA-3	 expression	
clearly	define	 two	populations	of	CD44+	CD4+	T	 cells	 in	Nb-treated	mice,	which	 is	 in	
line	with	studies	that	have	shown	that	BCL6	suppresses	GATA-3	expression	(253,	390,	
441).	Experiments	presented	in	this	chapter	and	in	Chapter	6	show	that	IL-4+	cells	are	




Nb	 immunisation.	 It	 is	 unclear	 whether	 these	 cells	 are	 specific	 for	 Nb	 antigen	 or	
microbial	 antigens	 associated	 with	 the	 cuticle	 or	 intestinal	 tract	 of	 the	 larvae.	 The	
number	and	frequency	of	IFNγ+	CD4+	T	cells	did	not	change	across	Nb	batches,	despite	
10-fold	differences	in	endotoxin	units,	which	would	suggest	that	bacterial	components	
may	 not	 be	 the	 antigen	 associated	 with	 Th1	 cells	 in	 this	 model	 (Shiau-Choot	 Tang,	
unpublished	observations)	(815).		
	
Finally,	 the	 response	 to	Ca	 comprised	 of	multiple	 CD4+	 T	 cell	 phenotypes,	 including	
Th1,	 Th2,	 Th17	 and	 Tfh	 cells.	 Ca	 was	 the	 only	 model	 to	 induce	 a	 measurable	 Th17	
response	 as	 determined	 by	 IL-17A/F	 staining	and	RORγt	 expression.	However,	 Th17	
cells	were	not	the	predominant	phenotype	of	activated	CD4+	T	cells	in	Ca-treated	mice.	
Experiments	that	employed	FTY720	to	block	the	egress	of	activated	CD4+	T	cells	from	






presence	 of	 IL-4+	 Th2	 cells	 in	 Ca-treated	 mice	 is	 somewhat	 surprising.	 Studies	
performed	15+	years	ago	do	report	 that	 IL-4+	cells	arise	 following	Ca	 infection	(805).	




3.4.3 LN-associated innate immune cells 
Time	course	experiments	revealed	distinct	patterns	of	innate	immune	cell	recruitment	
between	Ms-,	Nb-	 and	 Ca-treated	 mice.	 scRNASeq	 and	 flow	 cytometry	 were	 used	 in	
conjunction	 to	perform	a	detailed	 characterisation	of	 innate	 immune	cell	populations	
following	 i.d.	 immunisation.	 Together,	 these	 techniques	 allowed	 for	 the	 resolution	 of	
twelve	 innate	 cell	 populations,	 namely:	 monocytes,	 macrophages,	 migDC,	 resDC1,	
resDC2,	 pDC,	 NK	 cells,	 ILC,	 neutrophils,	 eosinophils,	 basophils	 and	 mast	 cells.	 LN	
macrophages	 and	 ILC	 are	 difficult	 to	 identify	 by	 flow	 cytometry	 due	 to	 their	 lack	 of	
defining	 surface	 markers	 but	 were	 clearly	 distinguishable	 by	 their	 transcriptional	
profiles.	 Conversely,	 basophils,	 mast	 cells	 and	 eosinophils	 were	 only	 detected	 using	
flow	 cytometry.	 The	 algorithm	 used	 to	 analyse	 scRNASeq	 data	 will	 only	 cluster	
populations	 that	 are	 greater	 than	 1%	of	 the	 total	 cell	 population,	 thus	 rare	 cells	 like	






Using	 these	data,	patterns	 in	 immune	cell	 recruitment	 could	be	 studied	over	 the	 first	
few	days	following	immunisation.	Notably,	the	composition	of	LN	innate	immune	cells	
in	 Ca-treated	 mice	 was	 much	more	 diverse	 than	Ms-	 or	Nb-treated	 mice.	 On	 day	 2,	














frequency	 was	 markedly	 higher	 in	Ms	 LNs.	 NK	 cells	 are	 rapid	 producers	 of	 IFNγ	 in	
response	to	IL-12	and	IL-18	(233,	235),	all	of	which	contribute	to	the	promotion	of	Th1	




groups.	 Importantly,	 scRNASeq	and	 flow	cytometry	data	 showed	 that	monocytes	and	
migDC	were	the	major	populations	of	antigen-carrying	cells	regardless	of	 the	 injected	
immunogen.	However,	the	distribution	of	antigen	between	migDC	and	monocytes	was	
distinct	 between	 immunogens.	 A	 significantly	 higher	 proportion	 of	 Ms+	 cells	 were	
identified	as	monocytes,	whereas	the	vast	majority	of	Nb+	and	Ca+	were	migDC.	This	
dichotomous	 distribution	 of	 immunogenic	 material	 between	 monocyte	 and	 migDC	
populations	suggests	that	distinct	APC	populations	may	be	important	for	driving	CD4+	
T	cell	responses	to	different	immunogens.	Indeed,	monocytes	have	been	shown	to	be	a	
major	 source	of	 IL-12	 in	a	number	of	 contexts	which	suggests	 that	 they	may	support	
Th1	 differentiation	 (47,	 591,	 605).	 On	 the	 other	 hand,	migDC	 populations	 have	 been	
implicated	 in	 Th2	 and	 Th17	 differentiation	 in	 vivo	 (557,	 563,	 566,	 567).	 These	
hypotheses	are	explored	further	in	chapters	four	and	five	of	this	thesis.		
	








This	 chapter	 describes	 an	 i.d.	 immunisation	 model	 that	 allows	 for	 the	 systematic	
assessment	 of	 CD4+	 T	 cell	 responses	 to	 bacterial	 (Ms),	 helminth	 (Nb)	 or	 fungal	 (Ca)	
material.	 These	 immunogens	 elicited	 distinct	 CD4+	 T	 cell	 responses,	 with	 Th1,	 Th2,	
Th17	 and	Tfh	 phenotypes	 detectable	 to	 different	 extents.	 In	 addition,	Ms,	Nb	 and	Ca	
were	associated	with	distinct	patterns	of	 innate	 immune	cell	recruitment	and	antigen	
distribution,	 unveiling	 potential	 processes	 and	 cell	 types	 that	 contribute	 to	 the	










4 Functional plasticity of migratory 








APC	 populations,	 in	 particular	 DC,	 are	 central	 players	 in	 regulating	 CD4+	 T	 cell	
responses.	 In	 keeping	with	 this,	 experiments	 that	 permitted	 the	 identification	 of	 Ag+	
cells	 after	 immunisation	 with	 fluorescently	 labelled	 immunogen	 revealed	 that	 the	
majority	 of	 antigen-carrying	 cells	 were	migDC,	 with	 a	 proportion	 of	 Ag+	monocytes	
present	in	Ms-treated	mice	(Fig	3.12).	This	chapter	presents	a	further	characterisation	





Typically,	 migDC	 are	 divided	 into	 LC,	 DC1	 and	 DC2	 populations,	 with	 the	 DC2	
population	 further	 resolved	 into	 CD11b+	 and	 TN	 subsets	 (111,	 229,	 333).	 The	
development	of	high-throughput,	multi-parametric	 technologies	constantly	challenges	
the	 way	 in	 which	 immune	 cell	 subsets	 are	 defined.	 One	 such	 study	 utilising	 mass	
cytometry	 technology	 called	 for	 a	 re-assessment	 of	 the	 markers	 used	 to	 classify	 DC	
subsets	across	tissues	and	species.	These	analyses	identified	XCR1	and	CD172a	(SIRPα)	
to	 be	 defining	 markers	 of	 DC1	 and	 DC2	 populations,	 respectively	 (507).	 XCR1	
expression	closely	correlated	with	CD103	expression	which	was	previously	considered	
to	be	 the	defining	marker	of	migDC1	 (513),	but	a	 small	population	of	XCR1+	CD103-	
DC1	 were	 also	 observed.	 Further,	 as	 CD172a	 expression	 universally	 identified	 DC2,	
CD11b	was	required	to	resolve	CD11b+	DC2	from	TN	DC2.	 In	 the	skin	and	associated	
LNs,	 CD326	 or	 CD207	 was	 required	 to	 resolve	 LC	 from	 DC2,	 as	 they	 also	 express	
CD172a	and	have	intermediate	expression	of	CD11b	(507).		
	
The	 presence	 of	 distinct	 DC	 subsets	 and	 their	 association	 with	 different	 immune	
responses	 has	 led	 to	 the	 hypothesis	 that	 each	 subset	 has	 evolved	 to	 promote	 a	




is	 also	 possible	 that	 signals	 from	 environmental	 factors	 or	 the	 immunogen	 itself	
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condition	 DC	 to	 instruct	 the	 appropriate	 differentiation	 of	 CD4+	 T	 cells	 through	
expression	of	the	required	polarising	molecules	(474).	It	has	been	well	established	that	












NK	 cells	 or	 T	 cells	 feedbacks	 on	 human	 monocyte-derived	 DC	 to	 promote	 IL-12	




The	 role	 of	DC	 in	 the	 regulation	of	 CD4+	T	 cell	 differentiation	 involves	many	 factors	
including	functionally	distinct	subsets	and	conditioning	signals	from	immunogens	and	
surrounding	 cells.	 However,	 studies	 assessing	 the	 role	 of	 DC	 subsets	 in	 CD4+	 T	 cell	
responses	have	focused	on	a	single	model	(10,	331,	339,	550-553,	559,	561-563,	566-570,	
771),	 with	 over-arching	 conclusions	 on	 the	 functions	 of	 DC	 subsets	 drawn	 from	 the	
collation	of	numerous	studies	performed	using	different	readouts,	 tissues	and	models	
(461).	 The	 immunogens	 selected	 for	 this	 study	 elicit	 distinct	 patterns	 of	 CD4+	T	 cell	
differentiation,	providing	an	excellent	platform	to	assess	the	responses	of	DC	subsets	to	
immunisation	 in	a	systematic	manner,	 and	determine	 their	 involvement	 in	regulating	
the	differentiation	of	CD4+	T	cells.	This	approach	uncovered	that	 functional	plasticity	
within	the	DC2	subset	was	an	important	factor	in	determining	the	outcome	of	CD4+	T	
cell	 responses.	Thus,	understanding	 the	 role	of	DC	subsets	and	 factors	 that	 condition	




The	 skin-derived	 DC	 population	 is	 made	 up	 of	 distinct	 subsets	 that	 have	 been	
attributed	with	 specialised	 functions.	However,	 signals	 derived	 from	 the	 immunogen	
and	surrounding	cells	can	directly	influence	the	functional	capacity	of	DC.	 	To	date,	no	
published	 study	 has	 assessed	 these	 factors	 in	 a	 systematic	manner	 to	 determine	 the	
contributions	of	pre-programming	and	functional	conditioning	of	DC	in	the	regulation	
of	 CD4+	 T	 cell	 responses.	 The	 overall	 aim	 of	 this	 chapter	 was	 to	 use	 the	 i.d.	















4.3.1 Identification of migratory DC subsets in the ear dLNs 
In	order	to	assess	DC	responses	 in	 the	skin-dLNs,	 it	was	necessary	to	design	a	gating	
strategy	to	distinguish	DC	subsets	by	 flow	cytometry.	MHCII	staining	 intensity	closely	
correlated	with	CCR7	expression,	making	it	a	useful	tool	to	distinguish	MHCIIhi	migDC	






To	 confirm	 the	 classification	 of	 DC	 using	 this	 gating	 strategy,	 DC	 subsets	were	 then	
assessed	 for	 expression	 of	 other	 typical	 DC	markers.	 In	 line	with	 published	 reports,	
resDC	 subsets	 highly	 expressed	 CD11c	 and	were	 negative	 for	 CCR7,	whereas	migDC	
subsets	 expressed	 varying	 levels	 of	 CCR7.	DC1	 subsets	 highly	 expressed	 CD24,	while	
DC2	 subsets	 expressed	 CD172a	 (Fig	 4.1B)	 (507,	571).	 Among	migDC,	 the	DC1	 subset	








TN	DC2	 subsets,	 a	 proportion	 of	 cells	 also	 expressed	 CD301b	 (Fig	 4.1B),	which	 is	 in	
contrast	 to	 published	 reports	 that	 show	 co-expression	 of	 CD301b	with	 CD11b	 (559,	
771).		
	
Given	 the	 role	 of	 DC	 in	 driving	 CD4+	 T	 cell	 responses	 and	 the	 reported	 functional	





3.7B),	with	 LC,	DC1	 and	DC2	 all	 increasing	 in	number	 (Fig	 4.1C).	 Interestingly,	when	
characterising	 the	 composition	of	migDC,	 the	proportion	of	CD11b+	DC2	significantly	
increased	 following	all	 immunisation	 strategies.	As	a	result,	 the	proportion	of	LC	and	
DC1	 were	 significantly	 reduced,	 whereas	 the	 frequency	 of	 TN	 DC2	 remained	 stable,	
occupying	~40%	of	the	migDC	compartment	(Fig	4.1C).	Thus,	these	data	did	not	reveal	
condition-specific	 patterns	 of	 DC	 migration,	 with	 DC2	 making	 up	 the	 majority	 of	
immunisation	induced	migration.		
	
Overall,	 these	 data	 show	 that	 migDC	 from	 skin-dLNs	 can	 be	 resolved	 into	 LC,	 DC1,	
CD11b+	 DC2	 and	 TN	 DC2	 using	 CD326,	 XCR1	 and	 CD11b	 expression.	 Use	 of	 CD103	
instead	 of	 XCR1	 can	 also	 resolve	 these	 populations;	 but	 resulted	 in	 a	 small	
contamination	of	XCR1+	DC1	in	the	TN	DC2	gate.	Following	immunisation,	the	number	
and	frequency	of	CD11b+	DC2	increased	across	all	conditions,	suggesting	that	CD11b+	












4.3.2 DC2 subsets carry Ms, Nb and Ca material to the LN 
To	 begin	 to	 understand	 the	 roles	 of	 distinct	 migDC	 subsets	 and	 their	 responses	 to	
different	immunogens,	it	was	of	interest	to	determine	which	DC	subsets	interacted	with	
immunogenic	 material	 and	 transported	 it	 from	 the	 skin	 to	 the	 dLN.	 Fluorescent	
labelling	 of	 Ms,	 Nb	 and	 Ca	 prior	 to	 i.d.	 injection	 allowed	 for	 flow	 cytometric	
identification	of	cells	that	had	taken	up	immunogenic	material	(Fig	3.11).	Interestingly,	
despite	 eliciting	 distinct	 CD4+	 T	 cell	 responses,	 the	 distribution	 of	 fluorescent	






As	 described	 above,	 the	 DC2	 population	 is	 heterogeneous	 and	 it	 is	 possible	 that	
functionally	distinct	 subsets	exist	within	 the	 current	DC2	classification.	To	determine	
whether	 separate	DC	 interact	with	 immunogenic	material	 from	different	 sources,	 co-
injection	 experiments	 were	 performed,	 where	 one	 immunogen	 was	 labelled	 with	
AF488	 dye	 and	 the	 other	 was	 labelled	 with	 CellTracker™	 Orange	 (CTO)	 dye.	 Co-
injection	 of	Ms	with	Nb,	Ca	with	Nb	 or	Ca	 with	Ms	 resulted	 in	 a	 clear	 AF488+	 CTO+	
population	 of	 migDC2,	 indicating	 that	 the	 same	 DC	 can	 take	 up	 material	 from	 two	
different	sources	(Fig	4.3).	Thus,	these	data	reinforce	the	conclusion	that	immunogenic	





Figure	 4.2:	 Antigen-carrying	 migDC	 are	 comprised	 of	 CD11b+	 and	 TN	 DC2.	 Mice	 were	 immunised	 with	
fluorescently-labelled	Ms,	Nb	 or	Ca	by	 i.d.	 injection.	 Control	 animals	 received	PBS.	Two	 days	after	 immunisation,	
migDC	were	assessed	for	immunogen	fluorescence	by	flow	cytometry.	(A)	Concatenated	flow	cytometry	plots	from	













4.3.3 Antigen-carrying migDC2 highly express activation markers 




DC2	 from	 immunised	 mice	 highly	 expressed	 CD86,	 markedly	 increased	 from	 their	
corresponding	PBS	controls.	Interestingly,	the	fold	change	in	CD86	expression,	relative	
to	 PBS	 mice,	 was	 much	 more	 striking	 on	 Ag+	 TN	 DC2	 than	 Ag+	 CD11b+	 DC2.	 In	
contrast,	 Ag-	 cells	 from	 all	 DC	 subsets	 had	 significantly	 lower	 CD86	 expression	 than	
Ag+	cells,	and	in	many	cases	their	CD86	expression	levels	were	not	significantly	higher	
than	those	of	DC	from	PBS-treated	mice	(Fig	4.4A-B).	The	exception	to	this	observation	
were	 Ag-	 DC	 subsets	 from	 Ca-treated	 mice	 that	 had	 significantly	 higher	 CD86	
expression	compared	to	PBS	controls,	suggesting	that	bystander	activation,	presumably	
due	 to	 cytokines,	 may	 be	 occurring	 following	 Ca	 immunisation.	 	 Ag+	 DC2	 from	 Ca-
treated	mice	 also	 expressed	higher	 amounts	 CD86	when	 compared	 to	Ag+	DC2	 from	
Ms-	 or	 Nb-treated	 mice,	 further	 supporting	 the	 notion	 that	 Ca	 immunisation	 is	





CD40	 is	 another	 co-stimulatory	 molecule	 used	 to	 assess	 DC	 activation.	 The	 CD40-
CD40L	 interaction	between	DC	and	T	cells	 is	known	to	promote	IL-12p70	production	
by	 DC	 through	 up-regulation	 of	 IL-12p35,	 thus	 supporting	 a	 Th1	 conducive	
environment	(148,	821).	Therefore,	CD40	was	a	marker	of	interest	to	assess	DC	subset	
activation	 as	well	 as	 the	 condition	 specificity	 of	 co-stimulatory	molecule	 expression.	







A	 recent	 study	has	 implicated	expression	of	 the	 IL-2	 receptor	 (CD25)	on	DC	as	being	
involved	in	promoting	the	differentiation	of	Tfh	cells	through	limiting	IL-2	availability	
(449).	As	all	immunogens	used	in	this	study	elicited	Tfh	cells	(Fig	3.5),	it	was	of	interest	
to	 assess	 the	 expression	 of	 CD25	 on	 DC	 subsets.	 Among	 resDC,	 LC	 and	 DC1	 subsets	
<15%	 of	 DC	 expressed	 CD25,	 even	 after	 immunisation.	 In	 contrast,	 >30%	of	 steady-
state	CD11b+	DC2	were	CD25+	and	this	 increased	to	80%	among	Ag+	cells.	Similarly,	
80%	 of	 Ag+	 TN	 DC2	 expressed	 CD25	 (Fig	 4.4D).	 A	 greater	 proportion	 of	 Ag+	 DC2	
expressed	CD25	compared	to	Ag-	DC2,	but	this	difference	was	not	as	striking	as	those	
seen	with	CD86	or	CD40.	These	data	suggest	 that	DC2	may	be	 involved	 in	supporting	
Tfh	differentiation	in	the	i.d.	immunisation	model.	
	
Together,	 these	 data	 show	 that	 Ag+	 DC2	 from	Ms-,	Nb-	 and	 Ca-treated	 mice	 highly	

















4.3.4 Langerin+ DC are not necessary for CD4+ T cell responses to Ms, Nb or Ca 
Several	studies	have	shown	LC	play	a	role	in	the	induction	of	Th17	responses	(331,	339,	
524).	 Given	 these	 reports,	 it	 was	 important	 to	 assess	 the	 role	 of	 LC	 in	 CD4+	 T	 cell	
responses	following	i.d.	immunisation.	The	C-type	lectin	receptor,	langerin	(CD207),	is	
highly	 expressed	 by	 LC	 and	 a	 proportion	 of	migDC1.	 Mice	 genetically	 engineered	 to	
express	 the	 human	 diphtheria	 toxin	 receptor	 (DTR)	 under	 control	 of	 the	 langerin	
promoter	allow	for	the	selective	depletion	of	LC	and	DC1	after	DT	injection	(Fig	4.5A)	
(740).	Assessment	of	LC	from	Langerin-DTR	mice	9	days	after	DT	treatment	showed	an	




To	determine	the	role	of	LC	 in	regulating	CD4+	T	cell	responses	to	 i.d.	 immunisation,	
Langerin-DTR	mice	were	treated	with	DT	two	days	before	 i.d.	 immunisation	with	Ms,	
Nb	 or	 Ca.	 On	 day	 seven,	 CD4+	 T	 cells	 were	 assessed	 for	 cytokine	 production	 by	
intracellular	cytokine	staining	(Fig	4.5B).	The	number	and	frequency	of	IFNγ+	CD4+	T	
cells	from	Ms-treated	mice	were	similar	between	Langerin-DTR	mice	with	retained	LC	
(-DT)	 or	 depleted	 LC	 (+DT)	 (Fig	 4.5C),	 suggesting	 that	 LC	were	 not	 required	 for	 the	
generation	of	Th1	cells	to	Ms.	Likewise,	the	data	inferred	that	LC	were	not	required	for	
Th2	 responses	 to	 Nb	 as	 the	 number	 and	 frequency	 of	 IL-4+	 CD4+	 T	 cells	 was	




















4.3.5 BATF3-dependent DC are not required for CD4+ T cell responses to Ms, Nb or Ca 
Like	 LC,	 migDC1	 have	 been	 previously	 implicated	 in	 driving	 particular	 CD4+	 T	 cell	




DC1	 in	 immunised	 BATF3-KO	 mice	 before	 assessing	 CD4+	 T	 cell	 responses.	 Both	
migDC1	 and	 resDC1	 were	 significantly	 reduced	 in	 Ms-treated	 BATF3-KO	 mice	





not	reduced	 in	BATF3-KO	mice	after	 immunisation	with	Ms,	Nb	or	Ca	(Fig	4.6B-D).	 In	
line	with	 the	 observations	 by	 Everts	 et	 al.,	 the	 frequency	 of	 IL-4+	 CD4+	 T	 cells	was	
significantly	 increased	 in	 Nb-treated	 BATF3-KO	 mice	 (Fig	 4.6C)	 (550).	 Thus,	 these	
experiments	 suggest	 that	 DC1	 are	 not	 required	 for	 the	 initiation	 of	 CD4+	 T	 cell	
responses	to	any	of	the	immunogens	tested	in	this	study.		
	










immunisation.	 (C)	 Number	 and	 frequency	 of	 IL-4+	 CD4+	 T	 cells	 following	 Nb	 immunisation.	 (D)	 Number	 and	






4.3.6 KLF4-dependent DC are required for promoting Th2 responses to Nb  
DC2	are	a	mixed	DC	population,	containing	at	least	two	distinct	subsets.	KLF4	has	been	
identified	as	a	 factor	required	 for	 the	development	of	a	subset	of	DC2.	 In	mice	where	
the	Klf4	 gene	 is	 excised	 in	 CD11c+	 cells	 (Itgax-cre	Klf4-fl/fl;	KLF4∆CD11c),	 TN	DC2	 are	
absent	from	the	skin	and	skin-dLNs,	and	CD11b+	DC	are	significantly	reduced	(Fig	4.7A,	
Appendix	 Fig	 C-III)	 (557).	 To	 determine	 the	 requirement	 of	 KLF4-dependent	 DC2	 in	
promoting	CD4+	T	cell	responses,	KLF4∆CD11c	and	KLF4WT	mice	were	 immunised	with	
Ms,	Nb	 or	Ca	 and	cytokine	production	by	CD4+	T	 cells	was	assessed	on	day	 five.	The	
total	 number	 of	 cells	 recovered	 from	 the	 LNs	 of	 immunised	 mice	 did	 not	 differ	
significantly	 between	KLF4∆CD11c	 and	KLF4WT	mice,	 indicating	 that	 cellular	 expansion	
could	 still	 occur	 in	 the	 absence	 of	 KLF4-dependent	 DC2	 (Fig	 4.7B).	 The	 number	 of	
IFNγ+	 CD4+	 T	 cells	 in	Ms-treated	 mice	 was	 significantly	 reduced	 in	 the	 absence	 of	
KLF4-dependent	DC2;	but	no	 statistical	 significance	was	detected	 in	 the	 frequency	of	
IFNγ+	cells	among	total	CD4+	T	cells	(Fig	4.7C-D).	The	high	IFNγ	background	in	these	
experiments	makes	 it	 difficult	 to	 confidently	 conclude	whether	KLF4-dependent	DC2	




















Representative	 flow	 plots	 showing	 IFNγ	 expression	 among	 CD4+	 T	 cells	 from	Ms-treated	mice.	 (D)	 Number	 and	
frequency	of	IFNγ+	CD4+	T	cells	following	Ms	immunisation.	(E)	Representative	flow	plots	showing	IL-4	expression	
among	 CD4+	 T	 cells	 from	 Nb-treated	 mice.	 (F)	 Number	 and	 frequency	 of	 IL-4+	 CD4+	 T	 cells	 following	 Nb	
immunisation.	 (G)	 Representative	 flow	 plots	 showing	 IL-17A	and	 IFNγ	 expression	 among	 CD4+	T	 cells	 from	Ca-
treated	mice.	 (H)	 Number	and	 frequency	 of	 IL-17A+	 and	 IFNγ+	 CD4+	T	 cells	 following	Ca	 immunisation.	Data	 is	
collated	from	two	independent	experiments,	with	at	least	10	mice	per	group.	Graphs	show	the	mean±SEM.	Statistical	











and	Nb	 in	KLF4∆CD11c	mice.	 Thus,	 KLF4∆CD11c	 and	 KLF4WT	mice	were	 immunised	with	
fluorescently	 labelled	 Ms,	 Nb	 or	 Ca	 and	 LN	 cells	 were	 assessed	 for	 immunogen	
fluorescence	 2	 days	 later.	 At	 endpoint,	 the	 total	 cell	 number	 recovered	 from	 the	 LNs	
was	similar	between	KLF4∆CD11c	and	KLF4WT	mice	(Fig	4.8A).	In	addition,	the	number	of	
monocytes	was	similar	between	KLF4∆CD11c	and	KLF4WT	mice	(Fig	4.8B).	In	Ms-treated	













Together,	 these	 data	 show	 the	 importance	 of	 KLF4-dependent	 DC2	 in	 transporting	
immunogenic	material	from	the	skin	to	the	dLNs.	Thus,	reduced	availability	of	antigen	





Ms,	 Nb	 or	 Ca	 by	 i.d.	 injection.	 Control	 animals	 received	 PBS.	 Two	 days	 after	 immunisation,	 LN	 cells	 were	
phenotypically	 profiled	 and	 assessed	 for	 immunogen	 fluorescence	 by	 flow	 cytometry.	 (A)	 Total	 cell	 number	
recovered	from	the	ear-dLNs	at	endpoint.	(B)	Number	of	monocytes	present	in	the	ear-dLNs	after	immunisation.	(C)	
Representative	 flow	 plots	 show	 the	 frequency	 of	 Ag+	 cells	 among	 CD3-	 B220-	 cells	 from	Ms-treated	mice.	 (D)	
Stacked	bar	graph	shows	the	number	of	Ag+	CD11b+	DC2,	Ag+	TN	DC2	and	Ag+	monocytes	after	Ms	immunisation.	
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Statistical	 significance	was	determined	 by	 Two-Way	ANOVA	with	 Sidak’s	multiple	 comparisons	 test.	NS=not	
significant,	**p<0.01,	****p<0.0001	
	
4.3.8 DC2 are necessary for driving optimal CD4+ T cell responses to Ms, Nb and Ca 
A	defining	feature	of	DC2	is	their	expression	of	the	transcription	factor	IRF4,	which	is	
important	for	their	migration	from	the	skin	to	the	skin-dLNs	(Fig	4.9A)	(558,	563).	Mice	
that	 specifically	 lack	 Irf4	 within	 their	 CD11c	 compartment	 (Itgax-cre	 Irf4-fl/fl;	
IRF4∆CD11c)	have	a	>80%	reduction	 in	CD11b+	DC2	and	a	>70%	reduction	 in	TN	DC2	
compared	to	IRF4WT	controls	(Appendix	Fig	BC-V)	(563,	565).	IRF4	is	also	required	for	
LC	 migration	 but	 not	 for	 DC1	 migration.	 As	 a	 chimeric	 system	 was	 used	 for	 these	





i.d.	 immunisation,	 IRF4∆CD11c	and	IRF4WT	mice	were	 immunised	with	Ms,	Nb	or	Ca	and	
the	 resulting	CD4+	T	 cell	 responses	were	assessed	on	day	 five.	The	 total	 cell	number	
was	 somewhat	 reduced	 in	 immunised	 IRF4∆CD11c	 mice,	 but	 this	 observation	 was	 not	
statistically	 significant	 (Fig	 4.9B).	 The	 number	 and	 frequency	 of	 Ms-induced	 IFNγ+	
CD4+	T	 cells	were	also	 reduced,	 significantly	among	 IFNγhi	 cells,	 suggesting	 that	DC2	
are	required	for	promoting	optimal	Th1	responses	(Fig	4.9C-D).		
	
Similar	 to	 the	result	with	the	KLF4∆CD11c	mice,	 IRF4∆CD11c	mice	had	significantly	 fewer	
IL-4+	 CD4+	 T	 cells	 following	 Nb	 immunisation	 compared	 to	 control	 mice,	 further	
implicating	 DC2	 in	 Th2	 induction	 (Fig	 4.9E-F).	 Interestingly,	 despite	 there	 being	 no	






The	 data	 presented	 thus	 far	 provides	 strong	 evidence	 that	 DC2	 are	 necessary	 for	






number	and	frequency	of	Tfh	cells	 tended	to	be	 lower	 in	 the	absence	of	DC2,	but	 this	
reduction	 only	 reached	 significance	 in	 Nb-treated	 mice	 (Fig	 4.10A-B).	 	 These	 data	




Overall,	 these	 data	 show	 that	 DC2	 play	 an	 important	 role	 in	 promoting	 cytokine-







Figure	4.9:	 IRF4-dependent	DC2	play	a	 role	in	promoting	Th1,	Th2	and	Th17	responses	 to	Ms,	Nb	 and	Ca,	
respectively.		IRF4∆CD11c	BM	chimera	mice	and	IRF4WT	BM	chimera	controls	were	immunised	with	Ms,	Nb	or	Ca.	On	
day	5,	LN	cells	were	isolated	and	CD4+	T	cells	assessed	for	cytokine	production	following	a	re-stimulation	with	PMA	
and	 ionomycin.	 (A)	 Schematic	 showing	which	DC	 subsets	 are	absent	 from	 IRF4∆CD11c	mice.	 (B)	Total	 cell	number	
isolated	from	the	ear-dLNs	at	endpoint.	(C)	Representative	flow	plots	showing	IFNγ	expression	among	CD4+	T	cells	
from	Ms-treated	mice.	(D)	Number	and	frequency	of	IFNγ+	and	IFNγhi	CD4+	T	cells	following	Ms	immunisation.	(E)	
Representative	 flow	 plots	 showing	 IL-4	 expression	 among	 CD4+	 T	 cells	 from	Nb-treated	mice.	 (F)	 Number	 and	
frequency	of	IL-4+	CD4+	T	cells	following	Nb	immunisation.	(G)	Representative	flow	plots	showing	IL-17A	and	IFNγ	
expression	among	CD4+	T	cells	from	Ca-treated	mice.	(H)	Number	and	frequency	of	IL-17A+	and	IFNγ+	CD4+	T	cells	
following	Ca	 immunisation.	 Data	 is	 collated	 from	 two	 independent	 experiments,	with	 at	 least	 8	mice	 per	 group.	














4.3.9 DC2 are required to carry immunogenic material from the skin to the dLNs 
It	 has	 been	 established	 earlier	 in	 this	 chapter	 that	 DC2	 make	 up	 a	 substantial	
proportion	 of	 antigen-carrying	 cells	 in	 the	 skin-dLNs	 after	 i.d.	 injection.	 Thus,	 it	was	
imperative	 to	 assess	 how	 immunogen	 transport	 was	 impacted	 by	 the	 reduced	
migration	of	DC2	 in	 IRF4∆CD11c	mice.	Fluorescently	 labelled	Ms,	Nb	 or	Ca	was	used	 to	
immunised	IRF4∆CD11c	mice	or	control	mice	and	Ag+	cells	were	assessed	on	day	2.	The	
total	 cell	 number	 recovered	 from	 the	 LNs	 at	 endpoint	was	 not	 significantly	 different	




and	 IRF4WT	 controls.	 Ms-treated	 IRF4∆CD11c	 mice	 had	 a	 significant	 reduction	 in	 the	
frequency	 of	 Ag+	 cells,	 as	 well	 as	 the	 number	 of	 Ag+	 DC2.	 The	 number	 of	 Ag+	
monocytes	was	maintained	in	the	absence	of	DC2	(Fig	4.11C-D).	Similarly,	the	number	
and	frequency	of	Ag+	cells	from	Nb-treated	IRF4∆CD11c	mice	was	significantly	lower	than	
Nb-treated	controls,	with	a	>50%	reduction	 in	 the	number	of	Ag+	DC2	 (Fig	4.11E-F).	
The	 number	 and	 frequency	 of	 Ca+	 DC2	 was	 reduced	 in	 IRF4∆CD11c	 mice,	 but	 this	
reduction	did	not	reach	statistical	significance	(Fig	4.11G-H).	
	
Together,	 these	experiments,	 alongside	 the	KLF4∆CD11c	 experiments,	highlight	 the	 role	
DC2	play	in	transporting	immunogenic	material	from	the	skin	to	the	skin-dLNs.	As	with	


















independent	 experiments,	 with	 8	 mice	 per	 group.	 Graphs	 show	 the	 mean±SEM.	 Statistical	 significance	 was	
determined	 by	 Two-Way	 ANOVA	 with	 Sidak’s	 multiple	 comparisons	 test.	 NS=not	 significant,	 *p<0.05,	 **p<0.01,	
****p<0.0001	
	
4.3.10 The transcriptional profile of DC2 varies with condition 
Collectively,	the	data	presented	in	this	chapter	provide	evidence	that	DC2	are	sufficient	
and	 necessary	 to	 promote	 the	 CD4+	 T	 cell	 responses	 associated	with	Ms,	Nb	 and	Ca	
immunisation.	Thus,	it	was	of	interest	to	assess	DC2	expression	of	molecules	associated	





















552).	 Indeed,	 the	baseline	expression	of	 Il12b	was	very	high	among	DC1	compared	to	
other	DC	subsets	(Appendix	Fig	D-I),	but	Il12b	was	not	up-regulated	by	DC1	in	response	
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the	 induction	of	Th2	responses	and	are	elevated	 in	allergic	 individuals	(185,	186,	194,	
195).	 In	 addition,	Nb+	 CD11b+	 DC2	 up-regulated	Tnfsf4	which	 encodes	 OX40L,	 a	 co-
stimulatory	molecule	thought	to	promote	Th2	differentiation	(114,	397,	399,	825,	826).	
In	 keeping	with	 our	 published	RNASeq	 data	 (229),	 the	 gene	 encoding	 for	 the	 IL-27B	




for	 Th17	 differentiation	 (276,	 278).	 Importantly,	 Ca+	 CD11b+	 DC2	 also	 up-regulated	
Il23a,	which	supports	IL-17A	production	by	CD4+	T	cells	and	γδ	T	cells	(827-829).		
	
Together,	 these	 qPCR	 data	 demonstrate	 that	 DC2	 subsets	 are	 able	 to	 alter	 their	
expression	of	known	polarising	genes	in	response	to	i.d.	immunisation.	Taken	with	the	
rest	of	the	results	presented	in	this	chapter,	these	qPCR	data	show	that	conditioning	of	


















DC	 play	 an	 important	 role	 in	 initiating	 CD4+	 T	 cell	 responses	 and	 are	 thought	 to	
regulate	 the	 differentiation	 of	 CD4+	 T	 cell	 responses	 through	 context-specific	
expression	 of	 polarising	 molecules.	 The	 characterisation	 of	 DC	 subsets	 with	 distinct	




provides	 evidence	 of	 functional	 plasticity	 within	 the	 DC2	 population,	 with	 IRF4-
dependent	DC	 required	 for	optimal	CD4+	T	 cell	 responses	 to	Ms,	Nb	 and	Ca.	 Further,	




4.4.1 The phenotype of DC subsets in the skin-dLNs 
A	gating	strategy	incorporating	MHCII,	CD11c,	CD326,	CD11b	and	XCR1	or	CD103	was	
used	 to	 identify	 all	 the	 known	 DC	 subsets	 in	 the	 skin-dLNs.	 The	 intensity	 of	 MHCII	
staining	 clearly	 distinguished	MHCIIhi	migDC	 from	MHCIIint	 resDC.	 This	 strategy	was	
supported	by	correlating	CCR7	expression	as	well	as	previous	observations	(69,	830).	
Within	the	migDC	population,	LC,	DC1	and	DC2	subsets	could	be	resolved	using	CD326	
and	 XCR1	 markers	 or	 CD326	 and	 CD103	 markers.	 The	 majority	 of	 migDC1	 co-
expressed	 XCR1	 and	 CD103;	 but,	 a	 small	 proportion	 of	 XCR1+	 DC	 were	 CD103-.	 As	
XCR1	 has	 now	 been	 identified	 as	 the	 most	 accurate	 marker	 of	 DC1	 (507),	 our	
experiments	 that	 utilised	 CD103	 to	 identify	DC1	will	 have	 a	 small	 proportion	 XCR1+	













expressed	 CD301b,	 a	 marker	 associated	 with	 Th2-inducing	 DC,	 which	 is	 contrast	 to	
reports	 that	 show	 co-expression	 of	 CD301b	with	 CD11b	 (559,	771).	 These	 published	
studies	 used	 a	 CD301b	 antibody	 clone	 that	 is	not	 commercially	 available	which	may	
explain	 the	 differences	 observed	 in	 staining	 patterns.	 PDL2	 is	 another	 molecule	




Together,	 these	 data	 highlight	 the	 heterogeneity	 of	 the	 DC2	 subset,	 with	 varied	 and	
non-overlapping	expression	of	CD11b,	CD301b	and	PDL2.	
	
4.4.2 LC and DC1 in the regulation of CD4+ T cell responses 
The	 present	 study	 found	 no	 evidence	 that	 LC	 and	 DC1	were	 required	 for	 promoting	
CD4+	T	cell	responses	to	Ms,	Nb	or	Ca,	which	is	in	contrast	to	some	published	studies	
(331,	 339,	551-553,	831).	 The	 use	 of	 Langerin-DTR	 and	 BATF3-KO	mice	 showed	 that	
CD4+	T	cell	responses	to	all	tested	immunogens	remained	intact	in	the	absence	of	LC	or	
DC1.	Further,	neither	LC	nor	DC1	were	detected	with	 i.d.	 administered	 fluorescently-
labelled	 immunogens,	nor	did	they	upregulate	markers	associated	with	DC	activation.	
These	 results	 indicate	 that	 LC	 and	 DC1	 either	 do	 not	 have	 direct	 contact	 with	 i.d.	
injected	material,	or	do	not	express	the	appropriate	repertoire	of	receptors	to	respond	
to	the	immunogens	used	in	this	study.	The	former	explanation	is	more	plausible	given	
the	vast	array	of	PRR	ligands	expressed	between	Ms,	Nb	and	Ca.	 It	 is	possible	 that	LC	
and	DC1	have	limited	exposure	to	i.d.	injected	material	due	to	their	positioning	within	
the	 skin.	 LC	 are	 located	 in	 the	 epidermis	 and	 are	 only	 found	 in	 the	 dermis	 when	
migrating	to	the	dLN	(508).	DC1	are	located	in	the	dermis	but	may	be	positioned	close	
to	 the	epidermal	layer	due	to	their	expression	of	CD326.	Thus,	 the	 i.d.	 injection	route	
may	bypass	LC,	and	possibly	DC1,	and	the	material	deposited	in	the	dermis	may	not	be	
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available	 to	 LC	 or	 DC1.	 Indeed,	 if	 fluorescent	 antigen	 is	 applied	 epicutaneously	 in	
combination	with	a	contact	sensitiser,	then	LC	and	DC1	can	be	detected	with	antigen	in	
the	 dLNs,	 albeit	 to	 a	 lesser	 extent	 than	DC2	 (111).	 Alternative	 administration	 routes	
were	 not	 explored	 in	 this	 study;	however,	 others	 have	 shown	 that	 fluorescent	 house	




The	 studies	 that	 proposed	 LC	 were	 necessary	 for	 Th17	 induction	 used	 a	 live	 Ca	
infection	 model,	 whereby	 Ca	 yeast	 was	 inoculated	 onto	 disrupted	 skin	 of	 human-
langerin-DTR	mice	 (331,	339,	831).	 In	 this	 case,	 LC	will	 have	 direct	 access	 to	 antigen	
and	 are	 located	 near	 the	 inflammatory	 site,	 thus	 the	 loss	 of	 LC	 is	 detrimental	 for	
initiating	a	protective	CD4+	T	cell	response.	It	is	not	clear	whether	the	use	of	a	different	
strain	of	langerin-DTR	mouse	could	account	for	some	of	the	discrepancies	in	the	results	
between	 their	 study	 and	 this	 one.	 As	 the	 name	 suggests,	 human-langerin-DTR	mice	
have	 been	 genetically	 engineered	 to	 express	 human	 langerin	 rather	 than	 mouse	







viruses	 than	 DC2	 (64,	 818,	 834),	 and	 thus	 may	 also	 be	 superior	 at	 responding	 to	




source	 of	 IL-12.	 If	 they	 receive	 the	 appropriate	 signals,	 then	 DC2	 are	 capable	 of	
producing	 sufficient	 IL-12	 to	 induce	 Th1	 differentiation	 in	Ms-treated	mice	 that	 lack	





Overall,	 LC	 and	 DC1	 may	 be	 involved	 in	 initiating	 CD4+	 T	 cell	 responses	 in	 certain	
contexts,	 relating	 to	 the	 location	 of	 infection/inflammation.	 LC	 may	 play	 a	 role	 in	
initiating	 responses	 relating	 to	 the	 epidermis,	 while	 DC1	 effectively	 respond	 to	
intracellular	 pathogens.	 As	 Th1	 responses	 are	 required	 for	 the	 neutralisation	 of	
intracellular	pathogens,	DC1	may	play	a	role	in	driving	Th1	differentiation.	It	would	be	
interesting	 to	 assess	 the	 role	 of	 LC	 in	 response	 to	 other	 epidermal	 infections	 to	
determine	 the	 plasticity	 of	 LC.	 Interestingly,	 LC	 are	 required	 for	 the	 induction	 of	 an	
atopic	 dermatitis-like	 phenotype	 following	 epicutaneous	 application	 of	 the	 vitamin	D	
analogue	MC903,	 suggesting	 that	 they	 can	 support	 the	 induction	 of	 Th2	 immunity	 in	
some	instances	(526).		
	
4.4.3 DC2 in the regulation of CD4+ T cell responses  
DC2	are	a	heterogenous	population	that	play	an	important	role	in	promoting	cytokine-
producing	 CD4+	T	 cells	 to	Ms,	Nb	 and	Ca.	 Interestingly,	 data	 presented	 in	 this	 thesis	
found	no	evidence	that	subsets	within	the	DC2	classification	specialised	in	interacting	
with	 particular	 types	 of	 immunogens,	 as	 individual	 DC	 were	 capable	 of	 taking	 up	
different	 immunogens	 if	 they	were	 co-injected.	Following	 i.d.	 immunisation,	Ag+	DC2	
subsets	up-regulated	DC	activation	markers	and	altered	their	transcriptional	profile	in	
a	condition-specific	manner.	Importantly,	DC	activation	and	up-regulation	of	polarising	






CD301b-	 DC2	 (Johannes	 Mayer	 and	 Shiau-Choot	 Tang,	 unpublished	 observations).	








Nb	 and	 Ca,	 respectively.	 Intriguingly,	 the	 KLF4-dependent	 subset	 appeared	 to	 be	
required	for	Th2	responses,	but	not	Th17	responses.	This	observation	is	in	line	with	the	
findings	 from	 the	 study	 that	 first	 reported	 the	 KLF4∆CD11c	 mouse	 model	 (557),	 and	
suggests	 that	 functionally	 distinct	 subsets	 may	 exist	 within	 the	 DC2	 population.	
However,	the	difference	between	DC	subsets	from	IRF4∆CD11c	mice	and	KLF4∆CD11c	mice	
is	not	striking.	Another	possibility	is	that	IRF4	signalling	in	DC	is	involved	in	promoting	
Th17	 responses.	 Comparing	 the	 expression	of	 Il23a	 and	 Il6	 transcripts	 between	DC2	
from	 IRF4∆CD11c	 mice	 and	 KLF4∆CD11c	 mice	 may	 assist	 in	 addressing	 this	 question.	
Indeed,	 IL-6	 levels	 were	 significantly	 lower	 in	 IRF4-KO	 mice	 subjected	 to	 an	
inflammatory	bowel	disease	model	compared	to	IRF4-sufficent	controls	(835),	and	Il6	




in	 this	 chapter.	 In	 both	 the	 IRF4∆CD11c	and	 KLF4∆CD11c	mouse	 models,	 the	 number	 of	
IFNγ+	CD4+	T	 cells	was	 reduced	compared	 to	 their	 respective	 controls.	 In	particular,	
IRF4∆CD11c	mice	 had	 a	marked	 difference	 in	 the	MFI	 of	 IFNγ	 among	 IFNγ+	 cells,	 with	
significantly	 fewer	 IFNγhi	 producers	 in	 the	 absence	 of	 DC2	 compared	 to	 control	
conditions,	which	was	not	the	case	in	KLF4∆CD11c	mice.	These	results	suggest	that	in	the	
absence	of	DC2	there	are	sub-optimal	conditions	for	the	induction	of	Th1	responses	to	
Ms.	 Importantly,	 in	 IRF4∆CD11c	 and	 KLF4∆CD11c	mice	 monocyte	 numbers	 are	 retained.	
Monocytes	make	up	a	significant	proportion	of	Ms+	cells	and	thus	may	be	contributing	





were	reduced	 in	 IRF4∆CD11c	mice,	but	 this	reduction	was	only	significant	 in	Nb-treated	
mice.	 It	 is	 known	 that	 skin-derived	migDC	 are	 required	 for	Tfh	 differentiation	 (836),	
but	 the	 involvement	 of	 particular	 DC	 subsets	 is	 unresolved.	 IL-2-quenching	 DC	 have	













cell	 responses	 induced	 in	 the	absence	of	DC2	 is	due	 to	 the	 reduced	DC2	number	and	
antigen	 availability	 or	 loss	 of	 specific	 signals	 provided	 by	 DC2.	 In	 either	 case,	
investigation	 into	 the	 signals	 that	 drive	 the	 activation,	 migration	 and	 CD4+	 T	 cell	
priming	 capacities	 of	 DC2	 are	 of	 great	 interest	 to	 dissect	 the	 key	 components	 that	
determine	the	outcome	of	CD4+	T	cell	responses.	
	
4.4.4 Immunogenic conditioning of DC2  
One	 of	 the	 key	 findings	 of	 this	 chapter	 is	 that	 Ag+	 DC2	 alter	 their	 transcriptional	
profiles	in	a	condition-specific	manner.	This	finding	suggests	that	DC2	are	functionally	








APC.	 PRR	 signalling	 synergises	 to	 promote	 IL-12	 production	 by	 DC	 (473,	 820)	 and	
signalling	through	fungal	glucan	PRRs	leads	to	the	up-regulation	of	IL-23	and	IL-6	(150,	
339).	 In	 addition	 to	 these	mechanisms,	 the	 tone	 of	 the	 local	 cytokine	milieu	 can	 also	
have	a	significant	impact	on	DC	function.	IFNγ	is	a	potent	Th1	cytokine	that	can	act	on	
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many	cell	 types,	 including	APC.	A	positive	 feedback	 loop	exists	between	APC-derived	
IL-12	and	IFNγ	(150,	822,	823),	with	each	factor	reinforcing	the	other,	creating	a	robust	
Th1	 differentiation	 environment.	 The	 role	 of	 IFNγ	 conditioning	 with	 respect	 to	
monocyte-derived	cells	is	addressed	in	Chapter	5	of	this	thesis.	
	
Cytokine	 conditioning	of	DC	 is	 also	a	 factor	 in	Th2	contexts.	 In	particular,	 the	 role	of	
epithelial	cell-derived	cytokine	TSLP	in	DC	conditioning	has	been	well	studied	in	mouse	
and	human	cells	(98,	111-115,	482).	TSLP-conditioned	DC	are	known	to	preferentially	
induce	 Th2	 differentiation,	 potentially	 through	 expression	 of	 OX40L	 (112,	 114).	
Further,	TSLP	has	the	capacity	to	induce	DC	activation,	migration	and	the	up-regulation	
of	genes	associated	with	Th2	responses,	including	Ccl17,	Ccl22	and	Tnfsf4	(OX40L)	(112,	






DC	 play	 a	 vital	 role	 in	 the	 initiation	 and	 direction	 of	 CD4+	 T	 cell	 responses.	 The	
presence	 of	 developmentally	 distinct	 DC	 subsets	 has	 led	 to	 the	 question	 of	whether	
lineage	 pre-determines	 function	 with	 regards	 to	 DC	 regulation	 of	 CD4+	 T	 cell	
differentiation.	The	data	presented	here	provides	evidence	that	the	DC2	subset	alone	is	
necessary	 and	 sufficient	 to	 induce	 Th1,	 Th2	 and	 Th17	 differentiation	 following	 i.d.	
immunisation.	 Transcriptional	 analysis	 of	 antigen-carrying	 DC2	 revealed	 context-
specific	 expression	 of	 CD4+	 T	 cell	 polarising	molecules,	 suggesting	 that	 conditioning	
factors	from	the	immunogen	or	surrounding	cells	play	an	important	role	in	determining	






5 Inflammatory monocytes 
regulate the T effector-T follicular 








monocytes	and	macrophages.	 In	 the	past,	DC	have	dominated	this	 field	of	study,	with	






can	 also	 influence	 CD4+	T	 cell	 responses,	 in	 particular	 Th1	 responses	 (13,	600,	605).	
This	 chapter	 focuses	 on	 the	 role	 of	 monocytes	 in	 the	 regulation	 of	 CD4+	 T	 cell	
differentiation.	
	
Monocytes	 are	 a	 bone	 marrow-derived	 population	 that	 is	 exceptionally	 plastic	 and	
versatile.	 Equipped	 with	 a	 vast	 repertoire	 of	 pattern	 recognition	 and	 cytokine	
receptors,	often	expressed	at	a	higher	level	than	conventional	DC	(463),	monocytes	are	
highly	 sensitive	 to	 environmental	 cues,	 and	 adapt	 their	 phenotype	 and	 function	
accordingly.	 Depending	 on	 the	 cytokine	milieu	 and	 antigenic	 signals,	monocytes	 can	
differentiate	into	macrophages	or	DC	capable	of	presenting	antigen	and	producing	pro-
inflammatory	or	anti-inflammatory	cytokines	(47,	328,	592,	602,	603).	The	factors	that	
regulate	 monocyte	 recruitment,	 differentiation	 and	 cytokine	 production	 are	 highly	
context-specific	 (604,	 607,	 617,	 837)	 and	 therefore,	 have	 the	 potential	 to	 play	 an	






resident	 macrophage	 populations	 (598).	 LN	 macrophages	 are	 also	 susceptible	 to	
conditioning	and	expansion	in	inflammatory	contexts	(839).	Recently,	a	LN	macrophage	
population	 residing	within	 the	T	 cell	 zone	 (TZ)	 has	 been	 described.	 TZ	macrophages	
highly	express	C1qa,	C1qb	and	C1qc	transcripts,	and	CD64,	CX3CR1	and	MerTK	protein	
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on	 their	 surface,	 but	 lack	 expression	 of	 CD169,	 a	 molecule	 typically	 associated	 with	






12	and	 IL-18	 (233,	235).	NK	cell-derived	 IFNγ	can	 subsequently	act	on	monocytes	 to	
promote	their	differentiation	into	IL-12	producing	cells	(47,	486),	creating	an	activation	
amplification	 loop	 to	 promote	 Th1	 immunity	 during	 the	 early	 stages	 of	 a	 bacterial	
infection.	In	addition	to	promoting	IL-12	production	by	monocytes,	IFNγ	has	also	been	
associated	with	regulating	the	differentiation	and	function	of	monocytes	(47,	486,	592),	
indicating	 that	 IFNγ	signalling	may	play	an	 important	 role	 in	 conditioning	monocyte-
derived	cells	to	support	Th1	differentiation.		
	






CD4+	 T	 cell	 responses.	 Further,	 the	 transcriptional	 profile	 of	 monocytes	 provided	
insight	 into	 the	 context-specific	 signals	 involved	 in	 their	 recruitment,	 activation	 and	
function.	 IFNγ	 was	 identified	 as	 a	 key	 signal	 for	 the	 recruitment	 of	 Th1-promoting	
monocytes	 following	 Ms	 immunisation.	 Thus,	 characterisation	 of	 condition-specific	
genetic	patterns	 in	monocytes	could	assist	 in	understanding	some	of	 the	early	signals	






Monocytes	 and	 monocyte-derived	 populations	 are	 known	 contributors	 to	 immune	
responses	 in	 a	 number	 of	 different	 contexts.	 However,	 a	 systematic	 side-by-side	
characterisation	and	analysis	of	monocytes	elicited	in	response	to	distinct	immunogens	
has	 not	 been	 reported.	 The	 overall	 aim	 of	 this	 chapter	 was	 to	 address	 this	 gap	 in	

















5.3.1 Targeting GR1 is the most suitable strategy for depleting monocytes 
Antigen-carrying	 cells	 in	 the	 skin	 dLNs	 can	 be	 broadly	 divided	 into	 two	populations:	
migDC	(discussed	in	Chapter	4)	and	monocytes.	Importantly,	among	Ag+	cells,	the	ratio	
of	 migDC	 to	 monocytes	 was	 distinct	 following	 immunisation	 with	 different	
immunogens.	Monocytes	make	up	a	considerable	proportion	of	Ms+	cells,	whereas	very	
few	monocytes	are	detected	with	Nb	or	Ca	material	 (Fig	3.12).	Given	 the	presence	of	
Ag+	monocytes,	 it	 was	 of	 interest	 to	 determine	whether	monocytes	 played	 a	 role	 in	
regulating	CD4+	T	 cell	differentiation,	particularly	Th1	differentiation.	While	 this	 is	 a	
relatively	 simple	question,	 it	has	been	a	 challenging	one	 to	answer	due	 to	 the	 lack	of	
specific	monocyte	 depletion/blocking	 reagents	 currently	 available.	 In	 our	 laboratory,	
blocking	 the	 recruitment	 of	 monocytes	 to	 the	 LN	 using	 anti-CCL2	 and	 anti-CSF1	





Finally,	 administration	 of	 anti-GR1,	 which	 targets	 Ly6C/Ly6G	 expressing	 cells,	 was	
effective	 at	 reducing	 the	 number	 of	 monocytes	 recruited	 to	 the	 LN	 following	
immunisation	(Appendix	Fig	C-V).	The	caveat	 to	 this	model	 is	 that	neutrophils,	which	
express	both	Ly6C	and	Ly6G,	and	eosinophils,	which	express	Ly6C,	are	also	depleted.	
Surprisingly,	 the	 number	 and	 frequency	 of	 CD44+	 CD4+	 T	 cells	 were	 significantly	
increased	 in	 anti-GR1	 treated	 mice.	 As	 a	 PBS+anti-GR1	 treatment	 group	 was	 not	
included	in	these	experiments,	it	is	difficult	to	draw	conclusions	about	the	cause	of	the	
increased	number	of	CD44+	CD4+	T	cells.	Potentially,	increased	antigen	persistence	in	
the	 absence	 of	 neutrophils	 and	monocytes	may	 be	 responsible	 for	 this	 phenomenon.	
Therefore,	to	highlight	potentially	important	changes	in	the	phenotypic	composition	of	
CD44+	 CD4+	 T	 cells,	 cytokine-producing	 CD4+	 T	 cells	 and	 Tfh	 cells	 are	 shown	 as	 a	
frequency	 of	 CD44+	 CD4+	 T	 cells	 throughout	 the	 present	 chapter.	 Despite	 the	









from	 the	 LN	 and	 assessed	 for	 expression	 of	 cytokines,	 transcription	 factors	 and	 Tfh	
markers	 (Fig	5.1A).	 	The	 total	 cellularity	 in	 the	 lymph	node	was	not	affected	by	anti-
GR1	 treatment	 (Fig	 5.1B),	 but	 the	 phenotypic	 composition	 of	 the	 CD44+	CD4+	T	 cell	
compartment	 was	 significantly	 altered.	 As	 mentioned	 above,	 anti-GR1	 treatment	
resulted	 in	 an	 unexplained	 increase	 in	 the	 number	 and	 frequency	 of	 CD44+	 CD4+	 T	
cells	 (Fig	 5.1C).	 Assessment	of	 CD44+	CD4+	T	 cells	 showed	 the	 frequencies	 of	 IFNγ+	
and	Tbet+	CD4+	T	cells	were	significantly	reduced	with	anti-GR1	treatment;	whereas,	
the	 number	 and	 frequency	 IL-17A+	 CD4+	 T	 cells	 were	 increased	 (Fig	 5.1D-E).	 In	
addition,	the	intensity	of	IFNγ	and	Tbet	staining	was	reduced	with	anti-GR1	treatment,	




GR1	 (Fig	 5.1G).	 This	 resulted	 in	 a	 significant	 change	 to	 the	 phenotypic	 make-up	 of	
CD44+	CD4+	T	cells	after	Ms	 immunisation.	Typically,	Teff1	cells	are	the	predominant	




the	 case	 of	 anti-GR1	 treatment,	 Tfh	 express	 baseline	 Tbet	 similar	 to	 Tfh	 present	 at	

















5.3.3 Ly6C/Ly6G expressing cells regulate the T effector:T follicular balance following Nb 
immunisation 
It	was	of	interest	to	run	the	same	anti-GR1	experiment,	but	with	Nb	immunisation	(Fig	
5.2A),	 to	determine	whether	monocytes	 influenced	CD4+	T	 cell	 responses	when	 they	
were	not	major	contributors	to	antigen	presentation.		Surprisingly,	the	number	of	total	
cells	was	 significantly	 reduced	with	 anti-GR1	 treatment	 (Fig	 5.2B).	 The	 frequency	 of	
CD44+	 cells	 increased	 among	 CD4+	 T	 cells	 with	 anti-GR1	 treatment,	 preventing	 a	
significant	decrease	 in	 the	 total	number	of	CD44+	CD4+	T	 cells	 (Fig	5.2C).	 IL-4+	cells	
and	GATA-3+	cells	were	both	 significantly	 reduced	with	anti-GR1	 treatment,	 as	were	
the	 frequencies	 of	 IL-4+	 and	GATA-3+	 cells	 among	CD44+	CD4+	T	 cells	 (Fig	 5.1D-E).		
Similar	 to	 observations	 with	Ms,	 anti-GR1	 treatment	 increased	 the	 frequency	 of	 IL-
17A+	and	Tfh	cells	following	Nb,	although	not	to	the	same	extent	(Fig	5.2D-F).	Tfh	cells	
are	 a	 major	 component	 of	 the	 CD4+	 T	 cell	 response	 following	Nb,	 and	 Tfh	 typically	
outnumber	Teff2	 cells,	 2:1.	With	 anti-GR1	 treatment,	 this	 ratio	was	 exacerbated	 (Fig	





Figure	 5.2:	 Ly6C+/Ly6G+	 cells	 regulate	 the	 Teff/Tfh	 balance	 in	 Nb-immunised	 mice.	 (A)	 Schematic	 of	
experimental	protocol.	(B)	The	total	cell	number	enumerated	from	each	LN.	(C)	Number	and	frequency	of	CD44+	
CD4+	T	cells.	(D)	Representative	flow	cytometry	plots	showing	IL-4	and	IL-17A	production	by	CD4+	T	cells	following	
a	 5h	 re-stimulation	 with	 PMA/ionomycin,	 and	 GATA3	 and	 CXCR5	 expression	 by	 unstimulated	 CD4+	 T	 cells.	 (E)	
Number	and	frequency	of	IL-4+,	GATA3+	or	IL-17A+	CD4+	T	cells.	(F)	Number	and	frequency	of	Tfh	cells,	identified	







5.3.4 Ly6C/Ly6G expressing cells regulate Th17 and Tfh cells following Ca immunisation 
Finally,	 the	 same	 experimental	 protocol	was	 used	 to	 assess	 the	 role	 of	monocytes	 in	
regulating	CD4+	T	cell	responses	to	Ca	(Fig	5.3A).	While	there	were	few	Ca+	monocytes,	
GR1+	 cells	 (monocytes,	 neutrophils	 and	 eosinophils)	 made	 up	 a	 considerable	
proportion	 of	 nonB/T	 cells	 in	 the	 LNs	 of	 Ca-treated	 mice,	 suggesting	 that	 they	 may	
influence	CD4+	T	 cell	 responses	 to	Ca	 (Figs	3.7	and	3.8).	However,	 five	days	after	Ca	
immunisation,	 the	 total	 cell	 number	 in	 the	 dLN	 was	 similar	 between	 anti-GR1	 and	
isotype	treatment	groups	(Fig	5.3B).	No	statistically	significant	difference	was	detected	
in	the	number	and	frequency	of	CD44+	CD4+	T	cells;	however,	anti-GR1	treated	mice	
tended	 to	 have	 a	 higher	 frequency	 of	 CD44+	 cells	 among	 CD4+	 T	 cells	 (Fig	 5.3C)	
Assessing	 the	phenotypes	of	CD44+	CD4+	T	 cells	 revealed	an	 increase	 in	 the	number	
and	frequency	of	IL-17A+	cells	and	Tfh	cells,	but	no	other	notable	changes	(Fig	5.3D-F).	
Despite	 the	 increased	 frequency	 of	 Tfh	 cells,	 the	 overall	 ratio	 between	 effector	 and	
follicular	 helper	 cells	 was	 not	 significantly	 different	 between	 anti-GR1	 and	 isotype	
treatment	 groups	 (Fig	 5.3G).	 These	 data	 do	 not	 support	 a	 role	 for	 monocytes	 in	








to	the	 inhibition	of	 IFNγ+	CD4+	T	cells	which	are	known	to	counter-regulate	 IL-17A+	





Figure	 5.3:	 Ly6C+/Ly6G+	 cells	 regulate	 IL-17A+	 CD4+	 T	 cells	 and	 Tfh	 cells	 in	 Ca-immunised	 mice.	 (A)	
Schematic	of	experimental	protocol.	(B)	The	total	cell	number	enumerated	from	each	LN.	(C)	Number	and	frequency	
of	CD44+	CD4+	T	 cells.	 (D)	Representative	flow	cytometry	plots	 showing	 IFNγ	and	 IL-17A	production	by	CD4+	T	
cells	following	a	5h	re-stimulation	with	PMA/ionomycin,	and	RORγt	and	CXCR5	expression	by	unstimulated	CD4+	T	
cells.	(E)	Number	and	frequencies	of	 IL-17A+,	RORγt+	and	 IFNγ+	CD4+	T	cells.	 (F)	Number	and	frequency	of	Tfh	
cells,	identified	by	co-expression	of	CXCR5	and	PD1.	(G)	The	ratio	of	Teff:Tfh	cells.	Bar	graphs	show	the	mean±SEM.	






5.3.5 Anti-GR1 treatment differentially affects transport of immunogenic material to the 
LN following Ms and Nb immunisation 
Anti-GR1	treatment	had	a	significant	impact	on	the	CD4+	T	cell	response	following	Ms	
and	Nb	 immunisation,	 restricting	Teff1	 and	Teff2	 development	 respectively	 (Figs	 5.1	
and	5.2).	Given	that	monocytes	can	transport	 immunogenic	material	 to	 the	LN,	 it	was	
important	 to	determine	whether	 reduced	accessibility	 to	antigen	was	 responsible	 for	
the	 T	 cell	 phenotypes	 observed.	 To	 do	 this,	 mice	 were	 treated	 with	 anti-GR1	 three	
times,	starting	one	day	before	 immunisation	with	 fluorescently	 labelled	 immunogens.	
On	day	two	after	immunisation,	LNs	were	harvested	and	digested	to	assess	monocytes	
and	Ag+	 cells	 (Fig	5.4A).	 The	 total	 cellularity	 in	 the	 LN	 on	 day	 two	was	 significantly	
reduced	in	Ms+anti-GR1	treated	mice	but	was	unchanged	in	Nb+anti-GR1	treated	mice	
(Fig	5.4B).	This	is	likely	due	to	the	depletion	of	monocytes	which	are	present	in	higher	
numbers	 in	 Ms-treated	 mice	 compared	 to	 Nb-treated	 mice.	 Indeed,	 the	 number	 of	




activation	 markers	 (47,	 592,	 602,	 603).	 Following	 Ms	 and	 Nb	 immunisation,	 a	
proportion	 of	 recruited	 monocytes	 expressed	 CD11c	 and	 MHCII,	 indicative	 of	 DC	
differentiation.	 In	 addition,	 >80%	 of	monocytes	 from	Ms-treated	mice	 expressed	 the	
IFN-response	 molecule	 Ly6A/E.	 The	 frequencies	 of	 monocytes	 expressing	 CD11c+,	
MHCII+	 and	 Ly6A/E+	 were	 similar	 between	 isotype	 and	 anti-GR1	 treated	 mice,	
suggesting	that	there	was	no	preferential	ablation	of	activated	monocytes	by	the	anti-
GR1	antibody.	However,	 it	was	 interesting	 to	note	 that	CD86+	monocytes	were	more	
abundant	 in	 anti-GR1	 treated	 mice,	 potentially	 due	 to	 the	 increased	 availability	 of	
antigen	and	cytokines	in	mice	with	reduced	monocyte	counts	(Fig	5.4D).	
	
Despite	 the	 reduction	 in	 the	 number	 of	 total	LN	 cells	 and	monocytes,	 the	 number	 of	
Ms+	 cells	 was	 unchanged	 in	 anti-GR1	 treated	 mice,	 and	 the	 frequency	 of	 Ag+	 cells	









In	 contrast	 to	Ms,	 the	 number	 and	 frequency	 of	Nb+	 cells	were	 significantly	 reduced	
with	 anti-GR1	 treatment,	 but	 the	 cellular	 distribution	 of	 Nb	 material	 remained	
unchanged	(Fig	5.4G-H).	This	is	somewhat	surprising	given	that	monocytes	are	only	a	
small	 proportion	 of	 the	 Ag+	 population	 after	 Nb	 immunisation.	 A	 more	 plausible	
explanation	 is	 that	neutrophils	and	monocytes	may	assist	 in	breaking	down	the	 large	
Nb	worms	in	the	ear	tissue,	which	then	provides	small	fragments	to	dDC	for	transport	
to	 the	LN.	 Indeed,	neutrophils	rapidly	surround	Nb	worms	after	 injection	and	release	
neutrophil	 extracellular	 traps	 (NETs)	 which	 encompass	 large	 areas	 of	 the	 worm’s	
cuticle	 (815).	 Therefore,	 the	 reduced	 Teff2	 response	 to	Nb	 with	 anti-GR1	 treatment	








and	CD86	expression	on	monocytes.	(E)	Number	and	 frequency	of	Ag+	cells,	 2	days	after	 immunisation	with	Ms-
AF488.	(F)	The	distribution	of	Ms	antigen	between	migDC	and	monocyte	populations.	(G)	Number	and	frequency	of	
Ag+	 cells,	 2	 days	 after	 immunisation	 with	 Nb-AF488.	 (H)	 The	 distribution	 of	 Nb	 antigen	 between	 migDC	 and	
monocyte	 populations.	 Bar	graphs	 show	 the	mean±SEM.	Data	was	 compiled	 from	 two	 independent	experiments,	
with	 at	 least	 eight	 mice	 per	 group.	 Statistical	 significance	 was	 assessed	 using	 a	 Student’s	 t-test,	 comparing	 the	





5.3.6 Monocyte populations in the LN respond to IFNγ following Ms immunisation 
Monocytes	 are	 highly	 plastic	 and	 have	 the	 capacity	 to	 acquire	 many	 different	
phenotypes	 and	 functions	 depending	 on	 signals	 they	 receive	 from	 the	 environment.	
Brief	 phenotypic	 characterisation	 of	monocytes	 in	 Fig	 5.4	 showed	 differences	 in	 the	
expression	 of	 the	 DC-lineage	 marker	 CD11c,	 MHCII	 and	 the	 IFN-response	 marker	
Ly6A/E	on	monocytes	from	Ms-	and	Nb-treated	mice.	Thus,	it	was	of	interest	to	explore	
the	transcriptional	landscape	of	monocytes	elicited	by	distinct	immunogens	to	gain	an	
understanding	 of	 their	 potential	 context-specific	 functions	 and	 activating	 signals.	
scRNASeq	 data	was	 utilised	 from	 a	 collaborative	 study	with	 Ido	Amit’s	 laboratory	 to	
address	this	question.		
	
Firstly,	 it	 was	 of	 interest	 to	 determine	whether	 condition-specific	 genetic	 signatures	
could	 be	 observed	 in	 monocyte	 populations	 following	 i.d.	 immunisation.	 To	 do	 this,	
Pierre	 Bost	 performed	hierarchical	 clustering	 on	 the	most	 variable	 genes	 to	 identify	
condition-specific	 gene	 modules	 among	 monocytes.	 This	 analysis	 uncovered	 a	 gene	
module	 specifically	 enriched	 in	Ms+	 monocytes	 that	 included	 Th1-associated	 genes	
such	as	Il12b	and	Tnf.	Further,	an	Nb-specific	module	was	identified	and	included	Apoe,	
Sepp1	 and	Mrc1	 transcripts	 (Fig	5.5A).	 	To	 further	dissect	 the	 condition-specificity	of	
monocytes,	Pierre	directly	compared	the	genes	up-regulated	by	monocytes	in	response	
to	Ms	and	Nb.	This	analysis	revealed	a	strong	enrichment	in	genes	associated	with	IFNγ	
signalling	 (Cxcl9,	Cxcl10,	Gbp2,	 Irf7,	 Isg15,	 Ifi47,	Zbp1)	 (170)	 specifically	 in	monocytes	
from	 Ms-treated	 mice	 (Fig	 5.5B).	 To	 validate	 the	 condition	 specificity	 of	 the	 IFNγ	
genetic	 signature,	 I	 used	 the	 scRNASeq	 data	 to	 compare	 the	 expression	 of	 four	 IFNγ	







expression	of	 the	assessed	markers	was	distinct	between	Ms,	Nb	 and	Ca	 treated	mice	




proportion	 of	 monocytes	 up-regulated	 CD11c	 and	 MHCII,	 indicating	 their	
differentiation	 into	 a	 DC	 or	 macrophage	 lineage	 (Fig	 5.5E).	 Together,	 these	 data	
indicate	that	the	transcriptional	profile	of	monocytes	is	condition-specific.	In	particular,	












Nb	 monocytes	 compared	 to	 PBS	 controls.	 Analysis	 was	 performed	 by	 Pierre	 Bost.	 (C)	 Violin	 plots	 show	 the	
expression	of	selected	IFNγ-related	genes	in	monocytes	across	treatment	groups.	(D)	tSNE	analysis	(iterations:1000;	








5.3.7 T cell zone macrophages respond to IFNγ following Ms immunisation 
Analysis	of	Ag+	cells	using	 scRNASeq	 revealed	a	population	of	Ms+	macrophages	not	




this	 set	 of	 genes,	 macrophages	 from	 our	 study	 were	 compared	 to	 two	 previously	
characterised	LN-resident	macrophage	populations:	CD169+	sub-capsular	sinus	 (SCS)	
macrophages	 (463)	 and	 CD169-	 T	 cell	 zone	 (TZ)	 macrophages	 (598).	 Of	 these	 two	
macrophages	 populations,	 Ms-associated	 macrophages	 were	 most	 similar	 to	 TZ	
macrophages,	 sharing	 14	 genes	 compared	 to	 just	 3	 genes	 with	 CD169+	 SCS	
macrophages	 (Fig	 5.6A).	 The	 paper	 that	 first	 described	 TZ	 macrophages	 also	
demonstrated	 that	 they	 were	 of	 monocytic	 origin	 (598).	 To	 determine	 whether	
monocyte-to-macrophage	 trajectory	 could	 be	 detected	 in	 Ms-treated	 mice,	 our	
collaborator	Pierre	Bost	constructed	a	pseudo-temporal	path	 in	silico	using	scRNASeq	
data.	 In	 this	 analysis,	 cells	 are	 ordered	 based	 on	 their	 gene	 expression	 profiles,	
generating	a	statistical	timeline	of	cell	states.	A	monocyte-to-TZ	macrophage	transition	
pathway	was	established	using	this	method	and	shows	the	transcriptional	changes	that	






also	 expressed	 IFNγ-regulated	 genes	 following	Ms	 immunisation.	 Cxcl9,	 Cxcl10,	 Ly6a	
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and	Stat1	were	all	up-regulated	by	TZ	macrophages	from	Ms-treated	mice,	whereas	TZ	
macrophages	 from	Nb-	 and	 Ca-treated	 mice	 were	 similar	 to	 control	 (Fig	 5.6C).	 This	
result	 was	 confirmed	 at	 the	 protein	 level	 by	 flow	 cytometric	 analysis.	 As	 LN	
macrophages	are	very	rare	and	difficult	to	identify	by	flow	cytometry,	LNs	from	several	
mice	 were	 pooled	 and	 enriched	 for	 CD11b+	 cells	 using	 magnetic	 beads.	 CD11b-
enriched	 cells	were	 then	 stained	 for	 CD64,	 Ly6C,	MHCII	 and	 CD169	 as	well	 as	 IFNγ-
induced	markers	CXCL9	and	Ly6A/E.		Using	this	approach	monocytes,	TZ	macrophages	
and	 CD169+	 SCS	 macrophages	 could	 be	 identified	 (Fig	 5.6D).	 Interestingly,	 CXCL9	
expression	 was	 restricted	 to	monocytes	 and	 TZ	 macrophages	 from	Ms-treated	 mice.	
Despite	 being	 recovered	 from	 the	 same	 LN,	 CD169+	macrophages	 did	 not	 alter	 their	
CXCL9	 expression	 following	 Ms	 (Fig	 5.6E).	 	 In	 contrast,	 Ly6A/E	 was	 strongly	 up-
regulated	 in	monocytes	 and	 both	macrophage	 populations	 after	Ms-immunisation.	 In	
macrophages,	 CXCL9	 is	 specifically	 associated	with	 IFNγ	 signalling,	 whereas	 Ly6A/E	













cells	 among	 monocytes,	 TZ	 macrophages	 and	 CD169+	 macrophages	 from	 Ms-treated	 mice.	 Graphs	 show	 the	








differentiation	 of	monocytes	 to	 IL-12-producing	moDC	 (47),	 suggesting	 that	 NK	 cells	
could	be	a	cell-type	of	interest	 in	 the	response	to	Ms.	Assessment	of	cell-type	clusters	
from	 scRNASeq	 (analysis	 by	 Pierre	Bost)	 and	 flow	 cytometry	 data	 showed	 a	 specific	
enrichment	in	the	abundance	of	NK	cells	in	Ms-d2	samples	(Figs	5.7A	and	3.8).	The	NK	






Pierre	Bost	constructed	a	pseudo-temporal	path	 in	silico	using	scRNASeq	data.	 In	 this	
case,	the	timeline	started	with	homeostatic	NK	cells	and	ended	with	activated	IFNγ+	NK	
cells.	 Genes	 associated	 with	 homeostatic	 NK	 cells	 included	 Klrd1,	 Klra4	 and	 Klra8.	
Activated	NK	 cells	 expressed	Ccr5,	Gzmb,	Ccl3,	Cxcl9,	Ccl4,	 Ifng	and	Hopx;	which	 have	
been	 previously	 associated	 with	 early	 effector	 NK	 cells	 following	 murine	
cytomegalovirus	 infection	 (844).	 Importantly,	 NK	 cells	 from	 Ms-treated	 mice	 were	
distributed	 towards	 the	activated	NK	phenotype;	whereas,	NK	cells	 from	Nb-	 and	Ca-
treated	mice	were	 distributed	 similarly	 to	 PBS	 controls	 (Fig	 5.7C).	 Intracellular	 flow	
cytometry	performed	by	myself	showed	NK	cells	from	Ms-treated	mice	produced	IFNγ,	
whereas	NK	 cells	 from	Nb-treated	mice	 did	 not	 (Fig	 5.7D-E).	 In	 addition,	 CD11b	has	
been	used	as	a	marker	of	activated	NK	cells	(844).	A	higher	frequency	of	NK	cells	from	







Nb	 or	 Ca.	 Control	 animals	 received	an	 injection	 of	 PBS.	 1-3	days	after	 immunisation,	 LN	 cells	were	analysed	 by	
scRNASeq	or	 flow	cytometry.	(A)	Bubble	plot	shows	the	enrichment	of	cell	 types	1	or	2	days	after	 immunisation.	
Colour	indicates	the	p-value	for	the	change	in	cell	frequencies	compare	to	PBS	controls.	Bubble	size	represents	the	





Graphs	 show	 the	mean±SEM.	 Flow	 cytometry	 data	 is	 representative	 four	 experiments	 that	 gave	 similar	 results.	
Statistical	 significance	was	assessed	using	a	One-Way	ANOVA	with	Holm-Sidak’s	post-	 test.	 *	p<0.05,	 ***	p<0.001,	
****p<0.0001	
	182	
5.3.9 NK cell depletion is not sufficient to alter monocyte recruitment or the T effector:T 





NK1.1	 depleting	 antibody	 (Appendix	 Fig	 C-VI),	 three	 times,	 starting	 one	 day	 before	
immunisation.	Monocytes	and	macrophages	from	the	dLNs	were	then	assessed	on	day	
three.	 	 The	 number	 and	 frequency	 of	 monocytes	 and	 TZ	 macrophages	 were	 not	
impacted	 by	 NK	 cell	 depletion	 (Fig	 5.8A-B).	 Further,	 neither	 monocytes	 nor	
macrophages	 showed	 any	 change	 in	 their	 expression	 of	 IFNγ-regulated	 molecules,	
CXCL9	 and	 Ly6A/E	 (Fig	 5.8C-D).	 This	 suggested	 that	 NK	 cell	 depletion	 was	 not	
sufficient	to	prevent	early	production	of	IFNγ.	
	
Despite	 this	 finding,	 it	 was	 of	 interest	 to	 determine	 whether	 NK	 cells	 and	 NK	 cell-
derived	 IFNγ	were	 important	 for	 the	 CD4+	T	 cell	 response	 to	Ms.	Mice	were	 treated	
with	anti-NK1.1	three	times,	starting	one	day	before	immunisation,	and	the	CD4+	T	cell	
response	was	assessed	on	day	five	(Fig	5.9A).	Surprisingly,	the	total	cell	number	in	the	
LN	was	 increased	 in	the	absence	of	NK	cells	(Fig	5.9B).	Likewise,	 the	number	of	 IFNγ	
CD4+	T	cells	was	increased	in	anti-NK1.1-treated	mice	immunised	with	Ms	(Fig	5.9C-D).	





defect	 in	 the	CD4+	T	cell	response	as	a	result	of	NK	cell	depletion,	which	was,	 in	 fact,	
increased.	Therefore,	this	experiment	did	not	uncover	evidence	to	suggest	that	NK	cells	







3,	both	ear	dLNs	were	 isolated	and	the	 cells	pooled	prior	 to	a	4-hour	 incubation	with	Brefeldin	A	and	GolgiStop.	
CD11b+	 cells	 were	 enriched	 using	 magnetic	 beads	 and	 stained	 for	 flow	 cytometric	 analysis.	 (A)	 Number	 and	
frequency	 of	monocytes.	 (B)	 Number	and	 frequency	 of	TZ	macrophages.	 (C)	 Representative	 flow	 cytometry	 plot	
showing	 CXCL9	 and	 Ly6A/E	 expression	 on	 monocytes	 and	 TZ	 macrophages.	 (D)	 Frequencies	 of	 CXCL9+	 and	











two	 independent	 experiments,	 with	 at	 least	 ten	 mice	 per	 group.	 Statistical	 significance	 was	 assessed	 using	 a	
Student’s	t-test,	comparing	the	isotype	control	group	to	the	αNK1.1-treatment	group.	**p<0.01,	***p<0.001		
 
5.3.10 NK cells are not the only source of early IFNγ 
The	 up-regulation	 of	 IFNγ-regulated	 genes	 in	 the	 absence	 of	 NK	 cells	 indicated	 that	
other	cell	types	may	also	produce	IFNγ	in	the	first	two	days	following	Ms	immunisation.	
The	scRNASeq	data	identified	NK	cells	as	the	sole	population	with	Ifng	transcript,	but	T	
and	 B	 cells	were	 removed	 from	 single-cell	 sorting	 by	 depleting	with	 TCRβ,	 CD3	 and	
CD19	antibodies.	Intracellular	cytokine	staining	for	IFNγ	one,	two,	three	and	five	days	




contributed	 to	 the	 IFNγ	 population,	 but	 this	 cell	 population	 only	 made	 up	 a	 small	
proportion	of	total	IFNγ+	cells	(Fig	5.10A-B).	Overall,	these	data	show	that	NK	cells	are	
not	 the	 sole	 source	 of	 IFNγ	 after	 Ms	 immunisation	 and	 thus	 explain	 why	 NK	 cell	












5.3.11 NK cell depletion combined with IFNγ neutralisation blocks monocyte recruitment, 
and prevents expression of CXCL9 and Ly6A/E by monocytes and macrophages 
To	further	investigate	the	role	of	IFNγ-conditioning	in	monocytes	and	macrophages,	the	
experimental	 strategy	 was	 adjusted,	 and	 mice	 were	 treated	 with	 anti-IFNγ	 in	
combination	with	anti-NK1.1	(Fig	5.11A).	Using	this	protocol,	the	results	were	striking.	
The	 total	 cell	number	 in	 the	 LNs	of	Ms-immunised	mice	 treated	with	 anti-NK1.1	 and	
anti-IFNγ	 was	 significantly	 lower	 than	 Ms-treated	 mice	 that	 received	 the	 isotype	
control	(Fig	5.11B).	Further,	the	number	and	frequency	of	monocytes	recruited	to	the	
LN	following	Ms	immunisation	were	substantially	reduced	(Fig	5.11C),	akin	to	the	level	
achieved	 following	 anti-GR1	 treatment	 (Fig	 5.4C).	 The	 overall	 number	 of	 TZ	
macrophages	was	also	reduced	with	anti-IFNγ	and	anti-NK1.1	treatment;	however,	the	
frequency	 was	 unchanged	 from	 the	 isotype	 control	 (Fig	 5.11D).	 Importantly,	 the	
expression	 of	 the	 IFNγ-responsive	 molecules	 CXCL9	 and	 Ly6A/E	 were	 reduced	 to	
baseline	 on	 both	monocytes	 and	TZ	macrophages	 (Fig	 5.11E-F),	 indicating	 that	 IFNγ	
neutralisation	was	complete.	In	addition,	the	frequency	of	monocytes	expressing	CD11c	
and	MHCII	were	significantly	reduced	in	the	absence	of	NK	cells	and	IFNγ	(Fig	5.11G),	




Ms+	 cells,	 it	 was	 important	 to	 assess	 the	 transport	 of	Ms	 material	 to	 the	 LN	 in	 the	
presence	of	anti-IFNγ	and	anti-NK1.1.	The	overall	number	of	Ag+	cells	were	reduced,	
likely	 due	 to	 the	 reduction	 in	 the	 number	 of	 total	 cells	 in	 the	 LN.	 However,	 the	
frequency	 of	 Ag+	was	 increased,	 which	may	 be	 due	 to	 increased	 antigen	 availability	
when	 monocytes	 were	 depleted	 (Fig	 5.11H).	 Assessing	 the	 phenotype	 of	 Ag+	 cells	
revealed	that	migDC	compensated	 for	 the	reduction	of	monocytes,	making	up	80%	of	
Ag+	 cells	 in	 anti-IFNγ	 and	 anti-NK1.1-treated	 mice,	 compared	 to	 55%	 in	 isotype	
controls	(Fig	5.11I).	This	result	is	in	contrast	to	anti-GR1	experiments	that	showed	no	
change	 in	 the	 distribution	 of	 immunogenic	 material	 between	monocytes	 and	migDC	
(Fig	 5.4F).	 This	 suggests	 that	 IFNγ-conditioning	 of	 monocytes	 may	 regulate	 their	
functional	 capacity	 to	 take-up/transport	Ms	material,	which	will	 not	 be	 perturbed	 in	
the	monocytes	that	escape	depletion	 in	anti-GR1-treated	mice.	Further,	blocking	IFNγ	
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IFNγ-recruited	 monocytes,	 migDC	 increase	 their	 transport	 of	Ms	 antigen	 to	 the	 LN,	










and	 frequency	 of	 TZ	 macrophages.	 (E)	 Representative	 flow	 plots	 showing	 CXCL9	 and	 Ly6A/E	 expression	 on	
monocytes	 and	 TZ	 macrophages.	 (F)	 Frequencies	 of	 CXCL9+	 and	 Ly6A/E+	 cells	 among	 monocytes	 and	 TZ	
macrophages.	(G)	Frequency	of	CD11c+	MHCII+	cells	among	monocytes.	(H)	Number	and	frequency	of	Ag+	cells.	(I)	




5.3.12 NK cell depletion with IFNγ neutralisation regulates the T effector:T follicular 
balance following Ms immunisation 
The	 marked	 change	 in	 the	 number	 and	 phenotype	 of	 monocytes	 following	 IFNγ	
neutralisation	and	NK	cell	depletion	warranted	an	investigation	into	the	T	cell	response	



















development	 of	 Tfh	 cells.	 Given	 the	 similarity	 of	 the	 phenotype	 observed	 in	 these	






(A)	 Schematic	of	 experimental	protocol.	 (B)	The	 total	 cell	number	enumerated	 from	each	LN.	 (C)	Representative	
flow	cytometry	plots	showing	IFNγ	and	IL-17A	production	by	CD44+	CD4+	T	cells	following	a	5h	re-stimulation	with	
PMA/ionomycin,	 and	 Tbet	 and	 CXCR5	 expression	 by	 unstimulated	 CD44+	 CD4+	 T	 cells.	 (D)	 The	 number	 and	
frequency	of	IFNγ+,	Tbet+	or	Tfh	cells.	(E)	The	ratio	of	Teff:Tfh	cells.	(F)	Frequency	of	Tbet+	cells	among	Tfh	cells.	
Bar	graphs	show	the	mean±SEM.	Data	was	compiled	from	at	 least	two	independent	experiments,	with	at	 least	ten	










shows	 that	 IFNγ	 is	 an	 important	 signal	 for	 the	 recruitment	 and	 conditioning	 of	
monocytes	 in	 Ms-treated	 mice.	 Further,	 monocytes	 played	 an	 important	 role	 in	
regulating	the	balance	of	effector	T	and	Tfh	cells,	particularly	after	Ms	immunisation.	
	
5.4.1 Monocyte plasticity  
Monocytes	make	 up	 a	 significant	 proportion	 of	 innate	 cells	 in	 the	 LNs	 of	 immunised	
mice,	 regardless	 of	 the	 immunogen	 administered.	 Given	 their	 receptiveness	 to	
environmental	 cues,	 it	 is	unlikely	 that	monocytes	 from	Ms-,	Nb-	 and	Ca-treated	mice	
have	 the	 same	 phenotypic	 and	 functional	 characteristics.	 Indeed,	 the	 transcriptional	
profiles	 of	 monocytes	 were	 distinct	 between	 treatment	 groups.	 Most	 notably,	 Ms	
monocytes	specifically	expressed	an	IFNγ	transcriptomic	signature,	as	well	as	Il12b	and	
Tnf	 transcripts.	 Interestingly,	 Nb+	 monocytes,	 though	 rare,	 had	 a	 distinct	
transcriptional	profile,	with	increased	expression	of	Apoe	and	Sepp1	as	well	as	the	M2-
realred	 gene	 Mrc1	 (625).	 These	 data	 provide	 evidence	 that	 the	 phenotype,	 and	
potentially	 the	 function,	 of	 monocytes	 is	 context-specific.	 However,	 further	
investigation	is	required	to	address	this	point	in	more	detail.	Unfortunately,	scRNASeq	
technologies	 are	 limited	 in	 their	 detection	 of	 lowly	 expressed	 transcripts	 such	 as	
cytokines	and	chemokines	and	thus,	the	interpretations	from	this	study	are	somewhat	
limited.	Similar	experiments	performed	using	bulk	RNA	sequencing	or	more	sensitive	
scRNASeq	 platforms	 will	 be	 of	 great	 interest	 and	 provide	 a	 wealth	 of	 additional	
information	about	the	roles	of	monocytes	elicited	in	different	contexts.	
	
The	 transcriptional	 distinctions	 between	monocytes	 from	different	 treatment	 groups	
suggests	that	the	signals	involved	in	their	recruitment	and	activation	are	also	distinct.	
This	 chapter	 primarily	 focussed	 on	 Ms	 monocytes	 due	 to	 their	 clear	 IFNγ	
transcriptional	 profile.	 Interestingly,	 IFNγ	 was	 found	 to	 be	 important	 for	 the	
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recruitment	 of	 monocytes	 in	 Ms-treated	 mice,	 as	 well	 as	 their	 activation	 and	
differentiation	into	DC	and	macrophage-like	cells.	IFNγ	has	been	previously	implicated	
in	 promoting	 the	 differentiation	 of	 monocytes	 into	 pro-inflammatory	 cytokine	
producing	DC	(47,	592),	but	the	role	of	IFNγ	in	monocyte	recruitment	has	not	been	well	
established.	 In	 a	model	 of	 L.	major	 infection,	 IFNγ	 played	 a	 partial	 role	 in	 recruiting	
inflammatory	monocytes	to	 the	skin	during	a	secondary	 infection	(592).	 In	 the	Ms	i.d.	




know	 at	 what	 stage	 in	 their	 recruitment	 IFNγ	 signalling	 is	 required.	 One	 study	 has	
described	 a	 role	 for	 NK	 cell	 derived	 IFNγ	 in	 conditioning	 monocytes	 in	 the	 bone	





Further,	 the	 small	number	of	monocytes	present	 in	anti-IFNγ	and	anti-NK1.1	 treated	
mice	 were	 transcriptionally	 distinct	 from	Ms-elicited	 monocytes.	 As	 expected,	 Cxcl9,	
Cxcl10	 and	Ly6a	 transcripts	were	 not	up-regulated	 in	 the	 absence	 of	 IFNγ	 signalling.	
CXCR3,	 the	receptor	 for	CXCL9	and	CXCL10,	 is	expressed	by	Th1	cells	(845)	and	thus	




treated	mice	were	not	 investigated	 in	 this	study.	The	 lack	of	 an	 IFNγ	signature	 in	Nb	
and	 Ca	 monocytes	 would	 suggest	 that	 IFNγ	 is	 not	 required	 in	 these	 settings,	 but	
additional	experiments	are	needed	to	confirm	this	hypothesis.	IFN-I	signalling	has	been	
shown	 to	 be	 important	 for	 the	 recruitment	 of	 monocytes	 after	 Nb	 immunisation,	
implicating	 another	 pathway	 in	 monocyte	 recruitment	 (Shiau-Choot	 Tang	 and	 Lisa	
Connor,	 unpublished	 observations).	 Further	 characterisation	 of	 the	 context-specific	
signals	 involved	 in	 monocyte	 recruitment	 and	 activation	 is	 pertinent	 to	 the	
understanding	of	the	roles	of	monocytes	in	regulating	CD4+	T	cell	responses.		
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5.4.2 Monocyte regulation of CD4+ T cell differentiation 





cells	 are	 currently	 unknown.	 One	 intriguing	 hypothesis	 suggests	 the	 relocation	 of	
recently	primed	CD4+	T	cells	plays	an	important	role	in	determining	T	effector	and	Tfh	
differentiation.	Full	differentiation	of	Tfh	cells	requires	the	presence	of	B	cells	and	the	
localisation	 of	 primed	CD4+	T	 cells	 to	 the	B	 cell	 follicles	 (207,	451).	 Thus,	 relocation	
away	from	B	cell	follicles	to	niches	containing	cytokine-producing	innate	cells	may	be	
required	 to	 support	 T	 effector	 differentiation.	 Indeed,	 in	 silico	 modelling	 utilising	
scRNASeq	 data	 suggests	 that	 recently	 primed	 Plasmodium-specific	 CD4+	 T	 cells	 co-
express	 the	 Tfh-associated	molecule	 CXCR5	 and	 the	 Th1-associated	molecule	 CXCR3	
(207).	 The	 subsequent	 chemotactic	 cues	 received	 by	 the	 T	 cell	 then	 determines	
whether	the	cell	traffics	to	the	B	cell	follicle,	promoting	Tfh	differentiation;	or	towards	
inflammatory	 innate	 cells,	 promoting	 T	 effector	 differentiation.	 The	 authors	 of	 this	
paper	then	go	on	to	show	that	monocytes	are	a	significant	source	of	the	CXCR3	ligand,	






In	addition	 to	 the	 regulation	of	 effector	and	 follicular	Th	cells,	monocytes	may	play	a	
role	in	specifically	promoting	Th1	differentiation.	As	noted	above,	IFNγ	production	and	
Tbet	expression	were	significantly	reduced	 in	Ms-treated	mice	when	monocytes	were	
depleted.	 IL-12	plays	an	 important	role	 in	directing	CD4+	T	 cells	 to	a	Th1	phenotype	
(236,	846),	and	monocytes	are	a	known	source	of	IL-12	in	vivo	(47,	605).	Indeed,	Il12b	
transcripts	were	specifically	detected	in	monocytes	from	Ms-treated	mice.	Further,	Ms	
monocytes	 highly	 expressed	 CXCL9	 at	 both	 transcript	 and	 protein	 levels,	 as	 well	 as	









Nb+	monocytes	were	 transcriptionally	 distinct	 from	monocytes	 elicited	 by	Ms	 or	Ca.	
Depletion	 of	 monocytes	 in	Nb-treated	 mice	 resulted	 in	 a	 shift	 in	 the	 T	 effector/Tfh	
balance,	 but	 also	 a	 significant	 reduction	 in	 Th2	 cells.	 Investigation	 into	 Nb	 antigen	
transport	 in	 anti-GR1-treated	 mice	 showed	 a	 significant	 reduction	 in	 the	 number	 of	
Nb+	 cells	 reaching	 the	 LN.	 Given	 the	 rarity	 of	 Nb+	 monocytes,	 this	 result	 was	
unexpected.	 A	 possible	 explanation	 for	 this	 observation	 is	 that	monocytes	 and	 other	
GR1+	 cells,	 such	 as	 neutrophils,	 are	 required	 to	 break	 down	 Nb	 larvae	 to	 free	 up	
antigen	for	migDC.	In	the	absence	of	these	cells,	migDC	are	not	effective	at	bringing	Nb	
antigen	into	the	LN,	and	thus	a	minimal	CD4+	T	cell	response	is	initiated.	The	reduced	
antigen	 transport	 makes	 it	 difficult	 to	 conclude	 whether	 monocytes	 are	 involved	 in	
specifically	 promoting	 Th2	 immune	 responses.	 A	 more	 specific	 monocyte	 depletion	




Finally,	CD4+	T	 responses	 to	Ca	were	assessed	 in	 the	mice	 in	which	monocytes	were	
depleted.	 Interestingly,	 the	Th17	response	was	enhanced	 in	anti-GR1-treated	mice.	 In	
fact,	 the	 IL-17A	 response	 was	 significantly	 increased	 in	 all	 models	 with	 anti-GR1	
treatment.	 It	 is	 unclear	 why	 Th17	 responses	 would	 be	 enhanced	 when	 monocyte	
numbers	 were	 reduced	 as	 monocyte-derived	 cells	 have	 been	 implicated	 in	 Th17	
induction	 in	 mice	 and	 humans	 (609,	 848).	 Th1-associated	 cytokines	 are	 known	 to	




Overall,	 monocytes	 have	 the	 capacity	 to	 significantly	 influence	 CD4+	 T	 cell	
differentiation.	From	the	experiments	presented	 in	this	chapter,	 it	 is	unclear	whether	
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monocytes	 are	 required	 to	 present	 antigen	 or	 serve	 in	 a	 supporter	 role,	 providing	
cytokines	 to	 encourage	 the	 differentiation	 of	 particular	 CD4+	 T	 cell	 phenotypes.	 In	
particular,	 CD4+	 T	 cell	 responses	 to	 Ms	 were	 significantly	 impacted	 by	 monocyte	
depletion,	with	reduced	Th1	differentiation	and	enhanced	Tfh	differentiation.	The	role	
of	 monocytes	 in	 regulating	 CD4+	 T	 cell	 responses	 to	 Nb	 and	 Ca	 remains	 to	 be	
determined.	 However,	 evidence	 in	 the	 literature	 and	 in	 this	 thesis	 suggests	 that	
conditioning	of	monocytes	may	be	 involved	 in	 creating	an	environment	 conducive	 to	
the	appropriate	differentiation	of	CD4+	T	cells.		
	
5.4.3 Sources of early IFNγ 
NK	 cells	 are	 a	 significant	 source	 of	 IFNγ	 in	 the	 first	 two	 days	 after	 immunisation.	
However,	other	cell	types	also	contribute	to	the	IFNγ+	population	from	day	two.	These	
cells	include	conventional	CD8+	and	CD8-	T	cells,	as	well	as	NKT	and	γδ	T	cells.	It	is	well	
established	 that	NKT	and	γδ	T	 cells	 can	produce	 IFNγ	 in	 response	 to	 cytokines	 (849-
851),	but	it	is	not	clear	whether	the	conventional	T	cells	are	responding	in	an	antigen-








not	 effective	 at	 blocking	 monocyte	 recruitment	 and	 activation.	 While	 subsequent	
experiments	used	NK	cell	depletion	in	combination	with	IFNγ	neutralisation,	it	is	likely	
that	administration	of	an	anti-IFNγ	antibody	alone	would	have	been	sufficient	to	limit	
monocyte	 recruitment	 and	 activation.	 Thus,	 it	 is	 not	 clear	what	 role	NK	 cells	 play	 in	
conditioning	 monocytes	 and	 regulating	 CD4+	 T	 cell	 differentiation.	 IFNγ	 expression	
was	 not	 measured	 in	 NK	 cell	 depleted	 mice.	 It	 is	 possible	 that	 compensatory	






5.4.4 IFNγ signalling and Th1 differentiation 
In	the	absence	of	NK	cells	and	IFNγ	signalling,	Ms-immunised	mice	exhibited	a	marked	
reduction	 in	effector	Th1	responses.	No	change	was	observed	 in	mice	where	only	NK	
cells	 were	 depleted,	 implicating	 IFNγ	 as	 the	 signal	 required	 for	 optimal	 Th1	
differentiation.	 Interestingly,	 the	 Tfh	 response	was	maintained	 in	 the	 absence	 of	 NK	







(372,	 373,	 853).	 In	 contrast	 to	 these	 findings,	 others	 have	 shown	 that	 there	 is	 a	
redundant	role	for	IFNγ	and	IL-12	signalling	in	promoting	Tbet	expression,	suggesting	
that	 IFNγ	 signalling	 may	 not	 be	 required	 in	 all	 settings	 (377).	 That	 said,	 all	 the	
aforementioned	experiments	were	 conducted	 in	vitro	 and	may	not	 translate	 to	 the	 in	
vivo	 setting.	 To	my	 knowledge,	 the	 role	 of	 IFNγR	 signalling	 on	 CD4+	 T	 cells	 in	 Th1	
differentiation	 has	 not	 been	 conclusively	 addressed	 in	 vivo,	 which	 would	 require	













sources	 of	 IFNγ	 are	 required	 to	 recruit	 monocytes	 to	 the	 LN	 where	 they	 play	 an	
important	 role	 in	 promoting	 effector	 Th1	 responses.	 CXCL9	 and	 IL-12	 production	 by	
IFNγ-recruited	 monocytes	 are	 potential	 signals	 that	 drive	 Tbet	 expression	 and	 IFNγ	
production,	supporting	the	development	of	effector	Th1	cells	over	Tfh	cells	(Fig	5.13).	




















6 IFNAR and TSLPR signalling 
regulate the magnitude and 
polarisation of CD4+ T cell 








also	 a	 driving	 factor	 in	 allergic	 disease	 (2).	 Initiation	 of	 Th2	 responses	 requires	 the	
presence	of	APC	 (9,	500),	 specifically	 the	DC2	 subset	 (Chapter	4)	 (111,	333,	557,	559,	






differentiation	 of	 CD4+	 T	 cells.	 Chapter	 4	 described	 the	 functional	 plasticity	 and	
context-specific	transcriptional	diversity	of	DC2,	while	Chapter	5	demonstrated	the	role	
of	 IFNγ-conditioned	 monocytes	 in	 a	 Th1	 context.	 Adoptive	 transfer	 of	 DC	 from	Nb-
treated	 mice	 is	 sufficient	 to	 promote	 Th2	 differentiation	 in	 naïve	 recipients	 (333),	
implicating	DC-conditioning	as	a	 factor	 in	Th2	contexts.	The	present	chapter	explores	
this	 observation	 further	 and	 assesses	 potential	 signals	 involved	 in	 promoting	 Th2-
inducing	function	in	DC.	
	




infection	 or	 allergic	 disease	 previously.	 Therefore,	 it	 was	 pertinent	 to	 determine	
whether	IFN-I	signalling	in	DC	was	required	for	inducing	Th2	differentiation.	There	are	
20	 species	of	 IFN-I,	but	 they	all	signal	 through	 the	 IFN-I	 receptor	 (IFNAR)	 (854-856),	
enabling	the	use	of	the	anti-IFNAR1	blocking	antibody	and	the	Ifnar1fl/fl	mouse	model	to	
ascertain	 the	 role	 of	 IFN-I	 in	 Th2	 immunity.	 The	 data	 from	 these	 experiments	 are	
shown	in	the	present	chapter	and	ascribe	IFN-I	with	a	role	 in	amplifying	CD4+	T	cell	





regulated	 by	Nb+	 DC2	 in	 both	 the	 qPCR	 and	 the	 RNASeq	 datasets	 (Fig	 4.12)	 (229),	
suggesting	that	Nb+	DC2	may	be	responding	to	a	Th2	specific	signal.	The	epithelial	cell-
derived	cytokine	TSLP	has	been	described	as	an	upstream	regulator	of	CCL17,	CCL22	
and	OX40L	 in	DC	(112-115),	and	has	a	strong	association	with	Th2	 immunity	 in	mice	
and	 humans	 (100,	 106,	 112-115,	 187,	 343,	 485,	 857,	 858).	 Previous	 studies	 have	
proposed	 TSLP-induced	 OX40L	 expression	 is	 a	 critical	 factor	 in	 driving	 Th2	
differentiation	(114,	115,	401,	482),	while	others	have	suggested	that	induction	of	Th2	
cell	 chemoattractants	may	play	a	 role	 (112,	113,	187).	However,	TSLP	can	also	act	on	
CD4+	T	cells	to	promote	IL-4	and	IL-13	production	(106,	107,	117,	118,	121),	making	it	






DC	 conditioning	 due	 to	 the	 actions	 of	 innate	 cytokines,	 such	 as	 IFN-I	 and	 epithelial-
derived	 cytokines,	 appears	 to	 be	 a	 factor	 regulating	 Th2	 differentiation.	 Intradermal	
immunisation	with	Nb	is	a	useful	model	to	test	the	individual	and	combinatorial	actions	
of	 these	 molecules	 in	 Th2	 priming	 utilising	 IFNAR∆CD11c	 and	 TSLPR-KO	 mice.	
Understanding	how	these	factors	co-operate	and	contribute	to	Th2	immunity	is	vital	for	




DC2	 play	 an	 essential	 role	 in	 promoting	 optimal	 Th2	 responses.	 The	 selective	 up-
















6.3.1 Allergens elicit similar CD4+ T cell responses 
Allergens	are	associated	with	the	 induction	of	Th2	cells	 (861-865).	Results	presented	
thus	 far	 in	 this	 thesis	 have	 demonstrated	 the	 variety	 of	 CD4+	 T	 cell	 phenotypes	
generated	 following	 i.d.	 immunisation	 protocols.	 Therefore,	 it	 was	 pertinent	 to	
compare	all	the	major	CD4+	T	cell	phenotypes	between	Nb-immunised	mice	and	mice	
immunised	 with	 a	 common	 household	 allergen:	 house	 dust	 mite	 (HDM;	 D.	
pteronussinus).		
	
The	 dominant	 CD4+	T	 cell	 response	 to	 both	 allergens	 consisted	 of	 a	 Th2	 phenotype,	
with	 IL-4+	and	GATA-3+	cells	being	 the	most	prominent	 (Fig	6.1A-B).	 IL-13+	CD4+	T	
cells	 were	 detected	 at	 a	 very	 low	 level,	 consistent	 with	 studies	 proposing	 that	
additional	signals	 in	 the	tissue	are	required	 for	 IL-13	expression	(Fig	6.1C)(106,	121).	
Tfh	 cells	 were	 abundant	 following	 both	 immunisations,	 with	 >60%	 of	 Tfh	 cells	
expressing	 IL-4	 (Fig	 6.1D-E).	 In	 keeping	with	 published	 data,	 a	 small	 but	 significant	


















6.3.2 Dendritic cells exposed to allergenic material specifically express the IFN-I regulated 
molecule, CD317 
RNA-sequencing	 experiments	 performed	 on	 DC2	 subsets	 (CD11b+	 and	 TN	 dDC)	
following	immunisation	with	Nb	or	PBS	treatment	revealed	an	IFN-I	response	signature	
(229).	Bst2	is	specifically	up-regulated	in	cells	responding	to	IFN-I	rather	than	IFN-II	or	
IFN-III	 (581).	 	 At	 the	 transcript	 level,	 Bst2	 was	 up-regulated	 following	Nb,	 reaching	
statistical	significance	in	the	Nb+	populations	(Lisa	Connor,	unpublished	observations).	
This	result	was	validated	by	flow	cytometric	analysis	which	showed	the	CD317	(BST2)	











Figure	6.2:	DC2	 express	 up-regulate	 CD317	 following	 exposure	 to	Nb	 or	HDM.	MFI	of	CD317	(BST2)	on	the	
surface	of	DC2	two	days	after	injection	of	Nb,	HDM,	Ms,	Ca	or	PBS.	CD317	MFI	is	shown	for	Ag+	DC2	from	Nb,	Ms	and	
Ca-treated	 mice.	 CD317	 MFI	 is	 shown	 for	 total	 DC2	 from	 PBS	 and	 HDM-treated	 mice.	 Bar	 graph	 shows	 the	
mean±SEM.	 Data	 is	 compiled	 from	 two	 independent	 experiments,	 with	 a	 minimum	 total	 of	 six	 mice	 per	 group.	
Statistical	 significance	 was	 assessed	 using	 a	 One-Way	 ANOVA	 with	 Holm-Sidak’s	 post-test.	 Asterisks	 denote	
significance	as	compared	to	PBS	control.	NS=not	significant,	**p<0.01,	****p<0.0001		
	
6.3.3 IFNAR blockade significantly impairs CD4+ T cell responses to helminths and 
allergens 
The	marked	up-regulation	of	IFN-I	associated	genes	in	DC	following	exposure	to	Th2-
inducing	 stimuli	 warranted	 an	 investigation	 into	 the	 role	 of	 IFN-I	 signalling	 in	 Th2	
polarisation.	 All	 IFN-I	 species	 signal	 through	 a	 single	 receptor,	 IFNAR,	 which	 is	
ubiquitously	 expressed	 (854-856).	 Administration	 of	 a	 blocking	monoclonal	 antibody	
against	 IFNAR	at	 the	time	of	 immunisation	and	two	days	 later	was	sufficient	 to	block	
signalling	 through	 IFNAR	 as	 shown	 by	 the	 lack	 of	 CD317	 up-regulation	 (229,	 815).	
Using	 this	 experimental	 protocol,	 the	 immune	 responses	 to	 multiple	 allergens	 were	
assessed	(Fig	6.3A).	The	administration	of	anti-IFNAR	resulted	in	a	marked	reduction	in	
the	 number	 of	 IL-4+	 CD4+	 T	 cells	 following	 immunisation	 with	 Nb,	 non-viable	 H.	
polygyrus	 larvae	or	HDM.	Cat	dander	elicited	a	much	smaller	response	than	the	other	
















also	 assessed.	 The	 number	 and	 frequency	 of	 IL-17A+	 CD4+	 T	 cells	 was	 comparable	
between	 anti-IFNAR	 and	 isotype	 treated	 groups	 following	 immunisation	 with	 Ca.	






Figure	 6.3:	 IFNAR	 signalling	 amplifies	 CD4+	 T	 cell	 responses	 to	 allergens.	 (A)	 Schematic	 of	 experimental	
protocol.	 (B)	The	number	of	 IL-4+	CD4+	T	cells	 in	the	presence	of	 anti-IFNAR	antibody	 (grey)	or	 isotype	 control	
(black)	following	i.d.	immunisation	with	Nb,	H.	polygyrus	(Hp),	HDM,	cat	dander	or	PBS	treatment.	(C)	Representative	
flow	cytometry	plots	depicting	Th2	and	Tfh	cells	following	Nb	immunisation	in	the	presence	of	anti-IFNAR	antibody	
or	 isotype	 control.	 (D-E)	 The	 number	 and	 frequency	 of	 IL-4+,	 Tfh,	 IFNγ+	 CD4+	 T	 cells	 seven	 days	 after	 Nb	
immunisation.	 	 (F)	 The	 number	 of	 IL-4+,	Tfh,	 IFNγ+	 CD4+	T	 cells	 seven	 days	after	HDM	 immunisation.	 	 (G)	The	
number	of	IL-17A+	and	IFNγ+	CD4+	T	cells	seven	days	after	Ca,	Ms	or	DNFB	treatment	respectively.	Bar	graphs	show	
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the	mean±SEM.	Data	presented	 is	compiled	from	at	 least	two	 independent	experiments,	with	a	minimum	 total	of	
eight	mice	per	group.	 Statistical	 significance	was	assessed	using	a	Student’s	 t-test,	 comparing	 the	 isotype	 control	
group	to	the	αIFNAR-treatment	group.	*p<0.05,	**p<0.01,	***p<0.001	****p<0.0001	
	
6.3.4 IFNAR signalling in CD11c-expressing cells is required for optimal CD4+ T cell 
responses to Nb 
The	strong	IFN-I	genetic	signature	detected	in	DC	from	Nb-treated	mice	suggested	that	
APC	 may	 be	 the	 target	 of	 IFN-I	 in	 vivo.	 To	 test	 this	 hypothesis,	 Ifnarfl/fl	mice	 were	
crossed	 with	 an	 Itgax-cre	 strain.	Mice	 that	 expressed	 cre-recombinase	 (IFNAR∆CD11c)	
had	significantly	reduced	expression	of	IFNAR	in	their	CD11c	compartment	and	failed	




littermates	 following	Nb	 injection.	Similar	 to	results	obtained	with	the	administration	
of	anti-IFNAR,	the	total	LN	cellularity	was	significantly	reduced	in	the	absence	of	IFNAR	
signalling	 in	 DC	 (Fig	 6.4A).	 	 In	 line	 with	 this	 result,	 the	 number	 of	 IL-4+,	 GATA-3+,	
IFNγ+	 and	 Tfh	 cells	 were	 also	 significantly	 reduced	 (Fig	 6.4B-E).	 In	 contrast	 to	 the	
results	 from	anti-IFNAR	experiments,	 the	 frequency	of	 IL-4+,	 IFNγ+	and	Tfh	cells	was	
similar	between	IFNARWT	and	IFNARΔCD11c	mice	(Fig	6.4B/D-E).	The	frequency	of	GATA-
3+	CD4+	T	 cells	was	 reduced	 in	 the	absence	of	 IFNAR	signalling	 in	DC,	however	 (Fig	


















6.3.5 IFNAR signalling in CD11c-expressing cells is required for optimal B cell responses to 
Nb 
An	 important	 role	 of	 CD4+	 T	 cells	 is	 to	 provide	 support	 to	 B	 cells,	 and	 promote	
germinal	 centre	 formation,	 class-switching	 and	 antibody	 production	 (311,	 867).	 Tfh	
cells,	a	subset	of	CD4+	T	cells,	are	key	to	these	processes	(315,	389,	390).	Following	Nb-
immunisation,	 Tfh	 accumulate	 (Fig	 6.1D)	 and	B	 cell	maturation	 can	 be	measured	 by	
flow	 cytometry	 (Fig	 6.5A).	 To	 allow	 sufficient	 time	 for	 the	 generation	 of	 B	 cell	
responses,	LNs	were	harvested	at	day	14	after	Nb	 injection.	The	number	of	 germinal	
centre	B	cells	and	B	cells	expressing	the	type-2	associated	antibody	isotype,	IgG1,	were	
significantly	 increased	 following	 Nb	 (Fig	 6.5B).	 Furthermore,	 the	 number	 of	
plasmablasts,	 a	precursor	 to	antibody	producing	plasma	cells,	were	also	 increased	at	








and	 antibody	 responses	 generated	 following	 immunisation.	 To	 test	 this,	 B	 cell	
responses	 were	 assessed	 14	 days	 post	 Nb	 immunisation	 in	 IFNARΔCD11c	 mice	 and	
compared	to	littermate	controls.	The	number	of	total	germinal	centre	B	cells	and	IgG1-
class-switched	B	 cells	was	 significantly	 reduced;	 however,	 the	 frequency	was	 similar	
between	 the	 two	 groups	 (Fig	 6.5C-D).	 Interestingly,	 the	 number	 and	 frequency	 of	
plasmablasts	was	 significantly	 reduced	 in	 the	 absence	 of	 IFNAR	 signalling	 in	DC	 (Fig	
6.5C-D).		
	
Together,	 these	data	provide	evidence	that	 IFNAR	signalling	 in	DC	 is	required	 for	 the	
















6.3.6 TSLPR signalling, but not IL-33 or IL-25 signalling, enhances Th2 polarisation to 
allergens 
It	 was	 of	 interest	 to	 assess	 the	 contribution	 of	 TSLP,	 IL-33	 and	 IL-25	 to	 the	





CD4+	 T	 cell	 response	 following	Nb	 in	 TSLPR-KO	mice	 revealed	 intact	 IFNγ	 and	 Tfh	
responses	suggesting	 that	TSLPR	signalling	was	primarily	 involved	 in	promoting	 IL-4	
expression	by	CD4+	T	cells	(Fig	6.6A-B).	Furthermore,	the	number	and	frequency	of	IL-
4+	 CD4+	 T	 cells	was	 reduced	 following	 HDM	 immunisation	 in	 the	 absence	 of	 TSLPR	




25-KO)	 signalling.	 It	 should	be	noted	 that	 IL-25-KO	mice	have	been	 reported	 to	have	
marked	 differences	 in	 the	 composition	 of	 their	 microbiota	 when	 housed	 separately	
from	 control	 mice	 (Catherine	 Plunkett	 and	 Elizabeth	 Forbes-Blom,	 unpublished	
observations).	 To	 address	 this	 potential	 confounding	 factor,	 breeding	 pairs	 were	
maintained	 as	 heterozygotes	 and	 littermates	 with	 a	 +/+	 (IL-25-WT)	 genotype	 were	
used	as	controls.	Following	Nb	immunisation,	no	significant	differences	were	observed	









PMA/ionomycin	 re-stimulation	was	 used	 to	 induce	 cytokine	expression.	 (A)	Representative	 flow	cytometry	 plots	
showing	the	frequency	of	Th2	and	Tfh	cells	in	TSLPR-KO	mice	and	WT	controls.	(B)	The	number	of	IL-4+,	Tfh	and	
IFNγ+	CD4+	T	cells	was	enumerated	and	compared	between	TSLPR-KO	mice	and	WT	controls.	(C)	TSLPR-KO	mice	
and	C57BL/6	were	 immunised	with	HDM.	On	day	 seven,	 the	number	of	 IL-4+	CD4+	T	 cells	was	enumerated	and	
compared	between	mouse	strains.	(D)	The	number	of	IL-4+	CD4+	T	cells	was	enumerated	and	compared	between	
C57BL/6	mice	treated	with	anti-IL-33	blocking	antibody	or	the	isotype	control.	(E)	The	number	of	IL-4+	CD4+	T	cells	







6.3.7 TSLPR signalling in CD4+ T cells is not required for IL-4 production in response to Nb 
Like	IFN-I,	TSLP	can	exert	its	effects	on	multiple	cell	types,	including	DC	(112,	114,	868)	
and	CD4+	T	 cells	 (118,	120,	121).	Being	a	 tissue-associated	 cytokine,	LN	CD4+	T	 cells	
are	unlikely	to	be	the	direct	target	of	TSLP	following	Nb	 immunisation.	To	investigate	
this	 possibility,	 competitive	 adoptive	 transfer	 experiments	 were	 performed,	 where	
CD4+	 T	 cells	 from	 TSLPR-KO	 and	 TSLPR-sufficient	 backgrounds	 were	 adoptively	
transferred	at	a	1:1	ratio	into	TSLPR-sufficient	recipients	(Fig	6.7A-B).	The	transferred	
cells	 also	 had	 the	 capacity	 to	 report	 IL-4	 transcription	 through	 expression	 of	 the	
fluorescent	protein	AmCyan	and	carried	different	CD45	alleles	for	easy	identification	by	




to	 the	population	IL-4	AmCyan+	cells	(Fig	6.8C-D),	 indicating	that	TSLPR	signalling	 in	
CD4+	T	cells	is	not	required	for	efficient	production	of	IL-4	in	this	model.	
	
This	 result	 suggested	 that	TSLP	was	 required	to	act	on	non-CD4+	T	 cells	 to	promote	
Th2	 differentiation.	 To	 test	 this,	 TSLPR-sufficient	 CD4+	 T	 cells	 were	 adoptively	
transferred	 into	either	TSLPR-KO	or	TSLPR-sufficient	 recipients	and	 immunised	with	
Nb	 one	 day	 later	 (Fig	 6.7E).	 Surprisingly,	 the	 number	 of	 transferred	 CD4+	 T	 cells	
expressing	 IL-4	 was	 similar	 regardless	 of	 whether	 they	 were	 primed	 in	 a	 TSLPR-
sufficient	 or	 -deficient	 environment.	 Likewise,	 the	 number	 of	 IFNγ+	 transferred	 cells	
was	 similar	 between	 recipient	 phenotypes	 (Fig	 6.7F).	This	observation	 indicates	 that	

















treated	mice.	 (E)	 Schematic	 of	 experimental	 protocol.	 Enriched	 CD4+	T	 cells	 from	B6-SJ	mice	were	 injected	 into	
C57BL/6	 or	 TSLPR-KO	 recipients.	 Mice	 were	 immunized	 with	 Nb	 one	 day	 after	 transfer,	 and	 the	 CD4+	 T	 cell	
response	was	assessed	 on	 day	 seven.	 (F)	The	 number	 of	 transferred	 CD4+	T	 cells	 expressing	 IL-4	 or	 IFNγ	 from	
TSLPR-KO	 and	 C57BL/6	 recipients.	 Bar	 graphs	 show	 the	 mean±SEM.	 Data	 presented	 is	 collated	 from	 two	
independent	experiments,	with	a	total	of	 twelve	mice	per	group.	Statistical	significance	was	assessed	using	a	One-




6.3.8 IFNAR and TSLPR signalling act independently to promote optimal CD4+ T cell 









C57BL/6	 mice,	 regardless	 of	 anti-IFNAR	 treatment	 (Fig	 6.8B).	 Thus,	 these	 results	
provide	 evidence	 that	 IFN-I	 and	 TSLP	 are	 two	 independent	 signals	 that	 function	





TSLPR-KO	 mice	 were	 immunised	 with	 Nb	 and	 treated	 with	 anti-IFNAR	 or	 the	 isotype	 control	 at	 the	 time	 of	
immunisation	 and	 two	 days	 later.	 CD4+	 T	 cell	 responses	 were	 assessed	 by	 flow	 cytometry	 on	 day	 seven.	
PMA/ionomycin	re-stimulation	was	used	to	induce	cytokine	expression.	(A)	The	number	of	IL-4+	CD4+	T	cells.	(B)	






6.3.9 IFN-I and TSLP genetic signatures are enriched in lesional skin from atopic dermatitis 
patients 
The	 identification	of	 IFN-I	and	TSLP	as	mediators	of	CD4+	T	cell	responses	to	Nb	has	
potential	 translational	applications	 in	 the	management	of	atopic	disease.	Thus,	 it	was	
imperative	to	assess	how	relevant	these	findings	were	to	atopic	disease	in	humans.	To	
address	 this,	 Evelyn	 Hyde	 assessed	 the	 translational	 relevance	 of	 IFN-I	 and	 TSLP	
pathways	using	gene	set	enrichment	analysis	(GSEA),	which	uses	pairwise	comparisons	
to	determine	the	statistical	concordance	of	a	defined	set	of	genes	to	a	test	data	set	(753,	













AD	 lesions	 compared	 to	 non-lesional	 skin.	 Further,	 these	 gene	 sets	 were	 not	




When	AD	data	 sets	were	 probed	with	 gene	 sets	 comprised	 of	 genes	 significantly	 up-
regulated	 (FC>1.5	and	p<0.01)	by	DC2	subsets	 (denoted	as	Nb	 CD11b	UP	and	Nb	TN	
UP)	 following	 Nb	 immunisation,	 an	 enrichment	 pattern	 similar	 to	 IFN-I	 and	 TSLP	
pathways	was	observed	(Fig	6.9B).	These	results	demonstrate	that	genes	up-regulated	




Finally,	 the	 disease	 specificity	 of	 Nb-conditioned	 DC	 gene	 sets	 was	 assessed.	 Other	
inflammatory	 skin	 conditions	 also	 involve	 DC	 but	 have	 very	 different	 associated	
cytokine	 profiles	 (355).	 Psoriasis	 vulgaris	 (PV)	 is	 a	 skin	 condition	 that	 presents	with	
similar	clinical	 features	to	AD	but	 is	associated	with	a	Th17	phenotype	(869).	Using	a	
comparative	 set	of	PV	 studies,	 a	 group	of	14	 “AD-skewed”	 common	Core	Enrichment	



































The	 signals	 involved	 in	 the	 initiation	 of	 Th2	 differentiation	 have	 been	 a	 topic	 of	
intensive	 study	 and	 debate.	 The	 data	 presented	 in	 this	 chapter	 suggests	 that	 DC	
conditioning	by	innate	cytokines	is	a	key	factor	in	the	regulation	of	Th2	responses.	IFN-
I	 and	 TSLP	 were	 found	 to	 regulate	 the	 magnitude	 and	 polarisation	 of	 CD4+	 T	 cells,	
respectively,	 indicating	 that	 the	 co-ordinated	 actions	 of	 multiple	 signals	 may	 be	
involved	in	promoting	optimal	CD4+	T	cell	responses	to	allergens.	
	
6.4.1 IFN-I and Th2 immunity 
IFN-I	 is	 a	 newcomer	 to	 the	 field	 of	 Th2	 immunity,	 and	 thus	 does	 not	 feature	
prominently	 in	 the	 literature.	 The	 data	 presented	 in	 this	 chapter	 clearly	 describe	 an	
association	of	 IFN-I	with	Th2	 immunity.	While	 IFN-I	does	not	appear	to	play	a	role	 in	
the	 polarisation	 of	 CD4+	 T	 cell	 responses,	 it	 does	 provide	 an	 amplification	 signal,	
boosting	 the	 expansion	 and	differentiation	 of	 all	 T	 helper	phenotypes.	This	 can	 have	




Firstly,	 the	 initial	 source	and	specific	 species	of	 IFN-I	 involved	 in	Th2	contexts	 is	not	
understood.	 In	vitro	 studies	have	shown	up-regulation	of	 Ifnα3	and	 Ifnβ	transcripts	 in	
BMDC	stimulated	with	Th2	antigens,	SEA	and	HDM	(230).	However,	 IFN-I	 transcripts	
were	below	the	level	of	detection	in	Nb+	migratory	DCs	directly	ex	vivo,	suggesting	that	
DCs	 were	 responding	 to	 IFN-I	 production	 from	 another	 source	 in	 vivo.	 A	 prime	
candidate	 for	 the	 source	 of	 IFN-I	 are	 pDCs,	 which	 are	 well	 known	 for	 their	 rapid	
production	of	 IFN-I	 in	 viral	 contexts.	 But,	 specific	 depletion	 of	pDCs	 using	 a	 SiglecH-
DTR	mouse	model	failed	to	reveal	a	significant	role	for	pDCs	in	the	Th2	responses	to	Nb	
(815).	qPCR	 analysis	of	 ear	 tissue	 lysate	 showed	an	up-regulation	of	 all	 IFNα	species	
and	IFNβ	as	early	as	two	hours	after	Nb	injection	(815).	These	data	suggest	that	the	cell	
type/s	responsible	for	IFN-I	are	likely	fast	responders,	such	as	monocytes,	which	have	





Secondly,	 it	 is	 important	 to	understand	 the	mechanism/s	 by	which	 IFN-I	 impacts	DC	
function.	 The	 reduction	 in	 the	 total	 CD4+	 T	 cell	 response	 in	 the	 absence	 of	 IFNAR	
signalling	suggests	an	alteration	to	fundamental	DC	processes	such	as	antigen	uptake,	
maturation	 or	migration.	However,	 no	 significant	 changes	 in	 the	 expression	 of	 CD86,	
antigen	 uptake	 or	migration	 kinetics	 have	 been	 noted	 in	 the	 presence	 of	 anti-IFNAR	
(229).	 Similar	 results	 have	 been	 observed	 in	mice	 specifically	 lacking	 IFNAR	 in	 their	
CD11c	compartment	(Shiau-Choot	Tang,	Hilligan	et	al,	in	preparation;	Appendix	Fig	C-
VIII).	 These	 findings	 are	 in	 contrast	 to	 a	 study	 comparing	 DC	 from	 IRF3-KO	 and	
C57BL/6	 controls	 in	 a	 model	 of	 HDM-induced	 allergic	 airway	 inflammation.	 In	 that	
study,	 the	authors	report	 that	 IRF3-KO	mice	 failed	to	develop	the	cardinal	 features	of	
allergic	airway	inflammation,	and	implicate	this	phenotype	on	their	inability	to	respond	
efficiently	 to	 IFN-I.	 Further,	 IRF3-KO	 DC	 displayed	 significant	 abnormalities	 in	 their	
maturation	phenotype	(CD86,	CD40,	CD70	and	OX40L)	following	HDM	compared	to	WT	






Finally,	 the	 component	 of	 helminth	 and	 allergen	 preparations	 inducing	 IFN-I	
production	is	of	interest.	Experiments	performed	and	published	by	a	colleague	showed	





These	 data	 suggest	 that	 the	 presence	 of	 bacterial	 components	 can	 play	 a	 role	 in	
enhancing	Th2	responses.	This	is	of	interest	because	natural	exposure	to	helminths	and	
allergens	 is	 highly	 unlikely	 to	 be	 sterile.	 Helminths	 and	 mites	 have	 their	 own	
microbiota,	 and	 a	major	 part	 of	 a	helminth’s	 lifecycle	 occurs	 in	 environments	 rich	 in	
bacteria,	such	as	soils	and	the	intestines	and	faeces	of	hosts	(334,	335,	872).	In	addition,	
epithelial	 barrier	 impairment	 is	 strongly	 associated	 with	 the	 development	 of	 atopic	
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disease	in	humans	(873-876),	and	exposure	to	an	inert	protein	on	tape-stripped	skin	is	
known	 to	 induce	 Th2	 responses	 in	 mice	 (119).	 In	 this	 scenario,	 allergen	 encounter	
could	occur	in	parallel	with	commensal	bacteria	exposure,	and	potentiate	any	resulting	









as	a	driver	of	allergic	airway	 inflammation	 in	an	OVA	model	(868)	and	 in	a	high	dose	
house	dust	mite	model	(877).	However,	the	phenotype	of	CD4+	T	cells	was	not	directly	
assessed	 in	 these	 studies,	 making	 it	 difficult	 to	 determine	 whether	 reduced	 Th2	
priming	was	responsible	for	the	ameliorated	pathology	in	the	absence	of	TSLP.	A	more	
recent	 study	 has	 described	 a	 role	 for	 TSLP-activated	 human	 DC	 in	 promoting	 Tfh	
differentiation	 in	 vitro	 (482).	 The	 data	 in	 this	 chapter	 suggests	 that	while	 TSLP	may	
support	Tfh	differentiation,	it	is	not	required	for	Tfh	development	in	vivo.		
	
TSLP	has	multiple	 targets	 in	vivo,	 including	DC	 (113-115)	 and	CD4+	T	 cells	 (106,	118,	
121).	Competitive	adoptive	transfer	experiments	showed	that	TSLPR	signalling	in	CD4+	
T	 cells	was	 not	 required	 for	 production	 of	 IL-4.	 This	 finding	 is	 consistent	with	TSLP	
secretion	 by	 epidermal	 keratinocytes	 (878)	 preferentially	 affecting	 local	 immune	
populations	such	as	migDC	in	the	skin.	 Indeed,	qPCR	and	RNASeq	analysis	of	Nb	DC2	
showed	an	up-regulation	of	the	TSLP-induced	transcripts	Tnfsf4	(OX40L),	Ccl17,	Ccl22	
and	Cish	 (Fig	4.12)	 (229),	 suggesting	that	DC2	were	exposed	 to	TSLP	 in	vivo	 after	Nb	
immunisation.	 The	 role	 of	 these	 TSLP-induced	 molecules	 in	 promoting	 Th2	
differentiation	 has	 been	 assessed	 previously.	 Most	 notably,	 the	 interaction	 between	
OX40L	on	DC	and	OX40	on	CD4+	T	cells	 is	reported	to	support	Th2	differentiation	 in	
vitro	 and	 in	 vivo	 (114,	 115,	 397,	 399-401,	 482,	 825,	 826).	 CCL17	 and	 CCL22	 are	
correlated	with	disease	severity	 in	 infants	with	AD	(186),	and	have	been	 identified	as	
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molecules	 of	 interest	 in	many	 other	 Th2	 contexts	 (112,	 113,	 185,	 187,	 194-196,	 857,	
879).	 CCL17	 and	 CCL22	 are	 chemoattractants	 that	 signal	 through	 CCR4,	 a	 receptor	
found	 on	 the	 surface	 of	 Th2	 cells	 (880).	 Their	 role	 in	 promoting	 the	 recruitment	 of	
primed	Th2	cells	is	well	established;	however,	it	is	not	clear	whether	CCL17	and	CCL22	
directly	 support	 Th2	differentiation,	 as	 CCR4	 is	 not	 expressed	 by	 naïve	 CD4+	T	 cells	
(Johannes	Mayer,	unpublished	data)	 (189).	Given	 these	examples	of	TSLP	specifically	
expressing	 Th2	 instructive	 signals	 in	 DC,	 it	 would	 be	 of	 great	 interest	 to	 perform	 a	
detailed	 comparison	 of	WT	 and	 TSLPR-KO	 DC	 to	 isolate	 additional	 potential	 signals	
required	by	DC2	to	promote	Th2	differentiation.	
	
The	 roles	 of	 IL-25	 and	 IL-33	 in	 supporting	 Th2	 differentiation	 in	 the	 LN	 were	 also	
addressed	in	this	chapter.	No	significant	differences	in	the	number	of	IL-4+	CD4+	T	cells	
were	 observed	when	 either	of	 these	 factors	were	 absent.	 The	 IL-25	 finding	 is	 in	 line	
with	 a	 previous	 study	 that	 reported	 IL-25	 deficiency	 had	 no	 effect	 on	 IL-4-eGFP	
expression	 in	 CD4+	T	 cells	 following	 immunisation	with	Nb	or	HDM	 (337).	 IL-33	 has	
been	 shown	 to	 specifically	 support	 IL-13	production,	 rather	 than	 IL-4	production,	by	
ILC2	and	activated	Th2	cell	populations	(140,	142,	881).	These	reports	support	a	role	
for	 IL-33	 as	 an	 effector	 Th2	 differentiation	 signal,	 which	 is	 more	 applicable	 in	 the	
context	of	tissue	immunity	or	immunological	challenge.	Assessment	of	CD4+	T	cells	in	
the	 skin	 following	 i.d.	 challenge	 with	Nb	 may	 uncover	 a	 role	 for	 IL-25	 and	 IL-33	 in	
promoting	IL-5/IL-13	expression	by	CD4+	T	cells.	
	
6.4.3 Integration of instructive signals in Th2 contexts 
One	 of	 the	 key	 findings	 exemplified	 by	 the	 data	 presented	 in	 this	 chapter	 is	 that	
multiple	signals	can	have	divergent	yet	complementary	roles	in	the	regulation	of	CD4+	
T	cell	responses	to	allergens.	IFN-I	acts	on	DC	to	boost	CD4+	T	cell	and	B	cell	responses,	
whereas	 TSLP	 acts	 on	 non-CD4+	 T	 cells	 to	 specifically	 promote	 Th2	 differentiation,	
potentially	via	OX40L	or	CCL17	expression	by	DC2	(Fig	6.10).	Importantly,	blockade	of	
IFNAR	signalling	in	TSLPR-KO	mice	further	reduced	the	IL-4+	CD4+	T	cell	population,	
indicating	 that	 these	 pathways	were	 independent,	 but	 complemented	 one	 another	 to	
support	Th2	responses	 in	WT	mice.	Previous	work	 in	our	laboratory	showed	that	 the	
IFN-I	 response	 was	 dependent	 on	 TLR4	 signalling	 (815),	 suggesting	 that	 bacterial	
	 227	





this	 chapter	 and	 published	 studies,	 Th2	 responses	 to	 Nb,	 HDM	 and	 S.	 mansoni	 are	
sensitive	 to	 IFNAR	 blockade	 (230)	 but	 the	 Th2	 response	 generated	 following	
application	 of	 dibutyl	 phthalate	 with	 fluorescein	 isothiocyanate	 (DBP:FITC)	 was	
unchanged	in	the	presence	of	anti-IFNAR	(229).	This	is	in	line	with	our	observation	that	
DC	 isolated	 from	 the	 LN	 of	 DBP:FITC-treated	 mice	 did	 not	 express	 an	 IFN-I	
transcriptomic	 signature	 (229).	 It	 is	 well	 documented	 that	 the	 DBP	 molecule	 itself	
induces	TSLP	expression	and	TSLPR	signalling	is	essential	for	the	development	of	Th2	
responses	 following	DBP:FITC	application	(98).	Therefore,	 it	appears	that	 the	relative	
contributions	 of	 IFN-I	 and	 TSLP	 to	 Th2	 responses	 are	 context-specific,	 with	 TSLP	
expression	 being	 a	major	 determinant	 of	 Th2	 induction.	 If	 sufficient	 TSLP	 levels	 are	













6.4.4 IFN-I and TSLP in atopic disease 
The	 primary	 aim	 behind	 this	 research	 is	 to	 uncover	 pathways/targets	 that	 have	
potential	to	positively	impact	human	health.	Therefore,	it	is	important	to	test	whether	











with	AD	 that	were	also	up-regulated	 in	Nb-conditioned	DC.	 In	addition	 to	CCL17,	AD-
enriched	 genes	 included	 CISH,	 a	 well-known	 TSLP	 regulated	 gene	 (110),	 CLEC10A,	
SERPINE1,	 TCIRG1	 and	 LY6D.	 CLEC10A	 is	 a	 characteristic	 marker	 of	 alternatively-
activated	macrophages	elicited	 in	 response	 to	parasites	and	allergens	 (185,	883),	 and	
requires	 IL-4R	 signaling	 for	 its	 expression	 (884).	 	 Further,	 CLEC10A,	 and	 its	murine	
counterparts	Mgl1	and	Mgl2	 (CD301b),	are	expressed	by	DC2	(885)	 that	are	required	
for	the	induction	of	Th2	immune	responses	(559,	563).	In	addition,	a	proteomic	study	
identified	 LY6D	 and	 another	 common	CEG,	 CAPG	 to	 be	 up-regulated	 in	FLG	 deficient	
skin,	 thus	associating	these	molecules	with	atopic	skin	(886).	The	 function	of	LY6D	in	
DC	 has	 not	 been	 well	 characterized;	 however,	 as	 an	 actin	 filament	 capping	 protein,	
CAPG	 supports	 the	motility	 of	 BMDC	 and	macrophages	 (887).	 SERPINE1	 and	TCIRG1	
encode	 plasminogen-activator	 inhibitor-1	 and	 a	 V-type	 proton	 ATPase	 respectively.	
The	 roles	 of	 these	 genes	 and	 their	 associated	 proteins	 in	 DC	 and	 AD	 have	 yet	 to	 be	
characterised	but	may	be	of	interest	for	future	studies.		
	
Together,	 these	observations	strongly	associate	 IFN-I	and	TSLP	with	atopic	disease	 in	
humans.	The	AD-specific	gene	set	shown	in	this	chapter,	while	limited,	provides	insight	






or	 allergen	 exposure.	 IFN-I	 and	 TSLP	 independently	 support	 CD4+	 T	 cell	 responses	
following	Nb	 or	 HDM	 immunisation.	 IFN-I	 acts	 primarily	 as	 an	 amplification	 signal,	
whereas	TSLP	provides	a	polarising	signal,	promoting	IL-4	production	by	CD4+	T	cells.	
Importantly,	 these	 signalling	 signatures	 are	 not	 restricted	 to	 the	 mouse,	 and	 were	
clearly	 evident	 in	 tissue	 samples	 from	 atopic	 dermatitis	 patients.	 Overall,	 these	 data	














7.1 The main findings of this thesis 
This	 thesis	 set	 out	 to	 determine	 the	 roles	 of	 innate	 immune	 cell	 populations	 and	
cytokines	in	the	regulation	of	CD4+	T	cell	differentiation	following	exposure	to	different	
types	of	immunogens.	An	intradermal	immunisation	model	allowed	for	the	side-by-side	
assessment	 of	 CD4+	 T	 cell	 responses,	 innate	 immune	 cell	 responses	 and	 antigen-




IFNγ+	 and	 IL-4+	Th	 cells	were	 predominant	 in	 the	 LNs	of	Ms-	 and	Nb-treated	
mice,	 respectively.	Ca	 immunisation	resulted	 in	a	mixed	CD4+	T	 cell	 response,	
which	 included	 a	 population	 of	 IL-17A+	 Th	 cells.	 Tfh	 cells	 were	 abundant	
following	immunisation	with	Ms,	Nb	or	Ca.	
• Ms,	 Nb	 and	 Ca	 were	 associated	 with	 distinct	 patterns	 of	 innate	 immune	 cell	




specific	 transcriptional	profiles.	 In	particular,	monocytes	 from	Ms-treated	mice	
highly	expressed	genes	associated	with	IFNγ	signalling.	












• LC	 and	 DC1	 did	 not	 alter	 their	 activation	 status	 or	 transcriptional	 profile	








7.2 Delineating the factors that regulate CD4+ T cell differentiation 
7.2.1 Lineage-defined APC function 
The	 skin	 and	 associated	 LNs	 contain	 many	 distinct	 DC	 lineages	 which	 have	 been	
proposed	to	specialise	 in	 initiating	particular	CD4+	T	cell	differentiation	programmes	
(461).	Data	presented	 in	Chapter	4	refutes	 this	hypothesis,	with	migDC2	shown	to	be	
necessary	 and	 sufficient	 for	 the	 promotion	 of	 optimal	 Th1,	 Th2,	 Th17	 and	 Tfh	
responses	following	i.d.	immunisation	with	Ms,	Nb	or	Ca	(Figs	4.5-4.11).	Further,	while	




from	 Ms,	 Nb	 and	 Ca	 (Fig	 4.3).	 Additionally,	 polarising	 molecules	 were	 similarly	
expressed	between	CD11b+	DC2	and	TN	DC2	from	immunised	mice	(Appendix	Fig	D-I).	
	
The	 requirement	 for	 migDC2	 in	 promoting	 CD4+	 T	 cell	 responses	 was	 determined	
using	 established	 cre-flox	 mouse	 models	 where	 IRF4	 (563)	 or	 KLF4	 (557)	 was	
specifically	 deleted	 from	 CD11c+	 cells.	 The	 CD4+	 T	 cell	 responses	 to	Ms	 or	Nb	 were	
reduced	in	both	IRF4∆CD11c	and	KLF4∆CD11c	mice,	indicating	that	the	migDC2	involved	in	
promoting	 CD4+	 T	 cell	 responses	 to	Ms	 or	Nb	 were	 dependent	 on	 IRF4	 and	 KLF4.	
Notably,	there	was	a	difference	in	the	induction	of	Th17	cells	to	Ca	between	IRF4∆CD11c	
and	KLF4∆CD11c	mice,	with	 the	Th17	 response	 only	 impacted	 by	 IRF4	 deficiency.	 This	
implies	 that	 there	 may	 be	 a	 specialised	 subset	 of	 KLF4-independent	 DC2	 that	
specifically	 promotes	 Th17	 differentiation.	 However,	 it	 is	 important	 to	 note	 that	 a	
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limitation	 of	 the	 Itgax-cre	mouse	models	 is	 that	 IRF4	 or	 KLF4	will	 be	 deleted	 in	 all	
retained	 DC	 subsets.	 Therefore,	 it	 is	 difficult	 to	 determine	 whether	 the	 phenotype	
observed	is	due	to	loss	of	the	transcription	factor	in	retained	DC	or	the	loss	of	the	DC	
population/s	 dependent	 on	 that	 transcription	 factor.	 DTR	 mouse	 models	 that	
specifically	target	DC2	may	assist	in	resolving	the	functional	requirements	of	DC2	from	
the	 functional	 requirements	 of	 particular	 transcription	 factors.	 Also,	 high	 resolution	




Tracking	 of	 Ag+	 cells	 by	 fluorescent	 labelling	 showed	 that	 DC2	 were	 required	 for	
transporting	 antigen	 from	 the	 skin	 to	 the	 LN	 (Fig	 4.11).	 It	 is	 not	 clear	 from	 data	
presented	in	this	thesis,	or	from	published	data,	whether	migDC2	are	directly	involved	




minimal	 changes	 in	 their	 expression	 of	 co-stimulatory	molecules	 after	 immunisation	
and	a	very	low	numbers	of	Ag+	cells	(Fig	4.1).	These	data	suggest	that	migDC2,	which	
highly	 express	 co-stimulatory	 and	 polarising	molecules,	 were	 involved	 in	 presenting	
antigen	 to	CD4+	T	 cells	 as	well	 as	antigen	 transport.	However,	 additional	 studies	are	
needed	 to	 validate	 this	 conclusion.	 A	 newly	 described	 technology	 that	 enables	 the	
tracking	 of	 cellular	 interactions	 in	 vivo	 may	 provide	 insight	 into	 which	 DC	 subsets	
directly	interact	with	CD4+	T	cells	and	instruct	their	differentiation	(889).	Alternatively,	






that	respond	accordingly	to	local	 insults.	 Indeed,	LC	are	the	only	DC	subset	located	 in	
the	 epidermis	 and	 are	 required	 for	 immune	 responses	 to	 some	 topically	 applied	
antigens	 (525,	 526)	 and	 pathogens	 (331,	 339,	 831).	 Likewise,	 resDC	 are	 involved	 in	
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promoting	 immune	 responses	 to	 lymph-borne	 antigen	 (572,	 573).	 Within	 tissue	
compartments,	such	as	the	dermis	and	LN,	DC1	and	DC2	subsets	may	exist	to	specialise	
in	 driving	 CD8+	 and	 CD4+	 T	 cell	 responses,	 respectively.	 The	 cross-presentation	
capacity	 of	 DC1	 has	 been	well-characterised	 (64,	535,	540)	 and	 the	 ability	 of	 DC2	 to	
drive	 CD4+	 T	 cell	 responses	 has	 been	 described	 here	 (Chapter	 4)	 and	 in	 published	
studies	(434,	476,	557,	559,	561,	563-568).	DC1	have	been	previously	attributed	with	a	
non-redundant	 role	 in	 driving	 Th1	 differentiation	 (331,	 551-553),	 which	 was	 not	




and	 cell-associated	 antigen,	 whereas	 DC2	 specialise	 in	 responding	 to	 extracellular	
pathogens	(Fig	7.1).	Overall,	this	thesis	demonstrates	that	distinct	DC	lineages	are	not	
necessary	for	promoting	particular	CD4+	T	cell	differentiation	programmes,	suggesting	







Figure	 7.1:	 Model	 outlining	 the	 lineage-defined	 roles	 of	 skin-associated	 DC	 subsets.	Tissue	 compartments	





7.2.2 Context-specific conditioning of APC function 
Antigen-carrying	 migDC2	 and	 monocytes	 were	 found	 to	 express	 condition-specific	
transcriptional	 profiles,	 which	 included	 molecules	 that	 are	 known	 to	 influence	 the	
polarisation	of	CD4+	T	cells	(Figs	4.12	and	5.5).	This	finding	indicates	that	antigenic	or	
environmental	 cues	 may	 play	 a	 significant	 role	 in	 determining	 the	 differentiation	 of	
CD4+	T	cells	by	modulating	APC	expression	of	polarising	molecules.	Indeed,	IFN-I	and	
TSLP	were	 identified	as	upstream	regulators	of	Nb-specific	 gene	modules	 in	DC2	and	
were	 subsequently	 found	 to	 influence	 the	 CD4+	 T	 cell	 response	 following	 Nb	
immunisation	 (Chapter	6)	 (229).	 Further,	 an	 IFNγ	 response	module	was	 identified	 in	
DC2	and	monocytes	 from	Ms-treated	mice	 (Figs	4.12	and	5.5).	Neutralising	 IFNγ	and	
depleting	 NK	 cells,	 which	 are	 an	 early	 source	 of	 IFNγ,	 blocked	 expression	 of	 this	
module,	restricted	monocyte	recruitment	and	prevented	optimal	 induction	of	effector	
Th1	 responses	 (Figs	 5.11	 and	 5.12).	 Thus,	 these	 data	 provide	 evidence	 that	 context-







surrounding	 cells	 have	 the	 capacity	 to	 influence	 APC	 phenotype	 and	 function.	 The	
enrichment	of	condition-specific	transcriptional	modules	within	Ag+	APC	indicated	that	
signals	 associated	 with	 antigen	 encounter	 may	 be	 particularly	 influential	 over	 APC	
function.	 However,	 the	 upstream	 regulators	 of	 Ag+	 APC	 transcriptional	 modules	
identified	 in	 this	 study	 (IFN-I,	 TSLP	 and	 IFNγ)	 were	 not	 expressed	 by	 the	 APC	
themselves.	The	 source	of	 IFN-I	 after	Nb	 injection	 is	 still	unclear	but	 transcripts	 that	
encode	 for	 IFN-I	species	were	below	the	 level	of	detection	 in	Nb+	DC2	(229).	TSLP	 is	
known	to	be	derived	from	keratinocytes	in	vivo	(94)	and	IFNγ+	cells	were	identified	as	
NK	cells	and	CD4+	T	cells	 in	Ms-treated	mice	(Fig	5.10).	Thus,	 these	data	suggest	 that	





a	 proportion	 of	 the	 conditioning	 signals	were	 derived	 from	 surrounding	 cells,	which	
would	presumably	have	a	broader	 impact	on	the	 local	 immune	cells.	Potentially,	PRR	
signalling	or	other	interactions	with	antigen	augment	APC	responses	to	environmental	
cues.	Indeed,	a	published	study	has	found	that	co-injection	of	TLR	ligands	and	IFNγ	was	
superior	 at	 promoting	 DC	 activation	 in	 vivo	 compared	 to	 injection	 of	 single	 agents	
(890).	 CD4+	 T	 cell	 proliferation	 was	 also	 enhanced	 by	 treatment	 of	 bone	 marrow	
derived-DC	with	TLR	ligands	and	IFNγ	compared	to	single	agents	(890).	IFNγ	signalling	
has	 also	 been	 shown	 to	 support	 TLR2-induced	 inflammatory	 responses	 by	 inhibiting	
induction	of	regulatory	molecules,	such	as	IL-10	(891).	Alternatively,	the	co-localisation	
of	 Ag+	 APC	 and	 cytokine-producing	 cells	may	 explain	 the	 preferential	 expression	 of	
condition-specific	transcriptomic	modules	in	Ag+	APC	compared	to	Ag-	APC.	In	fact,	it	
was	 noted	 that	 Ms+	 DC	 specifically	 express	 chemokines	 associated	 with	 NK	 cell	
recruitment	 one	 day	 after	 immunisation	 (Blecher-Gonen	 et	al.,	 submitted).	 Together,	
these	 data	 indicate	 that	 the	 integration	 of	 antigenic	 and	 environmental	 signals	 is	
required	to	induce	optimal	APC	activation	and	CD4+	T	cell	responses.	
	
Given	 these	 findings,	 it	would	be	of	 interest	 to	determine	which	Ag+	APC	 transcripts	
were	 specifically	 up-regulated	 by	 antigenic	 signals	 rather	 than	 signals	 provided	 by	
surrounding	 cells.	 This	 would	 be	 particularly	 interesting	 for	Nb	 as	 no	 specific	 PRR	
ligands	 have	 been	 identified	 for	 helminths	 and	DAMPs	 released	 by	 surrounding	 cells	
have	been	proposed	to	be	the	main	trigger	for	anti-helminth	immune	responses	(768).	
A	phenotypic	and	functional	assessment	of	APC	exposed	to	antigen	in	vitro	compared	to	
APC	 exposed	 to	 antigen	 in	 vivo	 may	 provide	 insight	 into	 this	 question.	 Additionally,	
comparing	 DC	 from	 mouse	 strains	 that	 are	 unable	 to	 respond	 to	 many	 PRRs	
(Myd88/Trif-KO)	 to	 DC	 with	 sufficient	 PRR	 signalling	 may	 be	 useful.	 However,	 IL-1	
family	members,	 including	 IL-18	 and	 IL-33,	 also	 signal	 through	MyD88	 (892)	 and	 so	
experimental	results	will	need	to	be	interpreted	with	this	in	mind.		
	




such	 as	 keratinocytes	 and	 NK	 cells,	may	 be	 important	 for	 eliciting	 condition-specific	
transcriptional	modules	and	optimal	APC	function.		
	
7.2.3 Co-operation of APC populations in regulating CD4+ T cell responses 
Effector	Th1	responses	in	Ms-treated	mice	were	diminished	in	the	absence	of	migDC2	
or	monocyte-derived	cells,	indicating	that	both	of	these	APC	populations	were	required	
for	 promoting	 optimal	 Th1	 differentiation.	 Co-operation	 between	 DC	 and	monocyte-
derived	cells	has	been	previously	demonstrated	to	support	CD4+	T	cell	responses	(13,	
600,	 605,	 893).	 DC,	 which	 are	 superior	 at	 antigen	 presentation,	 were	 found	 to	 be	
required	 for	 inducing	 efficient	 CD4+	 T	 cell	 proliferation,	 whereas	 monocyte-derived	
cells	were	involved	in	directing	CD4+	T	cell	differentiation	(600).	The	respective	roles	
of	migDC2	and	monocyte-derived	cells	in	promoting	CD4+	T	cell	responses	to	Ms	were	
not	 clear	 from	 the	present	 study.	Both	populations	were	 involved	 in	 transporting	Ms	
antigen	to	the	LN;	however,	migDC2	appeared	to	play	a	greater	role	in	this	function.	In	
the	 absence	 of	monocyte-derived	 cells,	migDC2	were	 sufficient	 to	maintain	 the	 same	
overall	 number	 of	 Ms+	 in	 the	 LN,	 whereas	 IRF4ΔCD11c	 and	 KLF4ΔCD11c	 mice	 had	 a	
significant	 reduction	 in	 the	number	of	Ms+	cells	 in	 the	LN.	Despite	 the	differences	 in	






noted	 to	 be	 specifically	 important	 for	 inducing	 effector	 Th1	 differentiation	 while	
limiting	 Tfh	 differentiation	 (Fig	 5.1),	 whereas	 migDC2	 were	 involved	 in	 promoting	





T	 cell	 responses.	 Depletion	 of	 monocyte-derived	 cells	 using	 clodronate	 liposomes	
reduced	IFNγ	production	in	the	spleens	of	mice	infected	with	Salmonella;	however,	the	
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number	 of	 plasma	 cells	 and	 antibody	 production	 was	 maintained	 (893).	 These	 data	





cells	 into	 Th1	 supporting	 niches	within	 the	 LN	 through	 chemokine	 gradients.	 This	 is	
discussed	further	in	section	7.2.6.	
	




detectable	 levels	 in	 migDC2	 (Fig	 5.5,	 Appendix	 Fig	 D-I	 and	 personal	 communication	
with	Pierre	Bost).	These	data	suggest	that	migDC2	are	the	main	source	of	bioactive	IL-
12	 following	 Ms	 immunisation.	 However,	 depletion	 of	 monocytes	 resulted	 in	 a	
significant	reduction	in	the	frequency	of	IFNγ+	and	Tbet+	cells,	which	is	consistent	with	
reduced	 availability	 of	 IL-12.	 Further,	 even	 though	 Tfh	 cells	 were	 increased	 when	
monocytes	were	depleted,	the	population	of	Tbet+	Tfh	cells	was	significantly	reduced,	
indicating	 that	 signals	 from	 monocyte-derived	 cells	 were	 required	 to	 induce	 Tbet	
expression	 in	 Tfh	 cells.	 Thus,	 additional	 studies	 employing	 intracellular	 cytokine	




not	 clear	 from	 the	 present	 study.	 The	 marked	 reduction	 in	 Th2	 and	 Th17	 cells	 in	
IRF4∆CD11c	mice	suggests	that	these	responses	were	more	reliant	on	migDC2	than	Th1	
responses	in	Ms-treated	mice,	which	maintained	a	sub-optimal	response	in	the	absence	




that	 migDC2	 are	 required	 for	 the	 activation	 of	 CD4+	 T	 cells	 in	 these	 contexts	 but	
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regulate	 CD4+	 T	 cell	 responses.	 This	 finding	 was	 most	 evident	 in	 Ms-treated	 mice	
where	migDC2	 and	 IFNγ-conditioned	monocyte-derived	 cells	were	 both	 required	 for	
supporting	 the	 differentiation	 of	 effector	 Th1	 cells	 (Fig	 7.2).	 Additionally,	 the	 data	





Figure	 7.2:	 Model	 outlining	 the	 role	 of	 APC	 conditioning	 in	 the	 regulation	 of	 CD4+	 T	 cell	 differentiation.	
Context-specific	 conditioning	 of	 DC2	 and	 monocytes	 is	 central	 to	 the	 regulation	 of	 CD4+	 T	 cell	 differentiation	






7.2.4 TCR signal strength and co-stimulation in determining CD4+ T cell differentiation 
The	 nature	 of	 the	 interaction	 between	 APC	 and	 CD4+	 T	 cells	 has	 been	 implicated	 in	
regulating	 CD4+	 T	 cell	 differentiation	 (section	 1.4.3)	 (490).	 Strong	 and	 sustained	
interactions	 are	 associated	 with	 Th1,	 Th17	 and	 Tfh	 differentiation,	 whereas	 weak	
interactions	 are	 associated	 with	 Th2	 differentiation	 (491-499).	 Co-stimulatory	
signalling	 is	 one	 aspect	 of	 the	 APC-T	 cell	 interaction	 that	 has	 been	 implicated	 in	
regulating	 Th1/Th2	 differentiation.	 A	 study	 by	 van	 Panhuys	 et	 al.	 showed	 that	 DC	
activated	 with	 a	 Th1	 adjuvant	 (LPS)	 expressed	 higher	 levels	 of	 CD80	 and	 CD86	
compared	 to	 DC	 treated	 with	 a	 Th2	 adjuvant	 (papain)	 in	 vitro.	 Using	 an	 adoptive	
transfer	 model,	 the	 authors	 showed	 that	 blockade	 of	 CD80	 signalling	 in	 mice	 that	
received	antigen-loaded	DC	stimulated	with	LPS	altered	the	phenotypic	composition	of	




In	 this	 thesis,	 the	 expression	 of	 co-stimulatory	 molecules	 was	 directly	 compared	
between	DC	stimulated	with	Th1-	or	Th2-associated	immunogens	in	vivo.	Interestingly,	
although	Ms	and	Nb	elicit	strong	Th1	and	Th2	responses,	respectively,	the	expression	of	
CD40	 and	CD86	 on	DC	 from	Ms-	 and	Nb-treated	mice	was	 comparable	 (Fig	4.4).	 The	
expression	 of	 CD80	 was	 not	 assessed	 in	 this	 study,	 nor	 was	 the	 strength	 of	 TCR	
signalling,	so	it	is	difficult	to	conclude	whether	TCR	and	co-stimulatory	signal	strength	
play	a	role	in	regulating	CD4+	T	cell	responses	to	bacterial	or	helminth	antigens.	In	any	




Importantly,	 conditioning	of	APC	by	environmental	 cues	 (section	7.2.2)	was	 found	 to	
significantly	influence	CD4+	T	cell	responses	to	Ms	and	Nb.	In	the	study	by	van	Panhuys	
et	al.,	DC	were	treated	with	LPS	or	papain	in	vitro,	in	the	absence	of	accessory	cells	that	





Further	 study	 is	 required	 to	 understand	 the	 relative	 importance	 of	 TCR	 and	 co-
stimulatory	signal	strength	in	regulating	CD4+	T	cell	responses	in	vivo.			
	
7.2.5 The regulation of CD4+ T differentiation in response to allergens 
The	CD4+	T	cell	response	elicited	by	allergens	is	multifaceted	and	includes	a	number	of	
distinct	CD4+	T	cell	subsets.	CD44+	CD4+	T	cells	from	the	LNs	of	Nb-	or	HDM-treated	
mice	 could	be	 resolved	 into	 IL-4+	Tfh	 cells,	 IL-4-	Tfh	 cells,	 IFNγ+	cells	 and	 IL-4+	Th2	
effector	cells	(Fig	6.1).	Notably,	IL-13+	Th2	effector	cells	were	absent	from	the	LNs	of	
Nb-	 or	 HDM-treated	 mice,	 which	 is	 in	 line	 with	 published	 observations	 (392).	 In	
contrast,	the	ear	skin	of	Nb-	or	HDM-treated	mice	contains	subsets	of	Th2	effector	cells	
that	produce	IL-4,	IL-13	or	both	cytokines	(392).	The	presence	of	these	distinct	CD4+	T	
cell	 subsets	 in	 the	 LNs	 and	 skin	 of	 allergen-treated	 mice	 indicates	 that	 the	 current	
classification	of	Th2	cells	 is	oversimplified;	and	suggests	 that	multiple	signals	may	be	
involved	 in	 regulating	 CD4+	 T	 cell	 responses	 to	 allergens.	 Indeed,	 data	 shown	 in	
Chapter	6	demonstrates	that	IFN-I	and	TSLP	co-operate	to	actively	support	and	instruct	
distinct	 aspects	 of	 the	 CD4+	 T	 cell	 response	 following	 allergen	 exposure.	 IFN-I	
signalling	 via	 DC	 was	 shown	 to	 support	 the	 differentiation	 of	 effector	 and	 Tfh	
populations,	 whereas	 TSLP	 signalling	 acted	 on	 cells	 other	 than	 CD4+	 T	 cells	 to	
specifically	support	IL-4	production	by	effector	and	Tfh	populations.	The	expression	of	




Th2	 effector	 cells,	 but	 not	 Tfh	 cells	 (392).	 Preliminary	 studies	 carried	 out	 in	 our	
laboratory	 using	 STAT6-KO	 CD4+	 T	 cells	 suggest	 that,	 unlike	 IFN-I	 and	 TSLP,	 IL-4	













DC.	 However,	 it	 is	 unclear	 what	 signals	 IFN-I	 and	 TSLP-conditioned	 DC	 produce	 to	





not	 been	 substantiated	 by	 fate-reporter	 experiments.	 The	 presence	 of	 IL-4+	 non-Tfh	




epithelial-derived	cytokines	TSLP,	 IL-25	and	 IL-33	have	been	 shown	 to	act	 as	 “tissue	
checkpoint	signals”	and	are	required	 for	 the	 induction	of	 IL-13	expression	by	effector	
Th2	cells	(106,	121).	As	such,	TSLP	signalling	appears	to	play	key	roles	in	both	initiating	
and	 potentiating	 Th2	 responses	 in	 vivo.	 IL-4	 signalling	 has	 also	 been	 implicated	 in	
supporting	 tissue	 effector	 Th2	 responses,	 with	 the	 number	 of	 IL-4+	 and	 IL-4/IL-13+	
Th2	 cells	 significantly	 reduced	 in	 IL-4-deficient	 mice	 (392).	 Together,	 these	 data	
demonstrate	 that	 signals	 operating	 in	 distinct	 spatial	 and	 temporal	 compartments	


















7.2.6 Lymph node niches and CD4+ T cell localisation as potential factors regulating CD4+ 
T cell differentiation 
Identical	CD4+	T	cell	clones	have	the	capacity	to	give	rise	to	multiple	CD4+	T	cell	fates	
in	vivo	(207,	499),	 indicating	that	additional	 factors	are	 involved	 in	regulating	CD4+	T	




relocation	 of	 newly	 primed	 CD4+	 T	 cells	 to	 specific	 LN	 niches	made	 up	 of	 cells	 and	
cytokines	which	reinforce	commitment	to	a	specific	lineage.	Thus,	it	has	been	proposed	
that	 the	 spatial	 positioning	 of	 recently	 activated	 CD4+	T	 cells	within	 LNs	may	 be	 an	
important	 factor	 in	 the	 regulation	 CD4+	T	 cell	 differentiation.	 Indeed,	 this	 is	 evident	




It	 is	 currently	 unclear	 whether	 similar	 processes	 also	 regulate	 the	 differentiation	 of	
effector	CD4+	T	 cells.	 Interestingly,	 transcripts	encoding	 for	 chemokines	were	among	
the	 genes	 expressed	 in	 a	 condition-specific	manner	 by	DC2	 and	monocytes	 from	 the	
LNs	of	immunised	mice	(Figs	4.12	and	5.5).	CXCL9	and	CXCL10	which	bind	to	the	Th1-
associated	 chemokine	 receptor	 CXCR3	 (190,	 191)	 were	 up-regulated	 following	 Ms	
immunisation,	whereas	CCL17	and	CCL22	which	bind	to	the	Th2-associated	chemokine	
receptor	 CCR4	 (189-191)	 were	 up-regulated	 following	 Nb	 immunisation.	 The	 LN	
localisation	 of	 chemokine	 producing	 cells	 and	 recently	 primed	 CD4+	T	 cells	was	 not	
assessed	 in	 the	 present	 study	 but	 have	 been	 evaluated	 by	 other	 research	 groups.	
CXCL9/10	producing	cells	were	found	specifically	within	the	cortical	ridge,	medulla	and	
interfollicular	 regions	of	 the	LN	and	not	 in	 the	paracortex.	CXCR3+	antigen-specific	T	
cells	 were	 required	 to	 relocate	 from	 the	 paracortex	 to	 areas	 rich	 in	 CXCL9/10	
producing	cells	for	optimal	Th1	differentiation	and	IFNγ	production	(206,	896).	 In	the	
LNs	of	Ms-treated	mice,	monocytes	were	a	significant	source	of	CXCL9	and	CXCL10	(Fig	
5.5)	and	were	 found	to	support	 the	differentiation	of	effector	Th1	cells	while	 limiting	
Tfh	differentiation	(Fig	5.1).	These	data	suggest	that	monocyte-derived	CXCL9/10	may	
be	 required	 to	 position	 CD4+	 T	 cells	 within	 niches	 that	 support	 effector	 Th1	
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differentiation.	 In	 the	 absence	 of	monocytes,	 CD4+	T	 cells	 are	 recruited	 to	 the	B	 cell	
areas	 instead	where	 they	differentiate	 into	Tfh	 cells.	This	hypothesis	 is	 supported	by	
published	 studies	 which	 propose	 that	 recently	 activated	 CD4+	 T	 cells	 go	 through	 a	
multipotent	phase	during	which	they	express	multiple	chemokine	receptors	(207)	and	
have	 the	 capacity	 to	 give	 rise	 to	 effector	 or	 Tfh	 cells	 (897).	 Cells	 producing	 the	
corresponding	chemokines	then	regulate	the	positioning	of	CD4+	T	cells	within	the	LN	
to	 support	 particular	 differentiation	 programmes.	 Indeed,	 the	 authors	 of	 one	 study	
show	 that	 monocytes	 were	 a	 significant	 source	 of	 CXCL9	 in	 a	 Plasmodium	 infection	
model	and	favoured	effector	Th1	differentiation	over	Tfh	differentiation	(207).	Another	
study	 showed	 that	up-regulation	of	Tbet	was	required	 to	 suppress	BCL6	and	 the	Tfh	
differentiation	 programme	 in	 a	 T.	 gondii	 model	 (897).	 Therefore,	 localisation	 of	
multipotent	 CD4+	 T	 cells	 to	 a	 niche	 that	 supports	 Tbet	 induction	would	 ensure	 Th1	
differentiation,	 whereas	 alternate	 positioning	 near	 B	 cells	 would	 support	 Tfh	
differentiation.	
	
Microscopy	 studies	 assessing	 the	 clusters	 surrounding	 CD4+	 T	 cells	 in	 the	 LN	 are	
needed	to	clarify	the	cellular	and	cytokine	components	of	niches	that	support	particular	
CD4+	T	cell	 lineages.	The	Th1	feed-forward	amplification	 loop	described	 in	Chapter	5	
that	 encompasses	 cross-talk	 between	 NK	 cells	 and	 monocytes	may	 constitute	 a	 Th1	
supporting	 niche	within	 the	 LNs	 of	Ms-treated	mice.	 Indeed,	NK	 cells	 express	 CXCR3	





the	LN	 to	 support	effector	Th2	differentiation.	To	date,	 the	 involvement	of	CCL17/22	
signalling	 within	 LNs	 has	 not	 been	 explored	 and	 the	 characterisation	 of	 CCL17/22	
expression	 in	 the	 LN	 has	 been	 limited.	 This	 is	 further	 complicated	 by	 the	 fact	 the	
CCL17/22	 are	 expressed	 in	 DC	 at	 steady-state	 (188)	 and	 are	 up-regulated	 upon	
exposure	to	helminth	and	allergens	(112-115,	185-187).	The	studies	that	have	assessed	
the	 distribution	 of	 CCL17/22	 have	 primarily	 done	 so	 in	 LNs	 at	 steady-state	 where	
CCL17/22	expression	is	found	throughout	the	paracortex	and	subcapsular	sinus	(188,	





7.3 Implications of findings 
The	 immune	 system	 is	 intricately	 involved	 in	 many	 aspects	 of	 human	 health	 and	






of	 many	 immune	 modulating	 therapies.	 As	 such,	 studies	 delineating	 the	 processes	
involved	 in	 the	 initiation	 of	 context-appropriate	 immune	 responses	 are	 required	 to	
inform	 the	design	of	vaccines	and	 immunotherapies.	This	section	details	some	of	 the	
potential	translational	applications	of	findings	presented	in	this	thesis.	
	
7.3.1 APC subsets in the context of vaccination 




is	 inefficient	 or	 has	 yet	 to	 be	 developed.	 An	 example	 of	 the	 former	 scenario	 is	
tuberculosis,	which	resulted	in	>1.5	million	deaths	worldwide	in	2016	(905).	The	BCG	
vaccine	was	 developed	 in	 the	 1920s	 to	 combat	 tuberculosis	 it	 has	 proven	 inefficient	
and	 inconsistent	(900,	906).	An	example	of	 the	 latter	scenario	 is	hookworm	infection,	
which	afflicts	440	million	people	worldwide,	causing	anaemia	and	decreased	quality	of	
life	 (907).	 Currently,	 no	 vaccine	 strategy	 is	 available	 against	 human	 hookworm;	
however,	research	groups	are	actively	pursuing	this	goal	(908).	
	
Vaccination	 takes	 advantage	 of	 immunological	memory	 to	 educate	 adaptive	 immune	
cells	in	a	safe	and	controlled	setting.	Successful	vaccination	relies	on	the	generation	of	
appropriate	 and	 long-lasting	 memory	 T	 cells	 and	 antibodies	 to	 ensure	 efficient	
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infection	 resolution	 upon	 exposure.	 Research	 advancing	 our	 understanding	 of	 APC	
instruction	of	adaptive	immune	responses	has	led	to	the	development	of	novel	vaccine	
formulations	 that	 have	 improved	 antigen-specific	 memory	 T	 cell	 responses	 and	
antibody	responses.	 Indeed,	 the	 identification	of	DC1	as	superior	cross-presenting	DC	
has	 led	to	 the	development	of	vaccine	constructs	 that	are	specifically	targeted	to	DC1	
with	anti-DEC205,	anti-langerin	or	anti-Clec9A.	These	targeted	constructs	have	proved	
efficacious	 in	 the	 promotion	 of	 Th1	 and	 CD8+	 T	 cell	 responses	 to	 HIV	 and	T.	gondii	
antigens	 in	mouse	models	 (909-912).	However,	 Th1	 responses	were	 not	 found	 to	 be	
greatly	 improved	 by	 DEC205	 targeting	 of	 DC1	 in	 non-human	 primates	 and	 antibody	
responses	 were	 actually	 10x	 higher	 in	 animals	 treated	 with	 a	 non-targeted	 vaccine	
formulation	 (913).	 Given	 the	 findings	 of	 this	 thesis,	 vaccination	 strategies	 requiring	
CD4+	 T	 cell	 responses	may	 benefit	 from	 specific	 targeting	 of	 DC2.	 In	 addition,	 there	
were	 indications	 that	 DC2	 support	 Tfh	 differentiation	 which	 suggests	 that	 targeting	





and	 CD301b	 targeting	 has	 been	 demonstrated	 in	 vitro	 (914,	 915)	 and	 constructs	
targeted	to	CD206	have	proved	efficacious	in	vivo	(916).	Thus,	it	would	be	of	interest	to	
test	whether	vaccine	constructs	targeted	to	DC2	improves	effector	and	follicular	CD4+	
T	 cell	 responses	 and	 antibody	 responses	 over	 DC1-targeted	 or	 non-targeted	
formulations.	
	
That	 said,	 one	 of	 the	 key	 findings	 of	 this	 thesis	 was	 that	 APC	 conditioning	 signals	
produced	 by	 surrounding	 cells,	 such	 as	 NK	 cells	 and	 keratinocytes,	 are	 central	 to	
directing	the	appropriate	differentiation	of	CD4+	T	cells.	Therefore,	direct	targeting	of	
DC	 may	 not	 be	 the	 most	 efficacious	 vaccine	 strategy,	 as	 signals	 that	 regulate	 DC	






This	 thesis	 also	 demonstrated	 that	 monocyte-derived	 cells	 support	 effector	 Th1	
responses	 but	 restrict	 Tfh	 differentiation,	potentially	 by	 regulating	 the	 positioning	 of	
newly	 activated	 CD4+	 T	 cells	 within	 the	 LN	 (206,	 207).	 In	 the	 context	 of	 infection,	
skewing	 CD4+	 T	 cells	 towards	 an	 effector	 Th1	 fate	 may	 be	 advantageous;	 but	 the	
generation	 of	 memory	 cells	 and	 antibody	 responses	 via	 Tfh	 cells	 is	 required	 for	
effective	 vaccine	 responses.	 Therefore,	 the	 promotion	 of	 cell	 types	 and	 signalling	
molecules	 that	 actively	drive	effector	 responses	over	memory	and	Tfh	differentiation	
are	 likely	 to	 be	 an	 undesirable	 characteristic	 of	 vaccine	 formulations.	 In	Ms-treated	
mice,	monocyte-derived	cells	were	a	significant	source	of	the	CXCR3	ligands	CXCL9/10.	
Importantly,	 published	 studies	 have	 shown	 that	 CXCR3-dependent	 recruitment	 of	
newly	 activated	 T	 cells	 to	 CXCL9/10	 rich	 zones	 within	 the	 LN	 is	 associated	 with	
enhanced	effector	T	 cell	 responses	and	 reduced	memory	CD8+	T	 cells	 (917-919)	 and	
Tfh	 cells	 (207).	 Together,	 these	 data	 indicated	 that	 CXCL9/10+	 monocytes	 are	
detrimental	to	Tfh	responses	and	may	also	restrict	memory	cell	formation.	It	would	be	
of	 interest	 to	 determine	 whether	 CXCR3	 expression	 also	 regulates	 memory	 cell	




that	 replicate	 the	 appropriate	 DC	 conditioning	 signals	 without	 inducing	 monocyte	
recruitment	 may	 be	 best-suited	 to	 supporting	 optimal	 memory	 and	 antibody	
responses.		
	
7.3.2 Immunotherapeutic targeting of APC conditioning factors in the context of AD 
Immune	 modulating	 therapies	 utilising	 monoclonal	 antibodies	 that	 target	 cytokine	
signalling	 pathways	 have	 proved	 efficacious	 in	 managing	 inappropriate	 immune	
responses	 in	 the	 context	 of	 allergy	 and	 autoimmunity.	 Some	 examples	 include	 a	
monoclonal	antibody	targeting	IL-4Rα	that	has	been	approved	for	the	treatment	of	AD	
(344)	 and	antibodies	 targeting	 IL-23,	 IL-17,	TNFα	and	 IL-6	 that	 are	approved	 for	 the	




IFN-I	 and	 TSLP	 were	 identified	 as	 DC2	 conditioning	 signals	 involved	 in	 promoting	
optimal	 Th2	 responses	 to	 allergens	 (Chapter	 6).	 Importantly,	 GSEA	 determined	 that	
transcriptomic	 signatures	 relating	 to	 IFN-I	 and	 TSLP	 signaling	 were	 enriched	 in	 the	
lesional	 skin	 of	 AD	 patients.	 Thus,	 inventions	 blocking	 IFN-I	 and/or	 TSLP	 signalling	
pathways	 could	 be	 of	 interest	 in	 the	 context	 of	 allergic	 disease.	 Tezepelumab,	 an	
antibody	 that	 blocks	 the	 interaction	 of	TSLP	with	 its	 receptor,	 is	 currently	 in	 clinical	
trials	 for	 the	 treatment	 of	 atopic	 disease,	 and	 has	 shown	 promise	 in	 patients	 with	
allergic	 asthma	 (902,	903).	 The	 publication	 of	 current	 Tezepelumab	 clinical	 trials,	 as	
well	as	 the	transition	of	highly	potent	TSLP	antagonists	(20-30	fold	more	potent	 than	
Tezepelumab)	 into	 human	 studies	 will	 likely	 provide	 further	 results	 of	 significance	
(922).	However,	the	prevention	of	Th2	development	in	the	absence	of	TSLP	was	modest	
in	Nb-	 and	 HDM-treated	 mice	 compared	 the	 blockade	 of	 IFN-I	 signalling.	 Therefore,	
combining	IFN-I	and	TSLP	blockade	may	be	a	more	robust	strategy	for	the	management	
of	 atopic	 disease.	 A	 monoclonal	 antibody	 against	 human	 IFNAR,	 Anifrolumab,	 is	
currently	in	clinical	trials	for	the	treatment	of	systemic	lupus	erythematosus	(SLE)	and	
is	reportedly	well	tolerated	(923).	Monoclonal	antibodies	against	IFNα	have	also	been	
well	 tolerated	 in	 SLE	 clinical	 trials,	 but	 have	 been	 discontinued	 in	 favour	 of	






7.4 Final summary and conclusions 
This	 thesis	 sought	 to	 determine	 the	 roles	 of	 innate	 immune	 cell	 populations	 and	
signalling	molecules	 in	 the	 regulation	 of	 CD4+	 T	 cell	 differentiation	 by	 performing	 a	
side-by-side	assessment	of	LN	immune	responses	following	intradermal	immunisation	
with	 different	 types	 of	 immunogens.	 This	 approach	 yielded	 evidence	 that	 context-
specific	 conditioning	of	migDC2	was	 central	 to	 determining	 CD4+	T	 cell	 fates	 in	vivo.	
Mouse	models	 that	allowed	for	 the	depletion/deletion	of	specific	DC	subsets	revealed	






in	 promoting	 Th1	 responses	 to	 bacterial	 antigen,	 the	 co-operation	 of	 migDC2	 and	
monocyte-derived	cells	was	required	for	the	induction	optimal	effector	Th1	responses.		
	
A	 detailed	 characterisation	of	 CD4+	T	 cell	 phenotypes	 in	 the	 LNs	 of	 immunised	mice	
was	 crucial	 for	 the	 identification	of	 cell	 types	and	 signals	 that	 specifically	 influenced	
CD4+	T	cell	differentiation.	Early	sources	of	 IFNγ,	such	as	NK	cells,	were	required	 for	
the	recruitment	and	activation	of	monocyte-derived	cells	and	the	induction	of	optimal	
effector	 Th1	 responses	 to	 bacterial	 antigen.	 Interestingly,	 IFNγ	 signalling	 and	
monocyte-derived	 cells	 were	 also	 implicated	 in	 restraining	 Tfh	 differentiation,	
indicating	that	these	factors	were	regulators	of	CD4+	T	cell	lineage	commitment.	In	the	
context	 of	 allergens,	 TSLP	 signalling	 was	 identified	 to	 specifically	 support	 IL-4	
production	 by	 effector	 and	 follicular	 CD4+	 T	 cells.	 IFN-I	 conditioning	 of	 DC2	 was	
required	 to	 “amplify”	CD4+	T	 cell	 responses	 to	allergens	but	was	not	 involved	 in	 the	
regulating	CD4+	T	cell	differentiation.	Together,	these	data	show	that	signals	involved	





7.5 Future Directions 
This	 thesis	 has	 broadly	 characterised	 the	 innate	 and	 adaptive	 immune	 responses	
following	 intradermal	 immunisation;	 and	 has	 assessed	 the	 roles	 of	 DC	 subsets,	
monocytes	 and	 several	 identified	 conditioning	 factors	 in	 regulating	 CD4+	 T	 cell	





439).	 Recent	 data	 indicates	 that	 distinct	 subsets	 of	 Tfh	 cells	 may	 exist	 in	 order	 to	
regulate	 the	appropriate	antibody	 isotype	 class-switching	 (315),	which	 is	 in	 line	with	
the	 presence	 of	 Tbet+	 Tfh	 cells	 in	 Ms-treated	 mice.	 As	 such,	 many	 immunisation	
strategies	would	benefit	greatly	from	ensuring	a	robust	antibody	response	by	eliciting	
the	 required	 Tfh	 cells.	 Data	 presented	 in	 this	 thesis	 suggests	 that	 monocytes	 may	
negatively	regulate	overall	Tfh	differentiation	(Figs	5.1,	5.2	and	5.3),	whereas	DC2	may	
support	Tfh	differentiation	in	some	contexts	(Fig	4.10).	However,	the	reduction	of	Tfh	
cells	 in	 IRF4∆CD11c	mice	compared	to	controls	was	not	significant	 in	Ms-	or	Ca-treated	
mice,	 which	 suggests	 that	 other	 cells	 types	 may	 be	 involved	 in	 supporting	 Tfh	
differentiation.	 Tfh	 cells	were	 not	 assessed	 in	all	 APC	 depletion	models	 presented	 in	
this	thesis;	therefore,	it	would	be	of	interest	to	assess	the	involvement	of	LC,	DC1	and	
KLF4-dependent	 DC2	 in	 Tfh	 differentiation	 following	 immunisation	 with	Ms	 and	 Ca.	
Additional	studies	that	characterise	the	phenotype	and	function	of	Tfh	cells	in	greater	
detail	may	also	provide	insight	into	the	regulation	of	Tfh	differentiation.	Indeed,	while	
monocytes	negatively	 regulate	Tfh	differentiation,	 they	were	 required	 to	 induce	Tbet	
expression	in	Tfh	cells	in	Ms-treated	mice	(Fig	5.1).	Likewise,	IFN-I	conditioning	of	DC	









CD4+	T	 cell	 responses	 to	 intradermal	 immunisation	 and	 did	 not	 explore	 CD4+	T	 cell	
memory	responses.	Therefore,	it	would	be	of	interest	to	assess	CD4+	T	cell	responses	in	
the	 skin	 and	 LNs	 following	 a	 second	 immunisation	 in	 the	 opposite	 ear.	 In	 these	
experiments,	cell	 types	or	signalling	molecules	would	be	depleted	during	the	primary	
and/or	 secondary	 immunisation	 to	 determine	 which	 factors	 are	 required	 for	 the	
differentiation	 and	 re-activation	 of	 memory	 cells.	 In	 addition,	 immunisation	 in	 the	






mice	 (Fig	 3.7)	 and	 express	 condition-specific	 transcriptional	 profiles	 (Fig	 5.5).	 In	
particular,	IFNγ	signalling	was	required	for	the	recruitment	of	inflammatory	monocytes	




greater	 detail.	 Firstly,	 the	 scRNASeq	 studies	 performed	 here	 were	 not	 sufficiently	
sensitive	for	characterisation	of	lowly	expressed	transcripts,	which	included	the	genes	
encoding	 for	many	cytokines.	Bulk	RNASeq	of	sorted	Ag-	and	Ag+	monocytes	may	be	




in	 the	 depletion	 of	 neutrophils	 and	 eosinophils.	 A	more	 specific	 depletion	method	 is	
necessary	to	address	the	role	of	monocytes	in	regulating	CD4+	T	cell	responses.	This	is	
a	 challenging	 task	 due	 to	 monocyte	 plasticity	 and	 the	 rate	 at	 which	 monocytes	 are	
replaced	 by	 cells	 from	 the	 bone	marrow	 under	 inflammatory	 conditions.	 The	 CD64-
DTR	mouse	model	(847)	or	the	CCR2-KO	mouse	model	(590,	926)	could	potentially	be	
useful	but	also	have	caveats.	Macrophages	as	well	as	monocytes	are	depleted	in	CD64-
DTR	mice	 and	 an	 intensive	DT	 treatment	 schedule	 is	 required	 to	maintain	 depletion	
(847),	 which	 may	 lead	 to	 the	 development	 of	 anti-DT	 antibodies	 (Sabine	 Kuhn,	
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Another	 approach	 would	 be	 to	 block	 the	 identified	 monocyte	 tissue	 recruitment	
signals,	 such	 as	 IFNγ	 in	 Ms-treated	 mice,	 to	 determine	 how	 reduced	 monocyte	
recruitment	 impacts	 the	 immune	 response.	 Without	 the	 development	 of	 better	














Recent	 studies	 have	 suggested	 that	 the	 positioning	 of	 newly	 activated	 CD4+	 T	 cells	
within	the	LN	influences	their	differentiation	(207),	with	Th1	differentiation	 favoured	
in	CXCL9/10	rich	regions	of	the	LN	(206)	and	Tfh	differentiation	promoted	in	the	B	cell	
follicles	 (207,	 450).	 In	 line	 with	 this	 hypothesis,	 chemokines	 were	 expressed	 in	 a	
condition-specific	manner	among	APC	(Figs	4.12	and	5.5)	and	CXCL9/10+	monocytes	
were	 found	 to	 regulate	 the	 balance	 of	 effector	 Th1/Tfh	 cells	 in	Ms-treated	mice	 (Fig	
5.1).	 However,	 the	 requirements	 of	 chemokine	 signalling	 were	 not	 assessed	 in	 the	
present	 study.	 Employing	 knockout	 mouse	 models	 or	 administration	 of	 chemokine	
neutralising	 reagents	 may	 assist	 in	 determining	 whether	 chemokine	 signalling	 is	
required	 for	optimal	 CD4+	T	 cell	 differentiation	 following	 i.d.	 immunisation.	 Further,	
the	 experimental	 techniques	used	 in	 this	 thesis	 required	 the	 dissociation	of	 LN	 cells,	
thus	 losing	 all	 spatial	 context.	 Confocal	 microscopy	 experiments	 comparing	 the	
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composition	of	 the	cellular	clusters	surrounding	CD4+	T	cells	 following	 immunisation	
with	 different	 antigens	may	 assist	 in	 determining	which	 cell	 types	 actively	 influence	
differentiation	 programmes.	 Intravital	 microscopy	 techniques	 could	 also	 be	 very	
powerful	 to	 address	 this	 question.	 Using	 this	 technology,	 the	 positioning	 and	




Experiments	 performed	 using	 IFNAR∆CD11c	 mice	 showed	 that	 IFN-I	 signalling	 was	
required	to	support	CD4+	T	cell	responses	to	allergens	(Figs	6.3	and	6.4).	Interestingly,	
loss	of	IFNAR	signalling	in	DC	globally	impacted	the	CD4+	T	cell	response	to	allergens,	
with	 the	 number	 of	 total	 CD4+	 T	 cells,	 Tfh	 cells,	 IFNγ+	 cells	 and	 IL-4+	 cells	 all	
significantly	 reduced.	 Transcriptomic	 analyses	 comparing	 DC	 from	 allergen-treated	
IFNAR∆CD11c	 and	 IFNARfl/fl	 mice	 may	 provide	 insight	 into	 the	 signals	 involved	 in	
supporting	CD4+	T	cell	responses	to	allergens.	A	less	exhaustive	approach	would	be	to	
specifically	focus	on	expression	of	genes	associated	with	MHCII	processing.	An	in	vitro	
study	 has	 previously	 shown	 that	 bone	 marrow-derived	 DC	 activated	 with	 IFNβ	
maintain	 transcription	 of	 MHCII	 associated	 genes	 (I-Aβb	 and	 CIITA),	 whereas	
transcription	of	these	genes	was	shut	down	following	exposure	to	TLR	ligands	(927).	As	
such,	 IFNβ-conditioned	 DC	 were	 more	 efficient	 at	 presenting	 antigen	 to	 a	 T	 cell	
hybridoma	(927).	Given	these	results,	and	that	CD4+	T	cells	require	antigen	recognition	
prior	 to	 each	 division	 (895),	 it	 would	 also	 be	 of	 interest	 to	 assess	 CD4+	 T	 cell	




TSLP	 was	 shown	 to	 specifically	 promote	 the	 development	 of	 IL-4+	 CD4+	 T	 cells	 in	




4	promoting	 signalling	molecules.	As	mentioned	elsewhere	 in	 this	 thesis,	Ccl17,	Ccl22	
and	 Tnfsf4	 (OX40L)	 are	 known	 targets	 of	 TSLP	 signalling	 (112-115)	 and	 were	 up-
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regulated	 by	 Nb+	 DC2	 (Fig	 4.12).	 Thus,	 further	 study	 of	 these	 molecules	 using	
neutralising	antibodies	or	conditional-knockout	mouse	models	would	be	of	interest	to	
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A-I Analysis of scRNASeq data 
Prepared	by	Pierre	Bost	for:		
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Bahar-Halpern,	 B	 Toth,	 S	 Itzkovitz,	 B	 Schikowski,	 F	 Ronchese†	 and	 I	 Amit†,	 Cross	 talk	 of	 antigen	




Cells	with	 less	 than	350	UMIs	were	excluded	 from	 the	analysis.	Based	on	 the	dataset	
studied,	genes	with	less	than	a	given	threshold	of	UMIs	were	removed.	scRNASeq	data	





on	 a	 L2	 distance	 of	 the	 top	 100	 principal	 components	 derived	 from	 the	 top	 3000	
variable	 genes	 from	 the	 variance	 adjusted	 expression	matrix	 using	 the	Multilevel	 or	
Infomap	community	detection	algorithm	(as	implemented	in	the	igraph	R	package).	For	
large	 datasets	 (more	 than	 10,000	 cells),	 the	 k	 parameter	 was	 set	 to	 40,	 Multilevel	
clustering	 method	 chosen	 and	 clusters	 with	 less	 than	 1%	 of	 the	 cells	 removed.	 For	
small	 datasets	 (less	 than	 10,000	 cells),	 the	 k	 parameter	 was	 set	 to	 20,	 Infomap	
clustering	method	used	and	clusters	with	less	than	5%	of	the	cells	filtered	out.		
	
Marker	 genes	 were	 detected	 using	 the	 getDifferentialGenes	 function	 with	 default	
parameters	(Z	>	3,	upregulated.only	=	TRUE).	To	 further	 filter	 the	 identified	markers,	
an	 additional	 step	 was	 added.	 Briefly,	 genome	 wide	 relation	 between	 the	 mean	
expression	of	 a	gene	and	 the	proportion	of	 cells	which	do	not	express	 this	gene	was	








To	 robustly	 detect	 differentially	 expressed	 genes	 between	 two	 cell	 populations,	 we	
assumed	that	differences	in	expression	were	mostly	due	to	changes	in	the	proportion	of	
cells	expressing	a	set	of	genes,	rather	than	a	few	cells	highly	expressing	the	same	set	of	
genes.	 Briefly,	 gene	 expression	 was	 dichotomized	 (set	 to	 one	 if	 more	 than	 one	 UMI	
expressed	 or	 to	 zero	 otherwise).	 For	 each	 gene	 a	 logistic	 regression	 was	 then	
performed	between	the	dichotomized	gene	expression	and	covariates	of	interest	using	























Flow	 data	 were	 analyzed	 using	 the	 FlowCore	 R	 package.	 Channels	 intensity	 were	
transformed	 and	 scaled	 using	 the	 Logicle	 transform.	 Transformation	was	 performed	
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using	 the	 logicleTransform	 and	 estimateLogicle	 functions	 with	 default	 parameters.	





given	 cell	 population	 and	 performed	 gene	 expression	 and	 variance	 normalization	on	
the	raw	UMI	counts.	The	variable	genes	were	 selected	using	the	getOdGenes	 function	
from	PAGODA2	package	with	default	parameters.	These	genes	were	then	grouped	into	
a	given	number	of	pathways	 (from	20	 to	30	based	on	 the	number	of	 variable	genes)	
using	 hierarchical	 clustering	 (Ward	 linkage	 and	 correlation-based	 distance).	 Over-
dispersion	 of	 these	 pathways	 was	 computed	 using	 the	 testPathwayOverdispersion	
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Figure	B-I:	CD4+	T	cell	responses	relative	to	immunisation	dose.	Mice	were	immunised	with	the	indicated	dose	
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skin-dLNs	were	analysed	by	 flow	cytometry	 two	days	after	 i.d.	 immunisation.	 (A)	Representative	flow	cytometry	
plots	showing	the	frequencies	of	LC,	DC1	and	DC2	among	migDC.	(B)	Number	of	LC,	DC1,	CD11b+	DC2	and	TN	DC2	in	








































Figure	 C-VIII:	 DC	migration	 and	 activation	 following	Nb	 immunisation	 is	 not	 impacted	 by	 the	 absence	 of	
IFNAR	signalling.	(A)	Representative	flow	plots	comparing	the	frequency	of	DC	subsets	between	IFNARΔCD11c	and	
IFNARWT	mice.	 (B)	 The	 frequency	 of	 migratory	 DC	 subsets	 from	 PBS-treated	 or	Nb-immunized	 IFNARΔCD11c	 and	
IFNARWT	mice.	(C)	MFI	of	CD86	on	the	surface	of	DC2,	two	days	after	 injection	of	Nb	or	PBS.	Bar	graphs	show	the	
mean±SEM.	Data	presented	is	 compiled	 from	 two	independent	experiments,	with	a	 total	of	eight	mice	per	group.	
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Gene sets used for Gene Set Enrichment Analysis 
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E-I Cellular response to IFN-I (Gene Ontology) 
PNPT1,	 TLR3,	 UBE2K,	 DDX41,	 CDC34,	 TRIM6,	 HTRA2,	 IFNB1,	 TMEM173,	 NDUFA13,	
UBE2G2,	AIM2,	STAT1,	 IRF1,	ACOD1,	 IFIT2,	 STAR,	TPR,	 IFIT3,	GAS6,	GATA3,	 IFNAR1,	
AXL,	BST2,	RNASEL,	CACTIN,	NLRC5,	WNT5A,	ABCE1,	IFIT1,	IFI6,	IRF5,	ADAR,	IFITM1,	
HLA-A,	 XAF1,	 MUL1,	 HLA-B,	 PTPN2,	 HLA-C,	 PTPN6,	 IFNA8,	 FADD,	 IFITM2,	 IFITM3,	
CNOT7,	OAS2,	HLA-G,	OAS1,	TYK2,	 IFNA14,	 IFNA7,	 IFNA10,	 IFNA1,	 IFI35,	HSP90AB1,	





E-II TSLP pathway (WikiPathways) 
AKT1,	BTK,	CCL11,	CISH,	CRLF2,	EIF4EBP1,	FES,	FYN,	GAB2,	HCK,	IL2RA,	IL6,	IL7R,	IL8,	
JAK1,	 JAK2,	LCK,	LYN,	MAP2K1,	MAP2K2,	MAPK14,	MAPK1,	MAPK3,	MAPK8,	MAPK9,	
MTOR,	 MYC,	 NFKB1,	 NFKB2,	 NFKBIA,	 PIK3CA,	 PIK42A,	 PTPN11,	 RELA,	 RELB,	 RPS6,	
SRC,	STAT1,	STAT3,	STAT4,	STAT5A,	STAT5B,	STAT6,	TEC,	TNFSF4,	TSLP,	YES1		
	
E-III Nb CD11b+ UP (229) 
ABCA1,	ABI3,	ABLIM1,	ABTB2,	ACE,	ACKR1,	ACSS1,	ADAM19,	ADAM22,	ADAP1,	AIDA,	
AIF1L,	 AIG1,	 APBB1IP,	 AP1S3,	 ARSB,	 ASAP1,	 ASPRV1,	 ATP1A1,	 ATP1B1,	 ATP2A3,	
B3GNT5,	 BAHCC1,	 BCL11A,	 BCL2L1,	 BCL6,	 BTG2,	 BTLA,	 CADM3,	 CALCRL,	 CAMK1D,	
CAPSL,	 CA13,	 CASS4,	 CCDC107,	 CCL17,	 CCL21,	 CCR9,	 CD180,	 CD1D,	 CD200,	 CD28,	
CD300A,	 CD300C,	 CD4,	 CD70,	 CD86,	 CD8B,	 CDK14,	 CHPT1,	 CHST3,	 CLDN1,	 CLEC10A,	
CLEC4E,	 CNGA2,	 CNN3,	 CREB3L2,	 CRISPLD2,	 CSF1,	 ARFGEF3,	 DBN1,	 DCLK2,	 DLL4,	
DNMT1,	 DNTT,	 DOT1L,	 DRAM1,	 DSCAM,	 EGR1,	 EGR2,	 ELDR,	 ELOVL7,	 ADGRE1,	
ENTPD1,	 EPHA2,	 EPHX1,	 ERLEC1,	 ESAM,	 ETHE1,	 ETS1,	 ETS2,	 EVI2A,	 FAM102A,	
RIPOR2,	FAM83F,	FAM89A,	FFAR4,	FLI1,	FLNB,	FLOT1,	FOSB,	FOXH1,	FRMD5,	FURIN,	
GAL3ST2,	 GAS2L3,	 GAS5,	 GAS7,	 GATM,	 GBP2,	 GBP5,	 GFRA2,	 GIMAP6,	 GLIPR2,	 GLRX,	
GNB4,	 GPR141,	 GRM8,	 GSTT1,	 GTF2A1,	 GTPBP1,	 GVINP1,	 HERC6,	 HIST1H4K,	
HIST2H2BB,	 HR,	 HSPA1A,	 HTR7,	 ICAM4,	 IFI35,	 IFI47,	 IFIT1,	 IGKC,	 IGSF6,	 IKZF3,	
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IL18BP,	 IL18R1,	 IL1R2,	 IL1RN,	 IL27,	 IL2RA,	 IL33,	 IL6R,	 INPP5B,	 INPP5J,	 INSL6,	 IRF4,	
ISG15,	 ITK,	 IZUMO4,	 KCTD12,	 KDM6B,	 KLF2,	 KMT2D,	 LACTB,	 LAIR1,	 LARS2,	 LEF1,	




OAS1A,	 OAS3,	 OASL,	 OCIAD1,	 OPRD1,	 PABPC1,	 PACSIN1,	 PADI2,	 PAFAH1B3,	
PDCD1LG2,	 PDE4A,	 PELP1,	 PGLYRP1,	 PIK3AP1,	 PLA1A,	 PLA2G16,	 PLA2G7,	 PLAC8,	
PLAUR,	 PLEK2,	PLSCR1,	PLXDC1,	POLG2,	POM121,	PPP1R12B,	PPT2,	PRNP,	 PSMB10,	
PTCHD1,	NECTIN1,	PXDC1,	RASGRP4,	RELL1,	RGS5,	RHEBL1,	RNU12,	RPGRIP1,	RTF1,	
RUNX1,	 RYR2,	 S1PR3,	 SCARNA6,	 SCUBE3,	 SEC24A,	 SELL,	 SELENOM,	 SEMA7A,	
SELENOP,	 SERPINB1,	 SERPINB9,	 SERPINC1,	 SERPINE1,	 SETD1B,	 SF3A2,	 SFXN3,	
SHISA9,	SIGLEC1,	SLC15A2,	SLC15A3,	SLC2A3,	SLC44A5,	SLC6A13,	SLC9A9,	SLCO4A1,	
SLFN5,	 SMIM5,	 SMYD3,	 SNORA23,	 SNORA73B,	 SNORA78,	 SNORA7A,	 SNORD118,	
SNRPF,	SP110,	SP140,	SPATA13,	SPEN,	SPHK1,	SPIB,	SPTB,	SRC,	ST18,	ST8SIA6,	STAT4,	
SUSD2,	 SUV39H2,	 TAGAP,	 TAPBPL,	 TARM1,	 TAZ,	 TCIRG1,	 TCP11L2,	 TDRD7,	 TEX15,	
TGTP1,	THBS1,	TLCD1,	TLR7,	TMEM106A,	TMEM140,	TMEM200B,	TMEM25,	TMEM64,	
TMTC4,	 TNFRSF14,	 TNFRSF4,	 TNIP3,	 TNS1,	 TRERF1,	 TRIM43B,	 TUBA1A,	 TUBB2B,	
TXNDC17,	 UBD,	 UCP2,	 UHRF1,	 VDR,	 VWA5A,	 VWF,	 METTL27,	 XAF1,	 YAM1,	 YPEL2,	
ZBP1,	 ZC3H12C,	 ZC3H12D,	 ZDHHC24,	 ZFHX2,	 ZFP36,	 ZFP36L2,	 ZNF385A,	 ZMIZ1,	
ZNRF3		
	
E-IV Nb TN UP (229) 
C15orf48,	 ABCA3,	 ABCC5,	 ABCD2,	 ABHD12,	 ABHD17C,	 ABRACL,	 ABTB2,	 ACKR1,	
ADAM22,	 ADPRH,	 AIDA,	 AIF1L,	 AIG1,	 AKAP9,	 ALCAM,	 ALG6,	 JAML,	 ANKS6,	 ANXA2,	
AP1S3,	 APEX1,	 APOBR,	 ARHGAP17,	 ARHGAP26,	 ARHGAP39,	 ARID1A,	 ARRB1,	 ASPM,	
ATF7IP,	ATG2B,	ATG9A,	ATP2A3,	ATXN2,	B3GNT5,	BAHCC1,	BANF1,	BATF2,	C6orf10,	
BCL2L1,	BCL6,	BCL7A,	BCL7C,	BPIFA2,	BST2,	CACNA1E,	CACNA2D2,	CADM3,	CALCRL,	
CALHM2,	 CALM1,	 CAMK1D,	 CAMTA2,	 CAPG,	 CAPN15,	 CA13,	 CA2,	 CASC1,	 CASP4,	
CATSPERG,	CBX7,	CCDC120,	 SVBP,	CCIN,	CCL17,	CCL21,	CCL22,	CCL4,	CCND2,	CD180,	
CD1D,	CD200,	CD300A,	CD302,	CD38,	CD69,	CD70,	CD80,	CD81,	CD86,	CDCP1,	CDH1,	
CDHR1,	 CDK14,	 CDK5R1,	 CEP85L,	 CEP97,	 CFDP1,	 CFL1,	 CGNL1,	 CHAC2,	 CHD7,	 CISH,	
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CLDN1,	 CLEC10A,	 CLN6,	 CMC2,	 CMPK2,	 CNN3,	 CNR2,	 COL23A1,	 COL4A1,	 COL4A2,	
COQ10A,	CORO2A,	CRAT,	CRIP1,	CRTC1,	CST3,	CTNNAL1,	CTNS,	CTSZ,	CXCL10,	CXCL3,	
CXCL9,	 CYFIP1,	 CYTIP,	 ARFGEF3,	 DBN1,	 DBP,	 DCK,	 DCLK2,	 DDAH2,	 DDHD1,	 INTS6L,	
DDX49,	 DDX58,	 DDX60,	 DHX58,	 DLGAP3,	 DLL4,	 DNAJC12,	 DNMT1,	 DRAM1,	 DSCAM,	
DTL,	DTX3L,	DUSP14,	DUT,	DVL2,	DYRK1B,	DYRK3,	EBI3,	EHD1,	ELMSAN1,	EMILIN2,	
ADGRE3,	 EPHA2,	 EPHX1,	 ERICH5,	 ETHE1,	 ETS2,	 ETV5,	 EVI2A,	 EXT1,	 EXTL1,	 FADS1,	
FAH,	FAM105A,	TCAF2,	C1QTNF12,	FAM168A,	FAM212B,	FAM43A,	FAM49B,	RIPOR1,	
FAM71A,	 FAM84B,	 FAM89A,	 FAP,	 FBLN5,	 FEN1,	 FFAR4,	 FGGY,	 FKBP4,	 FKTN,	 FLCN,	
FLNB,	 FLOT1,	 FN1,	 FOXRED2,	 FRMD4B,	 FSTL1,	 GADD45A,	 GADD45G,	 GAPDH,	GATM,	
GBP2,	GBP3,	GBP5,	GBP6,	GBP7,	GCNT2,	GDA,	GDPD1,	GFER,	GGTA1P,	GLIPR1,	GLIPR2,	
GLRX,	 BICRA,	 GM2A,	 GPR157,	 GPR162,	 GPR4,	 GPR55,	 GPR68,	 GPR85,	 GSTT1,	 GK,	
HCLS1,	HDAC10,	HDAC11,	HELZ2,	HERC6,	HFE,	HIST1H1A,	HOPX,	HPCAL1,	HSD17B11,	
HSF2,	HSPB1,	HSPB11,	HTR7,	HTRA1,	 ICOSLG,	 IFI27,	 IFI35,	 IFI44,	 IFI47,	 IFIT1,	 IFIT2,	
IFIT3,	 IFITM3,	 IFT122,	 IGSF6,	 IGSF8,	 IL18BP,	 IL18R1,	 IL18RAP,	 IL1RN,	 IL21R,	 IL23R,	
IL2RA,	 IL6R,	 IL9R,	 INPP5B,	 INPP5J,	 INSL6,	 IRF1,	 IRF4,	 IRF6,	 IRF7,	 IRF8,	 IRGM,	 ISG15,	
ITGAV,	ITGAX,	KCNA2,	KCNN1,	KCNQ1OT1,	KCTD12,	KCTD19,	KIF3B,	KIF5C,	KIT,	KLF6,	
KLRD1,	KMT2A,	KTN1,	LACTB,	LAMC2,	P3H2,	LGMN,	LMNB1,	LOXL4,	ADGRL1,	PLPPR4,	
LRMP,	 LRRFIP1,	 LSR,	 LXN,	 LY6D,	 MAPKAPK3,	 MBD6,	 MCTP2,	 MDK,	 MELK,	 MET,	
ETFBKMT,	 MFSD7,	 MGAT4A,	 MIR99AHG,	 MLF2,	 MMP14,	 MOV10,	 MROH1,	 MRPL52,	
MRPS6,	 MTAP,	 MTMR7,	 MXD4,	 MYH10,	 MYH15,	 MYLK,	 MYO1H,	 MYO5B,	 MYOM1,	
NANS,	 NAV1,	 NDRG1,	 NDRG2,	 NMI,	 NPHS1,	 NR4A1,	 NRP2,	 NT5DC3,	 NUP54,	 NUPR1,	
OAF,	 OAS1A,	 OAS3,	 OASL,	 OCIAD1,	 OCLN,	 OLFM1,	 P2RY13,	 PADI2,	 PANX1,	 PARD3B,	
PARP10,	PARP9,	 PDCD1LG2,	PDE2A,	 PDE4A,	PDK2,	PDLIM4,	PDLIM5,	 PER3,	PFKFB2,	
PFKP,	 PGAP1,	 PHF6,	 PIGB,	 PIK3R1,	 PIM2,	 PITPNC1,	 PKIB,	 PKP3,	 PLA1A,	 PLA2G16,	
PLA2G2D,	 PLA2G4A,	 PLA2G4F,	 PLAT,	 PLEK2,	PLEKHH1,	 PLIN2,	 PLK2,	 PLK4,	 PLSCR1,	
PLTP,	PLXDC1,	PNPLA7,	POLE4,	POLR2G,	POP7,	PPA1,	PLPP1,	PPFIBP2,	PROCR,	PRPS1,	
PSD3,	 PSMA6,	 PSMB10,	 PSMB8,	 PSME1,	 PSME2,	 PTCHD1,	 PXYLP1,	 PYHIN1,	 RAB8B,	
RAD21,	 RAI14,	 RALB,	 RAMP1,	 RAMP3,	 RANBP1,	 RAPGEF5,	 RASA3,	 RASA4,	 RASSF4,	
RBBP8,	 RBM43,	 RCN1,	 REC8,	 RFFL,	 RFK,	 RGL1,	 RGS10,	 RGS3,	 RHEBL1,	 RHOB,	RHOC,	
RHOF,	RILPL2,	RIN2,	RMDN3,	RNF150,	RNF152,	RNU12,	ROR1,	RREB1,	RTP4,	S100A10,	
S100A13,	S100A6,	S1PR3,	SCARB1,	SCHIP1,	SCMH1,	SCN3A,	SCUBE2,	SCUBE3,	SEC24A,	
SELL,	 SELENOM,	 SEMA7A,	 SERPINB1,	 SERPINB9,	 SESN3,	 SEM1,	 SHISA9,	 SHROOM1,	
SIK2,	 SIM1,	 SLAMF1,	 SLC31A2,	 SLC38A9,	 SLC43A2,	 SLC44A5,	 SLC46A3,	 SLC5A6,	
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SLC6A13,	 SLC6A4,	 SLC6A6,	 SLC7A5,	 SLCO3A1,	 SLCO4A1,	 SLFN5,	 SMAGP,	 SNED1,	
SNHG4,	 SNX10,	 SNX32,	 SNX7,	 SOCS3,	 SP110,	 SP140,	 SPEN,	 SPHK1,	 SPRED2,	 SPTB,	
SPTBN2,	 SRGN,	 SSBP2,	 SSBP3,	 ST18,	 ST5,	 ST6GAL1,	 ST8SIA6,	 STARD13,	 STARD9,	
STAT1,	 STAT4,	 STBD1,	 STK17B,	 STON1,	 STXBP6,	 SUGT1,	 SUSD2,	 SUV39H2,	 SYNE1,	
TBC1D24,	 TBC1D31,	 ELOC,	 TCIRG1,	 TCP11,	 TCP11L2,	 TCTN1,	 TDRD7,	 TNS2,	 TESC,	
TEX15,	 TGM2,	 TGTP1,	 THY1,	 TIPARP,	 TLR9,	 TMEM106A,	 TMEM158,	 TMEM246,	
TMEM25,	 TMSB10,	 TNFRSF14,	 TNFSF15,	 TNFSF4,	 TNS1,	 TPM4,	 TPPP3,	 TPST2,	
TRIM14,	 TRIM21,	 TRIM35,	 TRIM43B,	 TRIM69,	 TRIM7,	 TSPO,	TSSC4,	 TTC28,	TTC39C,	
TUBA1A,	 TUBA1B,	 TUBB2B,	 TUBB6,	 TXN,	 TXNDC17,	 TXNRD1,	 TYMS,	 UBE2L6,	
UBE2QL1,	UCP2,	UHRF1,	ULK1,	UVSSA,	UXS1,	VCAN,	VDR,	 VIM,	VWA5A,	VWCE,	VWF,	
WARS,	METTL27,	WDFY1,	WDR76,	WHRN,	 XAF1,	 XCR1,	 XIST,	 YES1,	 YPEL2,	 YWHAH,	
ZBP1,	 ZC3H12D,	 ZDHHC8,	 ZFAND6,	 ZNF385A,	 ZNF466,	 ZNF76,	 ZNF526,	 ZNF532,	
ZNF652,	ZNF831,	ZMAT3,	ZMIZ2,	ZNRF3	
	
E-V  AD Core Enrichment Genes (Nb CD11b+ UP and Nb TN UP) 
CA2,	CAPG,	CCL17,	CCL22,	CISH,	CLEC10A,	DDX58,	DTL,	EPHA2,	FEN1,	HCLS1,	HERC6,	
IFI27,	 IFI35,	 IFI44,	 IFIT1,	 IFIT3,	 IL1RN,	 IRF7,	 IRF8,	 ISG15,	 LRP8,	 LY6D,	 MAPKAPK3,	
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